var title_f19_37_20048="Lunotriquetral shear test";
var content_f19_37_20048=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70789&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70789&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lunotriquetral shear test for instability of the lunotriquetral ligament",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 412px; height: 482px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The lunotriquetral shear test is performed by stabilizing the lunate and moving the pisotriquetral mass back and forth past the lunate in the anterior and posterior direction. A positive test is increased movement and pain compared to the other side.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_37_20048=[""].join("\n");
var outline_f19_37_20048=null;
var title_f19_37_20049="Decision tree axial SpA rheum";
var content_f19_37_20049=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F59693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F59693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 553px\">",
"   <div class=\"ttl\">",
"    Decision tree on diagnosing axial spondyloarthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 533px; height: 585px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Starting point is the presence or absence of inflammatory back pain (IBP) in patients presenting with chronic back pain. In general, for making the diagnose of axial SpA a disease probability &gt;90 percent is suggested.",
"    <div class=\"footnotes\">",
"     * Dependent on which features are positive.",
"     <br>",
"      &bull; If the probability of disease exceeds 90 percent we consider the diagnosis axial SpA as definite. If the probability is 80 to 90 percent, we consider the diagnosis as probable.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rudwaleit M, van der heijde D, Khan MA, et al. How to diagnosis axial spondyloarthritis early. Ann Rheum Dis 2004; 63:535. Copyright &copy; 2004 BMJ Publishing Group.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_37_20049=[""].join("\n");
var outline_f19_37_20049=null;
var title_f19_37_20050="EP study tracings entrainment concealed fusion VT";
var content_f19_37_20050=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F80942&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F80942&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Intracardiac and surface ECG recordings during electrophysiologic study showing concealed entrainment during ventricular tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 318px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shown are three surface ECG V1, I, and II and intracardiac electrograms recorded from the right ventricle (RV) and from mapping catheters in two sites in the left ventricle (LV map1 and LV map2) during sustained monomorphic ventricular tachycardia (VT) in a patient with a prior myocardial infarction; noted are fractionated left ventricular electrograms recorded at LV map1. Pacing the ventricle (S) at a cycle length (CL) of 570 msec, which is slightly shorter than the cycle length of the VT (620 msec), accelerates the VT to a rate that is the same as that of pacing; however there is no change in the QRS morphology of the VT, confirming entrainment with concealed fusion. Additionally, the post pacing CL is the same as that of the VT (620 msec).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     With permission from: Bogun F, Knight B, Goyal R, et al. J Cardiovasc Electrophysiol 1999; 10:47.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_37_20050=[""].join("\n");
var outline_f19_37_20050=null;
var title_f19_37_20051="CT CAA-related ICH";
var content_f19_37_20051=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F50480&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F50480&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 565px\">",
"   <div class=\"ttl\">",
"    Lobar hemorrhage in cerebral amyloid angiopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 545px; height: 217px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Acute superficial lobar hemorrhage in the left frontal lobe seen on CT scan in a patient with cerebral amyloid angiopathy (Panel A). Flair MR image performed one week later shows the high signal intensity of subacute hemorrhage with surrounding edema extending into the subcortical white matter (Panel B). Hemorrhage (now low signal intensity consistent with hemosiderin) and edema are mostly resolved on a three-month follow-up study (Panel C).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eric D Schwartz, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_37_20051=[""].join("\n");
var outline_f19_37_20051=null;
var title_f19_37_20052="Multicyst dysplastic kidney";
var content_f19_37_20052=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66837&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66837&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Multicystic dysplastic kidney",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 321px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of: Laurence Baskin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_37_20052=[""].join("\n");
var outline_f19_37_20052=null;
var title_f19_37_20053="HIV-associated eosinophilic folliculitis";
var content_f19_37_20053=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87125&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87125&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    HIV-associated eosinophilic folliculitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erythematous papules and excoriated papules are present on the back.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_37_20053=[""].join("\n");
var outline_f19_37_20053=null;
var title_f19_37_20054="Butabarbital: Drug information";
var content_f19_37_20054=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"18\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Butabarbital: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?30/23/31092?source=see_link\">",
"    see \"Butabarbital: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F143477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Butisol Sodium&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F143492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Barbiturate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F143480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anxiety (sedative):",
"     </b>",
"     Oral: 15-30 mg 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Insomnia (hypnotic):",
"     </b>",
"     Oral: 50-100 mg at bedtime. When used for insomnia, treatment should be limited since barbiturates lose effectiveness for sleep induction and maintenance after 2 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Preoperative sedation:",
"     </b>",
"     Oral: 50-100 mg 1-1",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     hours before surgery",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F143487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Preoperative sedation: Oral: 2-6 mg/kg/dose; maximum: 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F143481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Use with caution; reduce dose if use is needed.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F5565309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduce dose if use is needed.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F5565310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduce dose if use is needed.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F143461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elixir, oral, as sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Butisol Sodium&reg;: 30 mg/5 mL (480 mL) [contains ethanol 7%, propylene glycol, sodium benzoate, tartrazine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Butisol Sodium&reg;: 30 mg, 50 mg [scored; contains tartrazine]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F143447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F143494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-III",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F143463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sedative; hypnotic",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F143500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Butabarbital may be confused with butalbital",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F143490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 3%: Central nervous system: Somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% or frequency not defined (limited to important or life-threatening): Abnormal thinking, agitation, agranulocytosis, anaphylaxis, angioedema, anxiety, apnea, ataxia, bradycardia, complex sleep-related activities, confusion, constipation, dependence, depression, dizziness, exfoliative dermatitis, fever, hallucination, headache, hyperkinesias, hypersensitivity reactions, hypotension, hypoventilation, insomnia, liver damage, megaloblastic anemia, nausea, nervousness, nightmares, psychiatric disturbance, rash, respiratory depression, Stevens-Johnson syndrome, syncope, thrombocytopenia, thrombophlebitis, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F143466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to barbiturates or any component of the formulation; porphyria",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F143451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Postmarketing studies have indicated that the use of hypnotic/sedative agents for sleep has been associated with hypersensitivity reactions including anaphylaxis as well as angioedema.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Paradoxical responses: May cause paradoxical responses, including agitation and hyperactivity, particularly with pain, and in pediatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sleep-related activities: An increased risk for hazardous sleep-related activities such as sleep-driving; cooking and eating food, and making phone calls while asleep have also been noted. Discontinue treatment in patients who report a sleep-driving episode.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression: Use with caution in patients with depression or suicidal tendencies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with respiratory disease; may cause respiratory depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use due to risk of overdose with low dosages, tolerance to sleep effects, and increased risk of physical dependence (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Use with caution in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tartrazine: Some products may contain tartrazine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Symptomatic treatment of insomnia should be initiated only after careful evaluation of potential causes of sleep disturbance. Failure of sleep disturbance to resolve after 7-10 days may indicate psychiatric and/or medical illness. A worsening of insomnia or the emergence of new abnormalities of thought or behavior may represent unrecognized psychiatric or medical illness and requires immediate and careful evaluation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Abrupt cessation may precipitate withdrawal, including status epilepticus in epileptic patients.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F143456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetaminophen: Barbiturates may increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Barbiturates may decrease the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Atenolol; Levobunolol; Metipranolol; Nadolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Barbiturates may increase the metabolism of Calcium Channel Blockers.  Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: Barbiturates may increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Barbiturates may diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible.  Management: Use of a non-hormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Barbiturates may diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.  Management: Use of alternative, nonhormonal contraceptives is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Barbiturates may decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Barbiturates may increase the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: Barbiturates may increase the metabolism of Disopyramide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May decrease the metabolism of Barbiturates. Barbiturates may decrease the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Doxycycline: Barbiturates may decrease the serum concentration of Doxycycline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etoposide: Barbiturates may decrease the serum concentration of Etoposide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etoposide Phosphate: Barbiturates may decrease the serum concentration of Etoposide Phosphate. Barbiturates may increase the metabolism, via CYP isoenzymes, of etoposide phosphate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: Barbiturates may decrease the serum concentration of Felbamate. Felbamate may increase the serum concentration of Barbiturates.  Management: Monitor for elevated barbiturate concentrations/toxicity if felbamate is initiated/dose increased, or reduced concentrations/effects if felbamate is discontinued/dose decreased. Refer to phenobarbital dosing guidelines for patients receiving that agent.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Barbiturates may enhance the CNS depressant effect of Fosphenytoin. Barbiturates may decrease the serum concentration of Fosphenytoin. Fosphenytoin may increase the serum concentration of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Griseofulvin: Barbiturates may decrease the serum concentration of Griseofulvin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of Barbiturates. Management: Consider a decrease in the barbiturate dose, as appropriate, when used together with hydroxyzine.  With concurrent use, monitor patients closely for excessive response to the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: Barbiturates may decrease the serum concentration of LamoTRIgine.  Management: See lamotrigine prescribing information for specific age-dependent dosing guidelines regarding concurrent use with a barbiturate, as well as for adjusting lamotrigine dosing if concurrent barbiturate therapy is discontinued.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: Barbiturates may enhance the CNS depressant effect of Meperidine. Barbiturates may increase serum concentrations of the active metabolite(s) of Meperidine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Barbiturates may enhance the CNS depressant effect of Methadone. Barbiturates may decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May enhance the CNS depressant effect of Barbiturates. Barbiturates may decrease the serum concentration of Phenytoin. Phenytoin may increase the serum concentration of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: May enhance the adverse/toxic effect of Barbiturates. Primidone is converted to phenobarbital, and thus becomes additive with existing barbiturate therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: Barbiturates may decrease the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pyridoxine: May increase the metabolism of Barbiturates. Apparent in high pyridoxine doses (eg, 200 mg/day)",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Barbiturates may enhance the hepatotoxic effect of QuiNIDine. Barbiturates may decrease the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Teniposide: Barbiturates may decrease the serum concentration of Teniposide.  Management: Consider alternatives to combined treatment with barbiturates and teniposide due to the potential for decreased teniposide concentrations.  If the combination cannot be avoided, monitor teniposide response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Barbiturates may decrease the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Barbiturates may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Barbiturates may increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May decrease the metabolism of Barbiturates. Barbiturates may decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Barbiturates may increase the metabolism of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: Barbiturates may decrease the serum concentration of Voriconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F143473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Rate of absorption is increased if given as solution on an empty stomach.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F143457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5565304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Barbiturates cross the placenta and can be found in fetal tissues. Acute withdrawal symptoms may occur in the neonate following",
"     <i>",
"      in utero",
"     </i>",
"     exposure near term. Withdrawal symptoms may include seizures and hyperirritabilility and may be delayed for up to 14 days after birth.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F143483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use with caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16265695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Butabarbital is excreted in breast milk. The manufacturer recommends that caution be exercised when administering butabarbital to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F143467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Elixir",
"     </b>",
"     (Butisol Sodium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg/5 mL (473 mL): $427.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Butisol Sodium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (100): $302.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $394.16",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5565311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC, renal and hepatic function with prolonged therapy",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F143462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum plasma: Habitual/therapeutic: 1-15 mg/L; toxic: 10-20 mg/L; lethal 30 mg/L",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F3429508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Brevinarcon (PL);",
"     </li>",
"     <li>",
"      Soneryl (GB)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F143450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferes with transmission of impulses from the thalamus to the cortex of the brain resulting in an imbalance in central inhibitory and facilitatory mechanisms",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F143465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 45-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~100 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/37/20054/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Repetto MR and Repett M, &ldquo;Habitual, Toxic and Lethal Concentrations of 103 Drugs of Abuse in Humans,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1997, 35(1):1-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/37/20054/abstract-text/9022645/pubmed\" id=\"9022645\" target=\"_blank\">",
"        9022645",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9174 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-4F9416D058-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_37_20054=[""].join("\n");
var outline_f19_37_20054=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143477\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143492\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143480\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143487\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143481\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5565309\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5565310\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143461\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143447\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143494\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143463\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143500\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143490\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143466\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143451\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298912\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143456\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143473\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143457\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5565304\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143483\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265695\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143467\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5565311\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143462\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3429508\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143450\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143465\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9174\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9174|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/23/31092?source=related_link\">",
"      Butabarbital: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_37_20055="RA PCW pressures VT";
var content_f19_37_20055=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F66693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F66693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 481px\">",
"   <div class=\"ttl\">",
"    Changes in pressure waveforms with VT",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 461px; height: 329px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFJAc0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArD0bxNaat4j8QaLbwXMdzorwx3DyKoRzLH5i7CGJOFIzkDr3rcrxX4W6hqi/GXxjbzWZGmalNeSpeytl5ntJYYtq85CqJivIx8oAxtIIB7VRXFW/jyOX4oTeEXsPIiSGTyr+a5RftFyiQSvBHF944iuI33Ejo2AQpNZfh74jLb/AAOtfHPifGVs/OmECEea+8ogA5wXbaPQFuwFAHcz6rBDr9lpDJKbm6tZ7tGAGwJE8KsCc5yTOmOOx6cZ0K+eH+Iba58QPhDeyPNZ6iZNR0vWbGFgpjuSkSNE6bz+78xVcZJOAp+8MDtvHXxcsvCfxG0fw/LAJ7GRB/at2rADTjK6LA8jE7VXO7cGwQrKwPZgD1Guf1nxXY6R4s8OeHrmK5a9137T9meNVMaeRGHfeSQRkHjAPPXFcN8G/FJn0j4i6prGpzXGnaf4j1B47iaYzJDaoqMFQ5OEVckAcc8V5NYfFW91v4jeAL7xhpf2HUdDsdT1O4NsAYri1l0/zonjG5jkopyM9cdCSqgH1D4k1eDw/wCH9S1i8SWS2sLaS6lWIAuVRSxCgkDOB3IrRr5L1z9oM6r4H1rTNcggnfV7GS1hmsYTElu7WQLhg0jlsTSBB04DNk8LWu3xy1uDxj41j1KGzH/CLaffwwiDekN1OLm2hjeSNn7OGxhshZCAc5JAPoXwh4gtvFPh+21exinht52kVUn27xskZDnazDqpPXp6HioP+Eqsv+E9HhLybn+0f7M/tXzdq+T5Xm+Vtzndu3c4xjHftXyxe+Pda0H4HeAIdLuLmCXWm1Fito5iYypqMbrhwQyjYZUwCQd/IPBHQ/A74j3vjj46LqmuR20U9xpFxptqlsm35ElSdS6l2I+UsM9DgAZOTQB9S0V5hd/FeC2+NMXgmexkgsdgt31GXARr2SNZYogSQADHuHdmdlAAAJan8OfiLcD9n238a+LLtLu8hhuHmfCQ+a6zukafKAqlvkUHHcE0Aelz6rBDr9lpDJKbm6tZ7tGAGwJE8KsCc5yTOmOOx6cZ0K+VfEfxE1jxH4s+Et1LBe6DrMOuTaNq9rFI0au4lsjInByY2DKdrZ9DuwGPqXxY+JOteCvENu1hoovvDunW0V3rs4K+bFFPK0UXlAupLZikJ4I5GdvWgD1iue8ZeLdP8Ix6RJqiTtHqeoxabE0QXEckgYh3LMMIApyRkj0NeX/D3xnJH45+Nup6lPcz6ZoksUot4pC4QQxzLJ5as2AzCEZ6ZIHYDHkfxn8Y+J/FXwkRPGGl29hONUstTsjFIp8yzuYrzysgMeV8phzg4xlQQSQD7NoryX48eOtV8MDR9P8ACt1FDrMgudUmE0SyxGztYHlkRx95fMIVVIxnDfMuK6vQ7mC8+JGt3NpNFPbTaHpcsU0TBkkRpr4hlYcEEYIIoA6+q2qXg0/TLu9aKWYW8LzGKLbvfapO1dxAycYGSB6kVxfxO8bTaFJp2geGjaXPjTV5UjsbSdWdI4937yeYKQyxqofkZORwCFbGJp/jXVb3wj4803x1o4sNb0Cwllu/sRJt7qB45WSSAlt3IjYYJ4OOQcqoB6ujbkVsEZGcGlpkC7YI1KlSFAwe3FPoA40eKr3/AIXGfCXk2/8AZ40Ear5uG83zftBi25zjbjnpnPeuyrxb4l2OqW3jzxl4hshJDbWvgC4gW7ilCvFOZZXTGDuBwhIYDAx1zivQvhbLJP8ADLwjNPI8ksmj2bu7kszMYUJJJ6k0AdPXLx+IrhvifP4aMcJtE0ePUQ4BEgdpnjwTnBUhRjgEEHrkY6ivP9PRbn48a3cwyB1s/D1nazAY+R3uJ3UHnOdoz079R3APQKjnnit4/MnkSJNwXc7BRkkADJ7kkAe5qSvNf2jpI4fg5rkk2fLSWzZsJu6XcJ6ZGfzFAGp4o8V3+lfEzwR4dtobVrHW1vmuZJFYyL5MQdNhBAHJ5yDx6V21ebeMtNvL343fDm6toGe20+31Oa5kPCorRRxrjPU7mXgc4Oegr0mgArE8Y6pcaPpNvc2gjMj6jY2p3jI2TXcUL/jtkbHviuS8C6je3Pxj+J9lcXtzNaWZ0z7PbySs0cG+2JbYpOF3Hk4xk9a3/iQpfw9aBRk/2zpR/LULc0AdTRXn3x71OfRvhVrGoWt5dWUsMlqfPtXZJFU3MQYAqQeQSDz0Jr0GgDE8dapcaH4J8QatZiM3Vhp1xdRCQZUukTMuRxkZAp/hnWV1XTLEzyQ/2k9hb3lxDFkBBKpwQDkhSyOByfums/4qIZPhh4vRcZbR7wDPvA9ct8NJGh+JvjTSGdZDoumaNp/miPZ5mIp33Yyevmfh07ZIB6jSEhQSxAA5JPalrzb48eILWx+EnjUW08Fxcw2os54Y5QXhNxtjXcAcqcSBgD1HsaALvwa8Sar4p8L3d7rrW7XUeoTwr5ERjCoCCqkEnld236AZyck95Xkv7LtibT4Q2Nz5u9L+5uLpE248pTIUC+/CZ7dcdsn1HUb+z0yze71K7t7O1QqGmuJBGiliFGWJAGSQB7kCgCfenmGPevmAbtueceuK4X4SeJNT8SQeLDq0scjad4ivdOtykYTEMZXYDjqRuPP0+tclouqLqH7Wuv2oQq2neGktSTk7sywy59v9cB+FdF8D7FLXS/FdwlwkhvvE2pXDQj79uRMY/Lfk/NiMN9HH1IB6PRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV88+GZrrw38QfFPinUNRm1K1trLxC0NgYhH9nS3vYpmRX3HduMvUgEYA6AV9DV8W/F/Q9X1rxfo+kX93plpY3/AIj1K3sGtiZZy8t3Cj+bhyo+R0YA7TwwIGVJAPa/DHw4m1z4VaHdS6zc23jK4ZdaTXiHkmt55ghdQvmYK+UFhK5CEKDtzWF4O8M+I28MfDLwTe3MVlFZ3N7qeqpI3mvNHZ3qeXANrFCrGZMgkgbQf4dp6TSvCHxW8PItnp/jnTNat7vatxdaxZP51iFRYw0AVyJGKjcQ5ALJk8u5PhfwJ0PXviV4i8U6jp/iCTw9cuxm1C/so38+X7TKkpiTEgEY3QOdyjPJB3AgKAem/FXwfZab8ZvCet6dKtsJ72C6ls45iAbhr21iknEefl3o4DMOGKDPJJPZ/DHwx/wknhPWNf8AGlrptxe+NoLe4vIrPzViFsLdFhjwzEhgCzFgQQz8H5VNeNfHTU/F/hnV/D1l4ovtHvZr2y/s/wC1W3nWxaFbi2kZ5X3/ACs5hwxUAAM2O2PSPhH4I8W2fhvw9r9j49mnN1pUAXTtQsmlsoYGhh8pEiSZAroFIMgPzbuQDuLAHC6doHiDTvGPib4S+Ebm3hsNQtbd9U1O5zIyI1uq3EyRPIcvKzYIHTjGPvKv7WtpbeFr7wXd6LAIJDpl9o4G4v8A6P5KxKgUk9FnkG4DPIyeBVHTrPxV8Q/jnrOi3fia60HXtD0mSwOq6fEYzeJHcqBI8auNu9ZQ21WADBSMYxVb4+eDvEMOr/DPw/4l8YnWVu7mSxt7x7ARS24LwIXc+YTKcMvJIPy8kkk0AZni/wCHFsni74l6GCFtNG0+616yljTakLSG3kWIRhgB8iSR56Yw2OAtX7Lwy/iu2+GMM4MF74y/tOPWJjK7ma2ivBdgKWLYPykhupJG7NU9R8G+LLrVvijLe+Nbp7vwzp0UFy7xf8hO3MEhVZMPjOxOrbyWbJO7JpmlfD3xW2qfCrS18a3FrZazZ3F9pd1AH8/Ti1rHJNGAGB2kbFGHA5Y7RkggGJ4a8PTeLPBfih2vblYPAdmRp1tuK7WkupZpJSRwGCRsDxz8vI2Cu38LJpfhX4xfDHWZ7mDTrS98LWk2o3V3cYRpXtZ1DM7nC58mNQBgccdTnzXwrYeI9P8Ah58Qtd03xA1qtuyadq1gYhIt3HM/lk5OQGBZucAgFsMMkGP4i+F/Emn6j4P0LWb3UNSnutGtZLazjtWa6tkJkItzETuZo2aVRk9OPlA2gA+rvAfge28SfCu2l8S6he3+pa/JF4he/V/KmtLp4k8t4GGfLMaqirjjgjAU7B578KbG61Ead8OoNet0tPDGt31xfRrCplvI7S7t2iVkL5RHeWRs8jKY5xz1Wg/B7xnodhBFpfxX1eCRYDa+XLZCaCOALGESOFpCsbLsb5wckEYxglvIPgT4e1Lxl8TNRfUrzXdJ1bTg39r3NpcSx+eVe3QQSyK+4NIY7hmwRyMj7uAAem/Hjw14e0rxpp3jCWyYahGiahcTiV2yYL7TYg2wuF4ieQY4Bzk8gEdV8J9A1PxJ4e1jxL46uY7uTxnYQLJp8G9Iba02SBI0O8sNyzFjgjBY98mvFPjn4W8Z+ELSxF14r1bxfHcaddpdRTJJHFDbIIE3sqyHcQ8qOWJ5KKWyAc+peCPhPaav4J8N6vbeK/Gek3V5o1j5i6fq7ogAhBCAMGIQM7kKDhd7YwDigDN8S+H4PDeq33gPwUbJNZ8WW0FvfXmrXMk89zE8WoGe4IDZMg8vO4DbmQAgcY0/2lvCeg31pYa9qGnLdahEl1Fl55VV44bC9uI0Kq4GBKgORg9s4OK86n8HRX3x+n8EeLW1fWIJsS2Op3d04nSx+y3TGNZCcuBNKozyCYjkYytbP7QPw3Xw94Vtp/DeueKFthJJFDpTak0trbQpY3LybFkbIBjjZT8x+VnAByFoA7/4e3ml+P8A4h+M/Ebx6dd6fHH/AMI1YDdvNxbxHzLlmXJR43eaPDDqoUEDJ3ZFlp+hfBW78ef2PqVtAZ9JgvdPtdWvkwZw16VgQFlYplVABJY5b5iemb8F/hN4S1nwLba5Yza3a3U9xeGxvbbUHgmtE8+SIOmxigdo0QMfmBxjnvw/xQ8FwaN8TBpUuoX3iHUp/Dax6c3iC985p7ue7NvsVmK/dSR3VRypXcMkcgHvPgvSNR0zxfca14+1fQZfFGs26WVlZ2SeWsMMO93SEyHzJAxYSNxwR6AYg+NfgzStU8K+JPEJa+s9cttEnhS9s7uSFjCgaXymUNtdGbO4MDkHsQCLF/8ABjwRqN9Be6lp+oXl3bqqQTXGr3kjwqpyqoxlyACSQOxJrG+Inw/ttO8CeKr9PEfi2UQaZezpbz63cPED5LkAjduZRgfKxIOOc5OQD1uNdiKu5mwAMt1P1ryjxv4a8Z+NPG9zp/8AaOqeGfDVlaSvY6ppN/5b3Vw6w7VmiDbiqMJT/DkcAjOT6wBgADOB6nNcR4i+Hia3rl5qbeK/GFgbmIR/ZbDVWht4iFC70QDhuM9xkk45oA8ovfhX4y1rxpqWl3/xPvXki0OCGWYaaqrcW8rXMZikQSgMRtc723Nl85BUGs3wpB8VNQ+Eul634S1IXq6hp39jJoaItsLGGJZYUuop2lB83Kq2RyS47Iu3oZvhPfzeNNb0zTviP43trlNLs54rubUmlbLTXClZANpdRsJUArgux5zVuz+Ad/pdhaWWhfErxXptnDCFNvBOyx+YeXZFVwFVmJO3nknk0Ab3ib4PPqqxx2XjbxZa2xspbWe3n1Oe5juJGRlSVg0g5DEMVHyttAwvJPmN18PvE9r8V7vwZofjrWIm1PT4davNanlka8VIZJ4Y4crIpdf3iA5PUAjAG2vVLT4QCGRmm+IHxDuFKOgR9cYAEqQG+VQcqSGHOMgZBGQee0T4UW6/EXxBDe+LPF11dQ6dZSW1+dUkS6hhkkug8BkB+dC0KvjAwQPfIBHp3gj4i+MLzVT448R6z4dnsbaOy0650HUBFBfMrS7rmWFWPJzGSP3eRxhe2V43+FHijSvh5r0l78StU1iwhsWvb6y1K3MyXT27NMio5l3wKdqA7TkkZJIwo9atvh7pkPmeZqviqfdIzjzPEV8NgJ4QbZRwOgzk+pNUtT+EvhTU7W8tryPWJYb2SOW6STW711uCm3b5gaUhuEUZIyABgggEAHk2q6P8WpvEeiiPxLHcy+JtPkMr2wjj/sRHe1+0GECTEgRdgVlYk/Mwwx3np2+FvjLRhK1v8ZtXt7KW5hKf2hbi4YOJAI08x5f4mYKVAAfIUg9K27/4deE4vFOg6O/9si3bS7yKG1Os3hjESNbAov73KgAr8gwpA5B2rie6+BHw5u3D3egzTuBjdLqV2xx+MtAHnCS+ItC+MesaBD428P2mrapYWt/q+uTWiqyeQoijgWBpCgkYYds4yspKhQqg5+sXGv65bSaz41+INr4b1uK+0+HT9KsdSt5LMIs8JN5JF5hEoy7SANgjyxklcAepyfAH4aS7fM8NliAACb+6JwAABnzOgAAA7VheL/gb8OtN0m3msvD3lStqNhCT9tuW+SS7ijccyd1dh+PHNAHDePbae68EeJYNQ+Ouh69bywtePpvkWwa4kiCukcZWbdHlokAVOMknbknMH/CXeKfEnhqPU4PifpOm/wDCRX+y50p7m1hm0O2Mn+tjlMyOSscafIACRIxxuy1e0SfA/wCHEkVtG3hWzC2+NhWSRScFj85DZflj97ORgHgACa8+DPw9vLiWe48LWJllkMrlS6ZYtuPAYADPYcdulAHk3jDw94MPhnXnf4x6trUQ06Q2+m3XiaKZJp1Ryu4A/P8AMIyFAHKn7wOBzMws9N+KEfhvT/ibK+h6x5ep6h4mTV1S7RYVuES1a48za3BTqM5IO3AxXsPjn4R+AtL8EeI7+x8MWEV3b6ZdSRSYZtjeS+GAJIyOoPYgEcgGtdPgf8OUimjXwzAI5p0uHX7RNjeocDHz8LiRvlGFPGQcDABw3gj+xYp7+28bfFez1q1thDb6bND4le0eRBukeWRYrn5m3SbAWJOIV9a3YPDvwlvdR1OVPE8F5NexpJeRnxTLJ5ywBnDyfviXCoP48hVTIxyTuy/BD4cyxlG8LWig945JUb8CrAiqbfs//DJs58Mjk5/4/rnP/oygDyT4U+E7jxL8LdBj8K/E/UdL8SmSQ3FimqM8UUDSOrKtuCCjBAZFPds8gFWT1y6+E/w58P8AhS5tNSjmsvD/AMhuludbuobZ23LtaQeaEyW244HOMVyvw1+CXw91vwda3+p+HxNdyT3Ks4vLhMhbiRFGFkAGFUDp2rqP+Gffhjz/AMUz/wCVC6/+O0Ac54m8D6XafGXwZYaTq+pWMl9FfXOpFdbmW7uIUSARxCRn8xkLR52g9FcjG3K9B+zv4Lk8J+Htbnvr86lqmo6tcm4u2Yln8qV4hu+ZgWLLIxOc5cgk7c1bX4F/DxJIJE0OdZIE8uJhqd2DGvPyqfN4HzHgeprc+GXg7QfB2j3Vv4Z8z7LdXUszk3Lyru3sAAGYgbQAmRydg3ZNAHYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUV4/+0Z431nwt4dW38OG5tLuWJ7iTUVtHmSFExiPIUqruxAy2AFDd8VxHjb4g69J/aF1ZeILvS00zw1aapaR+Usf2yd5ArtIsi5YZyu3gd6APpes7S9Lt7XEpihe4WS5KTeWAyLNMZHUHqASFz6lQewxPpc8t1plncXEflTywpI8f9xioJHPoazNL1i9uReCXw/qUAhuZYkd3g2zqrsBIn7zIUgA/MAee45oA3aq2GnWWniYafZ21qJ5DNKIIlTzHIALNgcthQMnnAHpWJH4j1Rnw3gvxAg/vNNYY/S5NMbxNqwHHgfxGfpPp/wD8lUAc1408P6X4p+KVlo2vWv2vTbnw7debD5jJu23lo68qQR8yg8HtXpccaRRpHEipGgCqqjAUDoAK8on17UpPjHp03/CJ60skegXKm3M1l5mHuIDu4uNuBsI+9nJGARkjtf8AhI9U/wChM8Qf9/rH/wCSaANVdH09ddfWhaRf2q9stmborlxCrFwgPYbmJOOvGc4GFudNsrjV7HUJ7WGS9tI5Ut5mXLRB9u/ae2QoB9uKxG8T6uGIHgbxIw9RPp//AMlVVk8Wa4NSgjXwB4hMDRSM7m5sNysCm0AfacEEFsksCMDAbJKgDfjSSPhd4iI4ItwQfQ7lrprzRtOvNU07UrqzilvtO8z7JOw+aHzF2vt9Mjg1538V/Etyvw71ltS8Ha7HaGJBKZJrTAUuvB8u4LD0yAa6n/hKNX/6ETxJ/wB/9O/+SqAM34Gx2/8AwqXw6sARovJYnB3At5jFiT3O7OffNSWf/Jb9W/7F2y/9KbqsL4TeIdUt/hp4Xhj8F67Oi6fD+/hlsQknyD5wHuQ3PX5gDzzUljqOtt8VNX1T/hD9ZSAaHawbJJrQOzC4nbCkTlTkMf4hjbzgFSQD1GiuWn8Sa3GyhPBOtSgorEpdWQ2kqCVOZxyCSOOOOCRWJf8AjDxzHdOth8ML6e3H3ZJtZs4mPHOVDsBznv8A4UAbWpf8lT8Pf9gXU/8A0fYV1VeJX/i3x2fH2jXB+Gky3qaXfpFanW7X96jS2hZ9/QbSqDB5PmZHQ1tyeNfiWHIi+ErMvq3iO1U/lg0AemrbQLdyXSwxC5kRY3lCAOyKWKqT1IBdyB23H1Ncr8QdLtNaufDGn6lEZrO51CeGaPcV3o+n3iMMggjKsRwQa5//AITH4l4b/i1UfCg4/wCEkt+SRnA+TqOnPH4c1ja34r+Ic2p+GZLn4bQ2sqag7QxN4ghYyv8AZbgbCQmF+Us2efugd+AD1Twv4f0zwtoVro2g2otNNttwihDs+3cxY8sSTksTye9M1fw1o+saxpGqanYxXN9pLvJZSuT+5ZwAxAzgngYyDggEYIBrjV8V/EgsQfhnaqAByfEcWD/5C/zmlHir4j7iP+Fa2mAAQf8AhI4sHr/0y9v1oA9Irlfix/ySzxl/2Bb3/wBEPUnhfVPFGoSP/wAJB4as9IiEYZTHqn2lixZgVIESgYChs5I+dR13AVPi+1yPhT4wMEULt/ZF0CHlKgL5TbjkKeQuSB3IAyM5AB2NFNjLmNDKqrIQNyq2QD3AOBn8hXE+KPEnjPTtYmttC8BNrNiiho7waxBbhyVBI2ONwwcj8M0AS2UpHxl1mHsdAsX6elxdj19/T/6/Z14Tp3iT4gSfE/U73/hXCx3x0e0ge0fxBCFSPzrhlkLBCGJJdcYyNhP8Vdpb+JfiJLMEk+HlhCpDHzH8RIQCFJA4hJ5IAHHUjOBkgA9CrldOP/F0vEIwP+QNpvP/AG3vqDfeN88eHvDeP+w9P/8AIdc1YXnjD/hZGusug+HzcnSdPDodamCBPOvdpDfZMkk78jaMYHJyQoB6fRXK/bvHH/QveG//AAfT/wDyHR9u8cf9C94b/wDB9P8A/IdADtQs5x8S9Evo4y0H9l3lvK/HyEyW7L787Tz049xXUV5vda342Tx1ptj/AGFoAaXTbqYxjW5yjBJbcZLfZeCN/Tac7jyu3DbwvvG+efD3hsD212f/AOQ6AOqrm/iD/wAgG1/7C2mf+l0FLDd+LmWXztF0GNgh8vZrEz5bsDm1GB78/SuV8cXfjQ6LbC60bw2kf9p6dhk1eYnd9th2jBtwMFsA85wcgMcKQD02ivPr6b4qtcObGx8DxQcbVmvbuRh0zkiJQe/b86q7vjEc/uvh8vT/AJaXjfX+Ef5/OgDpvicQvw28WFiABpN2ST2/cvXS14149X4oD4eeLJNYuvBkVqmmXBdLOC6aRo/Kffh2cBWx935SM9a3vL+L3n4+1+AvJ343fZbzdtz1x5nXHbP40Aej0VxM9r8RxEDBq/hB5NvKvpVyoz6ZFyePwp9tbfEQXUX2nVvCZt948wR6XcByuecZuMZxQBF8FZEm+HGnyQukkbz3ZV0YMrD7VLyCOoruK84+AI1E/DGwbUZIPMa5uiqJC6lB9okBDF3Ysd24544IGMgk9h4ls9ZvtKeDQdXg0q9ZlIupLP7TtAOSAhdRz0yfX15oA165H4V3Ml34QM04YSHUtRUhmZiNt9OACSSeg9axh4W+I+5T/wALJs8BgSP+Ecj5AOcH970PT157VH8A7TWbfwjdy6zrS6mk2pXphQWiweSy3cyyHIJ3B3BfB+7uxyAKAPS6KKKACiiigAooooAKKKKACiiigAooooAr6hZWuo2ctnqFtBd2ky7ZIJ4xIjj0ZTwR9apX3hzQ9Qls5L/RtNupLMAWzTWqOYAOmwkfL07YrVooAKw/DviKz1pbwWkV6htbu4tHMts6qXilaNir42sMqeQT6HBBA3K5X4af8i5ef9hrVv8A043FAHSTXCQxl3WUgED5ImY8nHQAmnRzJIiuokAYAjdGwP4gjIqSq899aW+7z7qCLbgnfIFxk4HX1II+ooA8wvvEdtB+0LZ2g03U5HbQWhe4isZWVN06spY7c7PlxuGQGbBxg47LxP4uh0G1SVdG8Qao7SGPydO02SVxgZLHIC7enOec8ZwcZEVz4Zk+J91rX9tW39ow6PDZ7PtSeUYnnkfPT72Y+zdOo6E9Bd+LvDdkEN54h0e3D52+bexJn6ZagDlJPiqFIx4F8evkA8aMePblqpS/GBE1GC1/4QLx4Z5IpJEj/stQzKpQMQDICQC65PbcPWuzbxv4UWRo28T6EJF6qdQiyPw3VyupeN/Co+JGiXP/AAk2h/ZoNJ1COWX7fFtjd5rIorNuwCwRyAeu0+hoA5T4p/EA694HvNNPgXxxF581tn7RpW1Di4jbaSHPJxgepIrrG+K7ADZ8P/iA/rjSFGPzkFVfix4z8L3/AIBvY7HxJotzIZ7RwkN9E5Ki5iJOA3THOa7FvHfhFSA3irQQTwAdRh5/8eoA87+F/wAQLm3+H3hy0i8DeMrkQWFtCJ4rOERS5QAOheVSUPXdjGOTiuli+I1y+qz2S+BfFxuYoYpnj8q0yqu0gUk/aMcmN/8Avn6U/wAD/EHwfN4S0Jf+Ej0W2m/s6F2tJdShMsIEQJVxkHKjrwOh4Fbuj+LvDWsa7c2Gka1pt7qEdrFcOlvOsh8pi21sg4I57HjepON65AKZ8X6gLdJB4J8TkscGMC03KMIQT/pGOd+OCT8rZAxXRPeTrZxzDTrtpGCkwBot6Z6gkvt474J9s1a82P8Avr+dRXN5bW0Ek9zcQwwRqWeSRwqqB1JJ4AoA8+vdf1FviHoszeDdeWVNLvkVDPY7irS2hJGLnGAVUHJz8wwDzjol8SaoULHwX4gU4ztM1hk+3/Hzj/8AXXDXvxc8BP4s0XV18T2BsE02/hdgW3q5ltCoMeN4yEYjjnacdK0x8dfhueV8SxsB1K2lwQPqfL4oA6r/AISHU84/4Q/XsevnWP8A8kVz/iXXdSfWPCjnwprUZj1SQhGls8yf6FcjC4uCM855I4B74Brj45fDo9PEPv8A8eVz/wDG6xPEHxm8BXOreGZYNcd47XUHmlYWNzhVNrcJn/V8/M68e+enNAHoR8Q6ngn/AIQ7Xjjt51jz/wCTNRy+JdVRsL4J8RSDHVZ7DH63QrHtfi94Nu0D2l7qVwhG4NDo166kZZcgiHBGVYZ9VPpTx8WvCBvIbT7Vqn2qbPlQ/wBi3298cnC+Tk4oA1f+El1X/oSPEX/f/T//AJKrE+KWq38vw88YWw8N6sEbSLlROZbXZ80TAn/XbsLkk8dFOMnAOoPiHoJYqE13I6/8SG//APjNc/8AETx5olz4A8TW8aa0JJdMuUXfol6igmJgMs0QCj3JAHegD0uF2khR3jaJmUEo+CVPocEjI9iRWRqWsX1ndyRW/hvVr+NQCJreS1CPxnAEkytx05ArXglWeCOVA4SRQ4DoUYAjPKkAg+xGRXFeJ/iv4J8L61NpOva7HZ6hCFZ4WglbAYBhyFIPBHQ0AZltrWpJ8RdXvV8G+InkbSrOExBrEYAmuSG3m5wc7mGByNuTjK56P/hJtW3Y/wCEH8R49fP0/wD+Sq8/tPjR4GPjrULtdaeWyk0y2SN49NuHO9ZZy/IjyBho+oweOeDXTW3xk8E3Umy21HUJn6bY9HvWPQnoIfY/kaANv/hJdV/6EjxF/wB/9P8A/kqsHTNY1E/EfXpz4X1lWfRrAeUZbPcCs14QP9fj5t5A5xlGzgYJ1k+ImguoZY9dKnkH+wL/AP8AjNYWl+NNLk+I+tyrHrJhk0mwVB/Y15uDLNelsr5WVGCMEgA4OM7WwAdG3ifVh08DeI2+k+n/APyVSf8ACUav/wBCJ4k/7/6d/wDJVdLLOkUbOwlKqMnbGzH8gMmueXxrpZJxaeIOCBzoF+Opx/zxoA5W58Qao/xO0iZvB2uxuuj3qCFp7HewM9qSwxclcDGDkg/MMA846dvE+rA8eBvEbfSfT/8A5Krlbrxppj/FvSwtrreIdDvC2dHuw533FtjEfl7yPkbLbdo4GcnFdevjLTGOBa6/+Og3w/8AaNAFnRtZv9QuHju/DWr6WiruEt3JaMrHI+UeVO5z35AHHWjxNLOba1ii0OTVA97bFlMkSLCBMrecdzc7Nu8AAksFAx1FWXxrpcZG618QHOfu6Bft0+kNTar4ms7Ky024a11SRb+4ggiVLCYMhkkRQZAyjygN2Tv2nggAtxQBo6jeXVtYGe20y5vJgU/0aOSJXILANgswXIBJ684xmqfiXVNU07ShcaP4futYvGdVFrHcQwlQerM7sBgY7ZJJHbJC6v4itNKkKT2urTEIHJtdNuLgcnAGUQ5Pt2A5xxWDffEewtrZpYtB8X3bg4EUPh+7DH/vpFH5mgDi/iN4r8dXPgHxTBefDeSzsZNMukkun1u2cwxmJwXKLkkgc7QTnGM10TeLviGCcfDDI7H/AISC3/8Aia5v4i/FCO/+H/ieyHgzxzb/AGjS7qET3OivHFHuiYbnYn5VGck9hXRL8WlZmCeA/iCQO50Rlz+bCgC03iX4hC2Eo+HtiW6+SPEKb+vT/U7c9/vY96Wz8RfEO4iLy+ANNtWDY2TeIlJI9fkgYY/HtVUfFcktnwB8QAB0J0cc/wDj9Ot/ilLcXMcEXw+8fb5HVFL6Wka5JAGWaUBRzySQBjnFAGD8E7zxnb/DTRo4PD+lXMJEkiXFxrTo8u+V3JKi3bHLf3jXc/2l43/6FjQv/B7J/wDItZXwHvJbr4VaE0lhdWwSIovnGPMgyTvAVjgckYbB4PGME97HK7rkwSpzjDFf6GgCjpc+sS2xbVLCxtZ88JBetMuMf3jEnf2rjfgTLqEnghhfWlpbwjUL8wmG6aZmJvZ94YGNNuG4BBO4ckL0rvbmeSGFnjtJ52GMRxlAx5x/EwHHXr2rzr9njVJtU+G8E0unXFojXd5Kskjxsku+7mYhNrFvlJ2ncFyRxkc0Aem0UUUAFFFFABRRRQAUUUUAFFFFAFHXr1tN0PUb5E3va20kwXBO4qpOMDk9K8T0H4v+JJPEegWmpDwhqFjqYgeQ6NdyyS26zTRwrvDcBg8q5U9g2Olep/Ei8nsPCV1Pa+ILLw7KrIBqF7EskUeWAIKsQOen415N+zhcxape3VzNrvha6mmSaSTS9O0u3tp1eOfYlw7RgEgjkZH/AC1HNAH0BRRRQAVx/wANdMsbXStUuLe0gS4utZ1KSeVYlDysL6cAsQMtgYAz2AFdhXHfDrTYI9G1Z0a5zdaxqbSA3MhUH7bOPkBbEfr8uOeevNAHWLbQKxZYYgx6kIMmsm68JeHLtt114f0idic5kso2Ock919z+dcxdfBrwPdxxR3WmXs8cRyiSateMqnaq8Ay4+6iD6KPSqzfAz4dN97w7kdMfbrn/AOOe1AHRJ4G8IfbpSPC+h+Z5aA/6BFjGWx/D9amPgXwkSD/wi2g5HIP9nw8f+O1yKfAn4bi9lb/hG4jmNF8s3MxVcFucb+/A/wCAj3rXT4RfD9EVR4R0jCjAzACfzPWgDctPBvhizkL2nhzRYHIwWisYlJHpwtYV/oekp8T/AA/Gul2Ko2j6kxUW6AEiaxAOMdRk/ma2PD3gbwv4cuZbjQtB0+wnlTy3kghCllznGfTiuZs/BPhrQPih4ebRdA0yy26VqMm+K3QMH82zUHOM5CvIB6B2H8RyAQfF/wAKeHbfwNqN3b6DpMVy11au00dlGHJNzHkk4BJwWzz3PrXdr4c0RVCro+mhQMAC1QAfpXM6v8J/AuoQlZvDGlxlplkLwwLGxPmBiMgZweQR6HHpXRaP4W0HRdPaw0rR7C0s3zviigUK2c53cc9T1oAyPhLZWkHw28JzW9rBFK+j2hZ0jCs2YUJycZ5PNVPCdpHbfFTxu0MSxI1ppigKgUYVZgMfhx+FWfg/ZWtv8KPB8dvbQRRtpNrIypGFBZ4lZ2IHcsxJPckk9a5rQ/BPhS7+J3jKK68M6HPHDDYOiSWETBGZZSxAK8E4GfXAoA9XormE+H3gyN98fhHw8j9Ny6bCD/6DUyeCPCiFinhjQ1LKUJGnxDKnqPu9KAItQZB8TNBUq/mHSNRIIfCgCayzlccnkYORjB4OeOmrlZvh94Plv7aeTwxorPDFJGi/Y49gDMjH5MbScqMEjI5wRuOZD8P/AAaYhEfCXh4xDon9mw4/LbQB01c14sQNr3gsnGU1eRhlwvP2C7HAP3uvQfXoDUX/AArnwRjH/CG+G8f9guD/AOJpB8PPBkU9vJD4T0GJ43YqY9PiTqjKQcLyCCeDx+QoA6ukDDcVyNwGSM8/54NYul+EvDmkyyyaV4f0ixklwJGtrKOIvg55KqM81dfR9MfUo9RfTrNr+JSiXJgUyopzkB8ZA5PGe9AF6ua8b6joT+Dddj1nVIbfTn02RrmWOUb0gkVkDrgE88hcA5PABPFbl7YWd9ay2t7aW9zbSrtkhmjDo49CCMEVzt/8PfBl1ask/hPQHCxGNf8AiXxAovJwp25Xkk8dzQB1dFMgijghjhgjSOKNQiIigKqgYAAHQCsbVPCHhrVryS71Xw9o97dyAK81zZRSuwAwAWZSTxxQBJbQ2I8YalPHMTqTWFqk0WRhYhJcGNsYzyxlHXt25zqzSxwwvLM6xxRqWd3OAoHJJPYVyEXw28CpqM8qeEvD/nNFGrJ9giKhQXwQm3AJJOSACcAEnaMXE+H/AINR1dPCXh5WU5BGmwgg+v3aAOmrnLGGJfiJrc63CtM+lWCNAAcoqzXhDE+jFmH/AAA0QeBfCNuSYPC2gxEjBKadCuR+C1oRaLpkeuXGqR2FquozQpDJciMb2RSxCk+nP8vQUATX+rabp5Iv9Qs7UgbiJ5lTA2u2eT6RyH6Ix7Gsr/hOfCf/AENGhf8Agwh/+KqbWPCHhvW7pbnWvD2j6hcqgjWW7sopXCgkhQWUnGSePc1R/wCFceB/+hN8N/8Agrg/+JoA4Cbxh4aT9oWPUH8RaMtgnhZ4WuTexCJZDdoQhfdgNjnGc13/APwsfwP/ANDl4b/8GkH/AMVXn6+DfDEP7QsVhD4c0aOwPhZ5zbJYxCMyfa0Xft243Y4z1xXpH/CDeE/+hX0L/wAF8P8A8TQBX/4WP4H/AOhy8N/+DSD/AOKpz+PfCUkNu9v4l0i5E91FZxC2u0mLzO6qqAISScsPoMk4AJrVtvD+jWsQjttJ0+GMdFjtkUdMdAPQCpbqzsEs0hltrVbYTxOqNGoQSCRShA6bg4Ug9cgY5oAztW8aeGNHunttV8Q6TZ3KEBop7uNHXIBGVJyOCD+NZ7/E3wOiFm8XaEAP+n2M/wBa6+igDyL4mfFDwVffD7xTYWPiKxubq50u7giSAmQM7QuFG4AjkgjOcZreHxh8DM2I9aeT96YQY7G4cFx2BEeD+Fdh4gexi0HUpNYEJ0xLaRroTqGj8oKd+4HgrtzkelX6AOIb4p+EVUs1/dgDqTpt0P8A2nTv+Fo+E/8An+vP/BZdf/G67WigDyH4Q+O9BtPht4etHk1Wa5js0Mwg0e8kCsw3HBWIgrkkBs4ODgnBr03S9YtdTWRrVL1fLIVhcWU0ByVDdJEUngjp9OoNReEYtOg8LaRHohU6WLSI2pVmYGIqCpBbkjGOta1AFe5u47aFpZFnZRgERwvI3Jx91QSevpXmX7Ml5HP8IdKgVLlZIJLneZbeSNTuuZWG1mUB+DyVJweDg8V6rXmv7OAI+C3hvdndtnJ9/wDSJKAPSqKKKACiiigAooooAKKKKACiiigDJ8VxQS+HNRNzaWN4kUDzLDfBTCzKpZd+7gDIHJ6da8e/Z/8AEdnruvuYr3wc10+mmaSz0bSXtZ4cvHkNIeGUE4IB5OD2r2bxIbYeHdUN+/l2f2WXzn2b9qbDuO3vxnjvXlHwKvLuS+itU1DxpdaPFpoFoNY0dLW12AxhDHKBlm29BnkEntQB7RRRRQAVx/w7s500jVXbULp1n1fUjHGyxbbcfbZxhMICc9fmLcn04rsK4SOy8fxmUWN94Ytbd764YRXFhPK6QNNIUbcs6hnKlSRheSeeOQCRfAuoKcjx94v6EcyWZ6jHe3pP+EDv/wDof/GP/f20/wDkevPbL4qeKbnxR/ZDvpkULazNoKXx0dmia6j6rtF7vC4IO7bjke+Oo0r4h3V9411DwOb2yXxDDuMWojTX+xOyCN3hCfaNzSKj5PzDH4fMAV4fAJ1DxdqkL/EjxnLPaQW5eCG+SIxbjIRv2xBDnGQAM9c5yK1rX4WrBcxyyeN/HdwiMCYpNZba/sdqg4+hFUdC0/xh/wALC8VyR6roUbGCyV520iVllIWTAVftQKkZ5yTncOmDnqWsfG38PiDw4ProU5/9vKAOe/4VR8uP+E++IH1/tj/7Cn6b4KXR/iTot4mo+JNQiTS7sNLe6lNNEjg2iAEZ25ceY+0jBYEgDYu3dNj437eIfDf/AIIZ/wD5MrOms/HQ8UaeP7e0M2v2O58zbpEqpv32+3K/aSSceZg7hgZBDZBABmeLfClppHh1bdvE/jCH7dq9pGlzHq7vNF5kwjWJS7f6v58H7zdCd22t/wAN+BYdDuPOfxD4o1NtjIF1DVZJF5J52jAzzgenHcZrl/iVaeKk0rR1v9a0KcvrmmrD5WjTR7JPtUZDEm7PAxyMc9BgkMOwWy8abyW1/wAOlewGhzA/n9roAq/CCzS2+FXhCNTPzpNq58yZ3ILRKxGWJIGScDoBgAAACsfwNo0EHxZ+IV+st0XZ7OIBrqVlwYFc5UsVPJ4OPlGQMAkF3w4t/FU3w88Ly2ms6HHbPpVq0SSaPKzKhhXAJF0ATjHOB9Kp+GLPxO/jDxqbPXtBS8W9t0ufM0WZwf8ARIShXF2MDDEY5ORnoQKAPT5IUkRkYyAMCDtkYH8CDkVzj+CNKeONDd+IQIwQCPEF+CcnPJE2T+OaIrLxmD+91/w8w/2NEmU/rdml/s/xd9rVv+Eh0f7MHBMZ0d9xXuN32jGevOPwoAqt4B0v+07e4F/4jAjhlj2f29ekNuMZySZd2Rs7ED5jkE4Iuf8ACF6X/wA/XiD/AMH99/8AHqy7zSPGr+ILWeHxXo8cK20qeQdIkIYlovmK/aPmI2nByNu4jB3ZEJ8PfELF0P8AhPdM/ffcP/CPD9xzn5P3/Pp8278+aANVvAukscm78R/h4i1Af+165bxV4V0y08UeDLOO+8RBb3UJkkVtf1BiVWznbgmb5TkLyMEjI6Eg2f8AhFPiRvJ/4Wba4wRt/wCEcix9f9b2rzBX8WeKdY8AXlj8RvP/ALQvNQWwuW0G3QweTFNHJLsEp3hsEDPADgnBwCAe3r4F0lel34j/AB8Ragf/AGvQvgXSV6XfiP8AHxFqB/8Aa9eWeP8A/hOvAthp17rfxZumt76+jsFa38LWrlHcMQzDeDtAQ5xk+gNdQvgn4m7hu+LZI7geG7Uf+zUAd9qugWeqSQvczamjRcKLbUrm3B/3hHIob8c07xFo9trWhXum3cl2kFxEUdre5kikA9nUg/0IyDkEiuH/AOEM+If/AEVaf/wQWn+FZ3iPwh49h8PapJdfFm4jt0tZTI40W3iKrsOTvT51+q/MO3NAHrNtCtvbxQxmQpGgRTJIzsQBjlmJLH3JJPesTVvCmnapfPd3VxrSSuACtrrV5bR8DHEccqqPwHNbkCNHDGjyPKyqFMjgbnIHU4AGT7ACuJ8U+HPG+o6vcT6B49i0XT32eVa/2JFctHhQG+dnGcnJ6cZxQBl2Pg3Sn+Iet2huvEWyLSrCUMPEN+GJea8BBbztxHyDAJIGTgDJz0q+BtJXOLvxHyMc+ItQP8568zsfCHxEbx/rUC/FAreppdi8l1/wj9sfMRpbsImzOBtKyHI5PmYP3RXRp4K+JIcb/iy5XPIHh21B/PNAHZ6f4V0+wn86C41p3xjE+s3ky/8AfLykfpVSbwTpc2oyXD3Wuh2hSPEetXkfCtIwyVlBPLnqT2xisEeDfHuOfileE+2iWf8A8TWTpfh7xm3jnWLC4+JOqOYdNspw6abaKp3zXAxsKFRxE4yACSy5JCBaAO2i8EaVExZbvxETjHzeIb9h+RmqX/hD9N/5+dd/8Hl7/wDHqi8S+FLrXJCU8V+ItLi+X93p0kEQyAedxiLc555xwPQVzj/CqZ+vxE8f/hqcY/lFQBhSeGrF/wBoWOx+0ayYF8LNMzDVrverG7UAeZ5m4AhT8ucHGccV6H/whel/8/XiD/wf33/x6vGW+G5l+OU2kN428bBh4cS6+3JqYW5P+ksnlbwn+r43bcdSTmu6i+D6p974g/EWT/e11v6KKAOtbwbpjDButex7a7fD/wBrVkePoNE06x8Nw6pJqrB9ZsrezVLyZ98/nI6eZl8Oo8vJL5xjI+bGc1fhJEGBPjr4gn2OvSc/pXIfEzwDbaMPB27xB4q1E3PiexhJvtZmk8tTvyUwRtb/AGh8w7Ec0Ae8+Wvq3/fRpkkCSRujGQKwKkrIynn0IOR9RXL/APCBab/0E/E//hQXv/x2tK28NWlvaiBLvWGQZ5k1O4dzk5+8Xz+tAHEeIfg98O47TUdU1fSbqULHJPczS6leSMRyzMf3pJ7k/U1Y/wCFG/DssWPh4kn/AKfrn/45TPi1oNtpvw/8RapaXevC9is38orrl4oViNoYIJdpIznBGCRg9TXRnwJpBOTeeJPw8R6gP/a9AHO/8KJ+G4BA8MxgNjcPtc+Gx6/vOadF8DPhtFKki+FrYshDANNKw49QXwR7GuiPgbSS+83fiPPXjxFqGPy8/FSDwZpYOftWv/8Ag+vv/j1AGFa/Bz4exxQEeE9MJREA3oWzgIBnJ5PyDJPXLE53Nm/b/C7wLbxiOLwlom0Y+9aIx6Y6kZ7VkfDnwnp+o/Drwvd3N54gaa50q1lkZddvowWaJGJAWYBeewAHbpW//wAIHpH/AD+eJP8Awo9R/wDj9AEo8BeEg0DDw1o+YCGjP2NPkICqCOPRFH4Vx/7MumWNn8INEu7Wxt7a5vUkknlSJUebE0mzewGWwpwM9uldbF4H0mKVJFu/ERZGDAN4h1BhkeoM2CPY1j/Azw9eeH/hvo0WrS3b6m9snnrNfSXCRgZ2KgZiqAKVGEAHHfFAHoFFFFABRRRQAUUUUAFFFFABRRRQBR16Ge40PUYLNnW6ktpEiZCAwcqQCM8ZzjrxXkvwK8M674fvo01vw9rmmiLTRA095r8d7bu4MeVSBWOzOCQegAI717RRQAUUUUAFczD4h1QmdW8K6tOI7iaJZYJ7QpIqyMqsN04PIAOCAQeK6avK/C3xNvbvRop38G+Jr15bq5QS2FvC8PFw6jDNIvAwBkgdCfegDgfBfhPTrr4u6vLpt3f6T420/VptauUvbKF1NpchT9mPl3DBsBshwQR5h4zjG9o/wpNgmn+Ir7WtV03WtL1SbVru8v8AyvImV8tOfLSdljVk2qWL5wnIxisfwd4muJ/izqfihPA2uGbUF1C3H2dYTJNFA1hCud8wUlHikDbeAZBgthiOp+LHiHVde8D3+iw+FvFWlnUZbSze7cWgCpNcQoyDFxyWWQpjplsMVGSADovAmqzal448X3ENpfTaVO1rJa3xkia3Zfs0ZAjIkJO4Pv4XGDyQTg99A7SRI7xPEzDJRyCV9jgkfkTXm/wK1t7/AMD6PZDQ9TtBZ6dZxSXU/kiKd/ssJBTbIWIKMhBKj0OGBA0vDXjO91f4m+L/AA1JpjR2eiRWpS4BTJeVWYh/n/iGCuF4CtuIJUUAdosrmQKbeUAoW3krgHj5euc/hjjrWDY6trVzrscVx4duLLTcXCGeW4hZyV8kxvtRzhXLTDHJHlgkDdWrLe3CajDbLpl5JDIpZrpWi8qMj+FgXD5PspHvXnU/jPXB8YU0pfDutvZx6M832NZrPc7G4VRPzMBtwpXlt3P3RySAJ8ebi8itvBLWOmXV9MniazlWGFkBcqJCFyzADPqeBgkkV6Jpt5eXGkQXV7pc9pePEHlszLG7RvjlAwbaeeAc4+lcZ4m1VtRvtBh1XwJ4jlMOprPaES2RXz0ikZXJW54AAY/NgZAHUgHbbxNqwRWHgfxGSc5UT6flfr/pWPyoAzfh1PrWk/DbRbLUvDOoRajptjDaNbJcWzmYxxhdyN5u3Bx/EQR+tYtp4u+JSSXjzfC9GDyq0aRa5bKyr5aAhieGbcG5+XjAwcZPSaH4t1HUdHsb1PBviBEuII5VDSWanDKCODcAjr0IB9QKy/C3iXV5Nb8WrL4a1+dU1RFSMz2h+zD7Fany+bjAySX+XI+fk53AAHPQ/FjxbN4uk8MR/DpW1yKz+3S2w16A+XFuCgswXaDlh8uc4IOMHNdC3izx1FaSXV54E02wt4keSWS88RRosaKASzMsTADG456AKc9q8+8Ka7av8eNb1q18P6m+o3zXumtGJrUOxgh03MfM+zKMspO0nIkHXawXuPipr2sz+ANXsrTwlqS3Goommp9rmtfLJuJFgwdlxuyfMwD6kZwM0AYeh+NfGniDxjoN1a+GtOhtrzw/Jfw20utMFZJJICrswgOGAwNu0/ePI6HSm+J+uaZ490jwz4h8LWVh/aBiU3qau0sUTS+aIkP7hcu5hcKuecdq4T4L6lrmm6xptlc6Jq+qXWi6RdaZKkc9o0gxfuq/M9yBtVYgm3HG3jKlTVv413+paha+NJLDw7qFvqdhpuj3kdyZLcyWhiubqXzSVmOMLvUbAWyWyNpBoA9p8bapdaL4K1/VbeKNrix0+4uY1LHBZI2YDjB6jtivmf4Xad4k8M/FD4feHNWsI4IYIZtRtYp74u8a3FkBMu3bmMCSKVthUAOzjLffr0z9qTxhrfhXwJF/YttcRx3szWlzdEIYxHJBKpTIbzFfJV1YDAKDJ52s/wAyPUP2mtMnu9G1CK9i8M+aiStD/ow86RTIxSUg/wCsaPADctnGPmABzH7UFxreo6bYaDqemaOtvLJfalaSx6hKzslrZzsS6GEYba6sAGI3KATg5HrTzfEQ+WEsfCS4QBy17cHc+TkgeUMDG3jJ78mvBNbvdX8UeN/inrF9YalLpWlaJqFrZQG7jdLB2ie3eQr5owHNrLlVVuTn0Y+4t8SHHhYeIx4P8SHRfsX9o/aQ9j/qPL8zdt+07vu84xn2oA5X4o6r8UtO8MXfkDwnF9u8vTrdLW5uFuzNO4iTyXbYocFwwJ6bSe1efePp/Hdt8O/HugX+o6DeaZpd7Ek6S3dzPexQzvFNGgkbl0HmbN0nzEI47CuvPjGL4nePdAbTNA8TPZ+Gnmvb7T3+zwt9q3iOASKbgbWRkmba2G4HylWJrM+LEk93N43jXwxqtnJqdtoH2gySWrEML+VFZts5+8FVBg9V+baPmIB9E23m/Z4vtPl+fsHmeXnbuxzjPOM1jatceJFe+TSdP0pwqZtZLi8dd7bf41EZ2/NxgE8c5BOBtxsXjRmRo2IBKNjK+xwSPyNYWra7qNjfPBa+FNa1GJQCLm1ls1jbIzwJJ0bjpyo/GgDg9BuPiAnxD183um+FZr46Xp+4Q6hcRRrH515swTAxLE+ZngAALjOTjozc/EneoGl+EAp5J/tK5O0c8f6jnse3Qj3rKsfEeqj4i65MPBfiBnfSrBDCJbDcgE14QxP2naQdxAAJI2nIGRno/wDhKNX/AOhE8Sf9/wDTv/kqgDKvG+KbY+xQ+CY+OfNlun/korK0WHx7J451kXeo+GIL4aXYFxHZTzRbfOvNuAZkYHg5J4PAHQk7+reOL3SNKvdS1DwT4khsrOF7ieTzbBtkaKWY4F0ScAHgAmuX+HHxFtfGvjLUdS0LRNWe0uNOsozJJJaqYQs14Nzr5xIBJPABbjJGCpIB3VjbeLQk4vtV0F32/umh02ZQG9WBuDkdeh5z2xyzxh4jh0XS9VaLU7GPUbCwk1R7VoxNMbePlnEPmoSDtKg5A3Ec9qbceI9ailKx+CtamUdHS6sgD/31OD/nvXz58YfFl5afE/WTe+HL+0l1LwPdaaIJri3LoGaaTzvkkZWUbDlc7sAkA4AIB2vhybxL4i+LsOuaXqOmJHe+Era5juJtHlKRwy3EjpE6rc4EvDEnfg7SAvBNelmy8bqCW8ReGgBySdBn4/8AJyvIPg54x1vRfhxY6le+GhJpFtZR2kep3Oq28C/u7mdNrtLINoBMaqMDkNzjaK6rx7498X2vgXVL+z8HtHBcWscdneWurRzSGW4CxxmNI1JYh5FxtPOMg8igDe8Pav4j1y00ua18U+GFl1Cxj1KKzk0WVbj7O4UhigvSQBuAJGRnjNc/8VrDxTJN4IiuNT0e5kfxJamIQ6XJFsdUlfe265O5QqsSowT2Pr5D8I/iDqOqfETwiNE0iO7uLXwsuifZH1FYgTExZpMlTgkRqduPTk459a+IOs+L5NT8FG48I2kLprqNCo1dW81/s1wNpPl/L8pY55+7jvkAHolpaeLUvEa81vQpbUZ3RxaPNG544wxumA5x/Cf61uxrOAfMkjY542xkYH/fRriR4o8VLfQWE+heGYtTmiMyWTeI285kHUhfs2SAeCRx71pXF34180/ZtF8OmLAx5mrzBs456Wx75x7enSgCl8ZLW9vPhtrdvYvb+fLGqASxlgcuoxwwwffP4Gp9f1vU9M8WeE9KW8sSurSSxSobCRmbyoWkZ1cSgIPlAwQx+bviuT+K1742XwNemfTNAt4/OtgZINVndxm4jAGPs65BPB56E9eh5/xxqHjf/hcXw5hktPDsV6f7Se2t4tTnaKQfZxkzHyQRgZ24VsnPTGaAPecSf3l/75/+vWR4msdZ1DS2t9C1mLSLtnU/ajZi4KqDkgKzBckDGTnAJ4zgjkrmX4uNK5trTwHHEcbFkurtyOOckRjPPsPxrlZfGfxSi+IUHg2SDwJHqk+n/wBopKZbryjH5hQqM4Yv8pOAOgJzwcAE/gLwj49l8BeG2s/iMdPtm0y1MdsuiW8pgXylwm8n5sDjJ69a3R4M+IeefircY/7AFp/hWF4DHxZbwP4dbTZ/An2E6dbm3+0RXZk8vyl27yGxuxjOOM10NtH8XmuIxc3XgGOEsod47a8dlXIyQpkAJAyQMjJ4yOtAElv4O8crOhuPifeyRBwWVNFs0JXuAdhwffH4VtfDvQta0HRIrfxB4lvNen8qJFaeGNBEFQAgFV3OSc5Z2YnA75LRCDx6t5NnUvC8loXAiP8AZ9wjhd8eS374gnZ5vAx8wTnBOLPw8n1288LaXe+I7izkubqygmMdvZvAYnZdzBt0jZ6qOAvKk45AUA6aiiigAooooAKKKKACiiigAooooAKKKKACiiigArzPwj4y8OeHvhJb63c31vFYxRTXHlfaE8x2LyP5ahm5kJVgEz1BHGOPTK+X9AvdR8TeDvB3wxj05dQhuTLda0003ltBYQaoYxtbcCW/dlTjnofXAB1PwivdE0PT/hhE+tWJW50HUB5stygLXU1xZStCCW5cMzjb975enWum+I+tWGreM/A/hmz1q2huDqi6pdbLuMfurdSViZd4ZjJI0YVQD9xmwQhqXxHoI0z4gfChdJtjFpWm/bdPX94W8qM2Z8tPmJJ/1PXk/Lyeea/wv8UaX8RfG2teKNHtdRWx0+0j0m3uLklY5GMjyS7EBI6CAlj8xBUEDHIBQ+AHjC0bwTq1trfiHT55NEv5rV7t71WRoEChJdzN9wgHDE4O04NeeeD/AI+eG7Px74z1iTTddmttbktJLWGCGOSRBFCIW3r5uASwGAOcYyTxj1Lwdc2XgLT/AIoajrEyRWVr4huNQkIkHIlt7eUKC20b2MgUL/eIAJ4J634XLs+GfhFNjx7dItBsf7y/uU4PA5/AUAecr+0n4Nlhiay0/wAR3kzbi1vBYqXjAC8tlwMEtjgnlTnHBPHX/wAcNCg+Ji+KbbR9WuEn8O/ZLeAGHcJPtLsRLtkbylyoBJyw67cYz9PVxFmjH416w4Vtg8PWQLY4BNzdYH6H8qAPLV/aXsJX0QyeF9VVnlc3scDxzsg8t9ohw6lznaSWCgAHgnGNsftHeHPtFpbnwz4xFxef8esX9nx77g7tuIx5uWOcjj0x1r13VLmO3vtHjkWNmuLpokLEZUiCV8rk5zhCOMnBPbJGjQB8/eFPjtFpvhjwpaar4V8ZXMsthDE989mD9rmCIu6Is+ZQzEndkHkHBzxl/Dz43agmreJJta8Ba+ov9Q+0FrGIyeU4ggiETBwgBCRqxOedw+UA5r2z4UsW+F3g5j1OjWZP/fhKf4RYNr/jUD+HV4wf/AC0P9aAPn7wl4g0nS/Euna9r8Gr6ZcSeLtTuxHPply7eTdWrqi7kBRjlIxtXceMjABNej/EH4g22o3fhjRtF0rWrv7Xqltd3UkmjXcawW1vPFIzgFFYneYhwCBn5sZAbpvi5pUWo6X4cuZWIbTfEel3ceDjLG5SLB9eJT/nisXwh4+03x18XLy38PQTXWn6Fp09vNqYYeS8ss0OFjwcMpELEMeu0445IBzPwlltrX42fEVbW31BbZN1y3m2UocNKwlbIIyMszlFKglRld3JBY66dY+HnxV8XSaXqumXWqWbyWUk1vMrPZrZ4tnUgsgwxlYlDxu3HAINWrHxLY+Dvib8atf1ZZ2srQaMXWBA0jFrcqqqCRyWZRyQOa7HSNBvtR+Adl4eMf2XUrnwylhsuQ0flStahMOMErhjzxkYPFAHn/iDUdH+Kviq4m1jStcuvBXhsSWbWsdjdeddak5w2Uiy22OMD7wRlaQ9QcVi/Fz4gvpnj3Qtb8NaN4is9YvtMvtGD3OlSRyXDMFNqsaSgBts5DHAzg4IOQD6j8L7q38I/D3SbfxjrWk2urXXm385kv0IdriaSUHeTh+GwWBIJU4JHNaknxL8HDxFFpv/AAkWkmQ2j3LTfa4/KRQ6qFL5xuOScA5wpJxxkA4rwl4uvtL8Dx6Z4r8J+KtV1K6e6e+NhpExifzppHIG/acYcDHboOBXk2j+M/F2u+DF8B2dtr0Nhpdo+lancWPh/wC23DMHmjEDK0qiNPJ8sE8OHUgcc19N/wDCwvBnmtH/AMJd4d8xSQV/tOHII68bqo6f41+HWnfaf7P8TeEbT7TM1zP5F/bR+bK2N0jYb5mOBljycUAcB4Q1+fTPiF411+HwV41aDXUspFhbSFhaN4UaNhlpAGzuVs8dWyOMnJ+LviK+Or2Wvx+HfEmn6Vb/AGSPWTfxIkLQJexSwtGPPCGVZAV552zMcgDNewf8LH8D/wDQ5eG//BpB/wDFVzfxE8V/DfxL4Ru9G1rxXo09heywQyLaanCZBmZNrcMcBWwxPQKCTwDQB6XC5khRyjRllDFHxlc9jjvXJa/41uNI1S8s4vB/inUktUV2ubG2haKQMM4QtKpYjkEAZB/DPSaNFHBo9jFBdy3sUcEapdSyCR51CgB2ccMW6k985rxn40eH9AeXxL4o/wCEy1K08S6TYO9jbR6rsWwn8pWxGmQVaVFVSufmDk4JIIAL2j/EWWbx14hvj4M8VwQppFkZVu4be2MKRy3ZMj+bOqhTv4IOfkfOAua6zRPH0+uaTZano/g/xDd2N3Cs8UqS2ABVs4BzcjnjkdR0ODkV8t/Fb4ww+IfGD6x4dbUbfRr3QJdKurO4uEj853W7RGeON3yEMu4buc/3QwY+jeC/i74c8A/B5NKsdQ0/UfEFjcXFva2KzuI5A12+xvNZcBAjbskjIHUZ4AO3+M3jx9M+GXiFdZ8L63psV9ZTWEU1xPYlTLLGyKNqXLM3XJ2qSACcYBrxrwrJ4u+DfjLxPcL4cnj0e5tJzaWtzfRSGBFS6nti6rMVOBbzbgDkDft5YBuq1H4n+FvGXxH8K65quvGw8KaXa/b4tLuIHkle/wDNnjUusO8KUWNZBuOQGXAw7Eafinxv8JfGPiXU4vFOoNe6SbOxaFRDdxjzo3vN3+rUMCFmHXg7hjOOACS18JeM761u7zX5/iOmu3Ymcpp2rWsNhbSSIQuyIXgZkiY5HzLuwMjBIrzT4ofD2/s73wUdZj8Yale3+oppt1f6pdwSSSo5XbBDtncJ1lIDsBljlsZx9JxfFjwjNGJILvU5oznDRaNeuODjqIaztb8a+Atck059Wh1a5bTrtL613aJqA8udAQr8Rc43Hg5GcHqBQB4V8HtL1fWPEGp6L4n0TWtS0vw2Bay6HZXMKQTStdzzK90slwiSbX34ADKwC54Hz+r6P4G8P6O9odN+F/i6BLS6W9hiGswtEs6lSJPLN+VJyidQc7RnpXG/Azxjpul/Ef4rXWonVDFe6sv2cR6ZdTMB51yQrKkZaM/MPlYKevHBx9H6XqltqdlHd2guPJkAZfNt5ImwRnlXUMOvcUAfIXg6G5+HPjXwvc6x4Z1uKUeI9Tt4SYolnvEmgiiiQAy4bDkHIPl8nazc112t+Lvipoepab4j+JfhS2TwxpmoJdsNPeJ3tyYZIMKFmJIPmk5YkZxyBxXrPxf0jUtbXwWNItppxZeJ7G9ugnGyCMvuY5xkDI4GT7VueMvF9n4XbTRdWWq3kl5LJHFFYWUk7syRPJjCjqduAOvU/dV2UA+T/iV4z1/xt4nHjbwfb3FjpnyeHbC4lu47edZmG98BZsh8y43D5dnXvX0v4A8S6zN4G8PSXXhvW765OnwebdJc2Ugnfy13SBjcZIY5OTzzzg1wfxR8X3HiA+EodH8IeNli0zXLHVLknQ50UwxqzNGBjlgxUYxtyuQSMGuN0v4oeJtJ+EmjeEvD2geJovGcjTW1pdTWavHtgnbzFQPuLlEAjKlRt55+UZAPYviTqeo6n4Wazk8HeIBHJfWO4iaz5UXcRIGy4LcgY7deSoyRxOt+Ib/Wf2jvDH2HRNRkOi2Uz3Vkk1o0sW+OVMsVmKjJeL5WYHoQORmv4r+OiR/Dq0u9b8GeII777TbpIZo/slq93DMGlRJBIZBtaGQD5TgqAw5NeYQeOJ9DuvF3jbQ9E1FotdjmU308vlvbi4uL1YXUrIcY8qJfu8NCwBXILgHr1l8eNRvXvfE1r4SvJPhzZbbWe7DxC+W6bZtIiMuCh82NcDP3t27qtcJ478Yt4w8QDxn4O0bW4rwLF4YsriaeO1ZLqaK8DxgCQkuGuLdgR0MZJIA59n+Hmr6n4e8EaBozeAvEaS2VhBFKYhZKjSBAHYZuAclgzHIB5yeTWd8S21/xWPCosPBmvRtpOv2mqy+fJZrvjiLblUi4PzENxnA9SOtAEvwp+IejWvwz8JLrDJo9sNMit4LrUb20hjungVYpBGPO3HDDuo4xnBIFYM/7T3hGKYxjTNZk4BzGIGH6Smsf9mv4batYpoviPxIt75VpDcf2dZXVxuS3EyW7LNFHnCFs3IYHHVPlBBNe5ahr2o2t5JDB4T1u8jXGJ4JbMI/GeA9wre3IHT8aAPGZf2q/CIUeVo+tu24DDJEvGRk539hk+/t1rt/2fPHH/Cb+AraTybrfpkcGnzXN1KHe5nSCMyOeSfvMeSec565A6dfEuqlgD4I8RAE4yZ9PwPf/AI+qqfB68kvfhl4aaSwubJU062jjE5jPnIIUxIux2wpzwG2txyooA7KiiigAooooAKKKKACiiigAooooAKKKKACiivn/AOM3jDXtN8VeJ4rLXp9Hi0TRINQsoYwgW6laYKxcMCXH8GBx+NAH0BXGeAvhx4W8GrJcaHo1ta311Eq3EwZpGboSFLk7VJ52rgcDjgV1Olzy3WmWdxcR+VPLCkjx/wBxioJHPoa4rwz8PLOHw3pMV/eeKI7xLSJZkPiK8BVwgDDEc2wc5+78vpxQBz/7SPhFPEvhTRbe2tLRZzrFtaG9eJWaziuH8lnUcbvmeP5c+h4Kgju9E8C+FNDs/s2k+HdJtojEsDlbVC0qAYAdiNz+5YknJzmq3/CAaV/0EPE//hR6h/8AHqUeAtJBGb7xMeMc+I9Q/P8A11AHikHgPwf4o+P3iLwve+G7aPTtKja/ItB9mRzLb2Kxxny9pwpE74Bxucnuc+2/8K48D/8AQm+G/wDwVwf/ABNYWg/DPQ7fXPEV55viJbi4uYlab+2b6J5US3iC5cSgygEvhiTgsyj7uBu/8IHpH/P54k/8KPUf/j9ACr8O/BKhgvg/w4AwwcaZByPT7tVIfhx4NXW57geHdFYi0igW1NlF5cKiSVtyptwCxc5OOdo9Ktf8IHpH/P54k/8ACj1H/wCP1zdz8KfC+p+K76TU7bXbsLY2yJJc6teOn+snyqyGXcTyMqSQuVIA3HIBb8R+CPCkWs+FVi8MaGiy6k6SBbCIB1+x3Jwfl5GQDj1AreXwD4OX7vhPw+Oc8abD/wDE1xus/B/wkmpaL9m0a/mjmvXW6kOq3rGNPs8zb8+bxlwi5/2sd60/+FM+B/8AoG3/AP4N73/47QBH8OPB3hnU/hZ4L/tLw5o15t0m2kH2ixikw7xIzsMqeWPJPc8mtay+HHgSOe/8nwn4fZpZR5ymxicKdifKAQQowFO0YGTuxkknkPBnwY8H3fgjQG1jRdQW9fT7driKbUbuNlk8tSwZBIApBzwAMdMDpV7Tfgz4L+1aqsljqrR/aw0ayaldoqZghB2ESjeCV5Y5OcrnCgAA0/it4Ci8R/D+XR/D+m6NDqFu0D6f9pgVYYPLkRiowp2gohTAHIODxV/4deBdJ8JeH9IiTR9Hh1uDT4bW8vbS2RXndUXeS+0MwZlzz14J5rM/4Uz4H/6Bt/8A+De9/wDjtNX4K+BFd3XSrwO+NzDVrwFsdM/veaAPMoPA+i6/+1l4ng17Sre7sYtPi1KGI7lQSgWyguowGyRISpyp3HINfQ/9l6f/AGb/AGd9htf7P8r7P9m8lfK8rbt2bMY244xjGOK8m0/4IeF38X+IHvtBuV0iS3to7V/7VuMzNiTzSxE289Y1w3GFGB1J1o/gL8N49wj8PyruG1tupXYyM5wf3vqB+VAHVTeAfB06wrP4T8PyLCnlxh9NhIRck7VyvAyScDuTXnX/AAg3hX/hfn2D/hF9D/s7/hGfP+z/ANnxeV5v2rbv27cbtvGeuK1/+FAfDPOf+EbbPTP9oXX/AMdrDj/Z/wDBbeNbsS+F1Ph/+z4TCx1CfcbrzJPMH+t3Y2eV149Oc0Aejp8PPBUZynhDw4p9tMgH/stTReBvCUM3mw+F9CjlyDvTT4QeOnO2uM/4Z8+GH/Qs/wDk/df/AByj/hnz4Yf9Cz/5P3X/AMcoA7V/BPhV3Z38M6GzMckmwiJJ9fu1gfEDwj4dbQrLboOlKU1HTYlK2kYKxm+hygO37pBYFehBI71k/wDDPnww/wChZ/8AJ+6/+OVR1j9nj4fy2ka6X4fjhuBcQMzSX9yQYhKhlX755aMOo9yOR1AB7HTHijc/Oit25GafXAeKfg74E8Va9dazr2hfa9Sudvmzfa54921Qi/KrgD5VA4HagCn4o8IeH/F3jjXbTxZZxXWnx6ZptyEa4aLa6SagN5KMDgK568dfTjzj4caULz9oDxPb6jrFtNo2mX761p1j9q3JPc3cfmJKiH5XCRF2yOVZgQcE12qfs7fDhdRnnbQ2a2eKNEtvtlwBG6lyz7vMydwZBg8DYMdTVj/hnz4Yf9Cz/wCT91/8coA67RPDXhjwje69rOnQw2E2qy/a9SuJLlysjAu2472KoMyOeMDn2FQ23iHQl8Wa051TTFMNpaRzS70XbmS5Co0meTuV/lzxzwM88v8A8M+fDD/oWf8Ayfuv/jlVof2dvhxHqVxcNojyW0kcax2zXk+2JlLbmDeZk7gy8EkDZxjJoA9F/wCEq8Pf9B7Sf/AyP/Go7jxj4Zt4jLceI9GijXGXe+iUDJwOS3rXFf8ACgPhl/0LC/8Agbc//HKsw/Az4bwoVTwtakHn55pXP5lzQBBpvibwdpPxP8TTDW/D9il3punvJJ9rhjE0wlvNxJyNzhTHk9cFfaunb4ieCV+94w8OD66nB/8AFVhW3wV8AQXN648N2Lw3UMURhkTcIyjOd6MfmVm3gEg8hF987n/CuPA//Qm+G/8AwVwf/E0AH/Cx/A//AEOXhv8A8GkH/wAVXG+LfHPg658e+BbiPxToUsNpcXckkiajEUizauoLENgZLYGfXiuy/wCFceB/+hN8N/8Agrg/+JqjefCjwPc6jp92fDGjRGzZ2EMVhCsU25SuJF2fMBnI9DzQBPffFHwJZWzzzeMNBZFwCIb6OV+SBwqEsevYcdeleV/DPxf8OvDereKdW1XxFoE2qanrN1d2t3HG7zR2khXZEXKAjG0naCVHFet/8K48D/8AQm+G/wDwVwf/ABNH/CuPA/8A0Jvhv/wVwf8AxNAHkWpeIvgRp93e6pDDoeq6jqt/E9z9pikueZJv3ko81WEYAd3IXaDtA/uiuQ8c+KPhfq2h+I/D+g6tYWenvpGm22mF7S4CJNBcXUj8+UzBtsq5YjLeYeSSxr6Guvhh4FuY1jk8H+H1UOkmY9PijOVYMBlVBxkDI6EZBBBIqb/hXHgf/oTfDf8A4K4P/iaAOX/4X/8ADL/oZ1/8Arn/AON00/tBfDEHH/CTf+SF1/8AG66r/hXHgf8A6E3w3/4K4P8A4mj/AIVx4H/6E3w3/wCCuD/4mgDjbD9ob4aS2NvJLr8ltI8as0MtjcF4yRyrFUK5HQ4JHoTU/wDw0H8MP+hm/wDJC6/+N101t8M/A8FvFCPCHh5xGgTdJpsLM2BjJJXk+9S/8K48D/8AQm+G/wDwVwf/ABNAHG3H7RXw1i3eXrk0+FLDy7GcZPHyjcg5P5cda1v2fvE+n+Jvhbov9med/wASq2g0u4Mibf30UEW7bzyPmHNbn/CuPA//AEJvhv8A8FcH/wATWp4Y8OaR4W0mPTPD+n29hZpj5IUC72Chd7nqzkKMsck45NAGtRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWbqmgaPq11b3Oq6Tp97cWxzBLc2ySPEc5+UsCV/CtKigAoorhPinfXNndeB0tLm5txc+I7eCXyZWj8xDFMSj4+8p2jKnjgelAHd0UUUAFFc18Tbmez+G3iy6s5pYLmDSbuSKWJyrxusLkMpHIIIBBFWvA7yy+CvD8lxPNcTPp9uzzTNueRjGuWY9yTyTQBt0UUUAFFcD8Bb671P4ReGrzUru4vLuaBmknuJGkkc+Y3JZiSa76gAoormPCF1Nc6740SaWV47fWEiiR2yI1+w2jYUZ4BZmbA7sT1JoA6eiiigAorzm1mlH7Q2oQCaXyD4YgcxbzsLC6lAO3pkAnn3Pqa9GoAKKK8t8QFv+GhPC+JJQBpcw2hyFwfMJ4zjkqpPrtX0GAD1KiiigAoryr4+/wDNOP8Asc9N/wDaleq0AFFFFABRXhnwG8W6PD42+IfhSe5EOtS+J9QvoInGBNGWCkIe7Dy2JXrjkZAbHr/irVx4f8L6xrLQmddOs5rsxBtpcRoX255xnGM0AalFc/8AD/xIvi/wXpGvJbta/boBI0LENsbJDDI6jIODwcYyAeKZ418aaL4MtLefXbiRPtDlY4oYmmkZVXdJJsUE7I0Bd2xgAepAIB0dFICGAKkEHkEd68l8YeLLnV9O+NHh2e3hSHQdHzDMhO6RZ7J3IYHjIYHkdiOOMkA9bork5/GenDSrifSJEvmsdXttEukG5BFNJcQwuMkclBMDxkEjGeuPJfGHxL8N+OfFvgW18O3d662fiGzl+1shhhmV1lXaocgk7lK/Mg7hTzyAfQ1FeDfGn4j6J4i+B+vnw7qjJqT2dpcSWgk8u5t4pbiNSJFB44yrAE8MP4XUnovA3xj8K6vcT6fayvBp1tPp+m2F1Izym7luYiUjIwWVlKOpLEj5clqAPV6K+bPg38Y/Dlpa+IbjUrq78zWvF7/Z4pdoe3guVHlPIWYKI18pg20ttwOMEZt6T8WvDuofGvXNdsNUuJNAtvDi24Dv5KXl0JfMVIkkZcyFWdVBAJIftyQD6IoryLx5470nVdF8ETade8ahrujtParKnnQJN+/iE6hjsBCKffHGRSeOfi74bk8MeN7TTdVaG5sbP7PbahDKPJnuJ7SWWIQSxsfmHlsMnb8wABJxQB69RXzz4K+Nel+HPhV4afVLu41TUIbq0stXkneUvaJcCWRZixRjLhIydqkntkdK67Q/ifpCS6jqSz32paZrHiW00vTHhUkKZrG2YDa5UooYOSMZBY8ZJoA9Yor5j8Q/F6fX/ih8LtO0u61LSZma2l1WGN/9HuBdxW8iR4BO8AOy5ZRgtkeo19A+Kmoa74I+I8OqSarp+qHT77WtCae2Fs401kKwMjJ/Er/xE5O4EM2CQAfQtFeK+IfEWs/8KU8CWOh3t6fGXiC301LG4Vi7eYqxTSyzMckxhVbeSGyG5BBONv4H+NH8Yafqt7dzu91PdJmHa6pA8dlZCeNFflVWZ349STznJAPT6KKKACiiigAooooAKKKKACiiigAooooAKKKKACvFtA1FvGXhr4c6m0s8kd54rvbuL7blnESDUJI1IVuCqogABKrtHBAwfaa+UfBHw81zxVqfjC10nxRrWg6foHiKe10do7yWWOEqbjzFCGQEHbLGC+ckM3Xc1AH1S1zAt3HatNELmRGkSIuA7IpUMwHUgF0BPbcPUVzfwqupr74Z+Fbq6uJbm4m0u2klmlkMju5jUsWY5JOc5zXL+Evgf4O8O21jJDa3g1iG3WKbULXUru2eZ9oDvhJRtDEZ2jjt2ryj4IeBdc8ZfCZ54PFnijw9dxajLFZTW17OtvJABFuPklgCN4n5Ur87NnOMAA93+MtzHa/Cbxe8rFVbSrmIEAnLPGUUcepYCrPwskeb4Y+EJJXZ5H0ezZnY5LEwpkk9zXm/i/4MeCfDnw61WPTbO7g3RQrPI2pThZ9sifNKnmrG3PPIAB5GMCsbwb8KNS8V/CXwaLnxh4j0pZ7UtqEEd9LKl5aScpEEMpjjAiwowpGD8ynpQB6n8atdbw38K/EupRSTxTLaGCKW3YrJHJKREjqRyCrODxjp1HWtnxl4u0PwXpC6n4mv1sbFpVhWQxu5ZyCQoVASThSenY15r8S/hF4Js/htrM8elXMh0bTLu40+ObU7uSO2cRFvkRpSoBKqSAOcDNYfh74VR+NNP8D6hr3iXWdX0uTS4tQ1XSdR1WaYSSywYieMBgYxuaXJzyF2jq1ABYT614W+D3wds455rCe81/T7e5WKTBkgleSTYSOzDbkfge4r6Dr5Z8cfDsaZ8CrHxVaeJvFM13YWVlfWdjcaoTaWshEah4lwChQOxTDcEAcjg99oHwq8Q6d43thqvjbxXrPhj7A7uH1eaBxdgxrhijhijAuygH5SuCT/ABAHWeMfEeoab8Ufh7olpMUstXbUDdptU+YIbfcgyQSPmIOQR0wc5q34BmWfXfHroCANeCc+q2Nop/UV4v8AGH4az+HX8H32l+M/GV3q91rcWlW9xqGq+YbZbhHVzGwUFCdqg4PI454xrfDbwNqV1438Y20viDX5/C9ncS2yXh1ueO9nvTHbgs5icKwjVGUFgPvgENjCgHrN5qjf8LT0jSY7iQJ/Y17dTQDIQnz7VY3PYkfvQO4yfXnqq+Y/Hfw5v9E+J/gix0Lxh4ynvNf8+1vL241TdcRWsLRSsscgCkDDOcHIz2PQ+g/Dj4Z6zYxaqPHnifxBrF0Lry7KaHW7uBDbKi7W2RyKQ7EncCW5UYJ5ZgCDwa11eftMfEGWVy9tY6dZWqBn5QOiSBVHpnzCfc+9exV856Z4T0mT9ovWvD9lqXiGIp4ZVru9TV7hbqS58yMLK0gfLERumFb5Mj7uMV3GgfB2C10dv7Z8VeKb7xJLH5UmtxatcQzKgbcI0G8rsBzwwblmPcAAD/g346uPGviDxzuuZJ9P0/URBY5VEQRYYcAKGySpJLMc5GAuCDT1u1d/2kbXVZp2i07RvC7XM5xuGXmlXGOoOAxyAfuY7ivPNI+FUtn4r+JOjeDtd8SaS+lWVlLpkFhqZhW6ne2c5nJ65lQn+EDccYGMbFj8KX1Hxg2g6/4r8Vvep4ZtjqFzb6sz/anlmuFljbzFbMXGFXAAAyQWJNAHpPwF8Q6n4q+E+h6zrtz9q1K58/zZvLVN22eRF4UBRhVA4Hat/wCIWoXWkeAfEupafL5N7Z6Zc3EEm0NskSJmU4IIOCBwQRXzdp/hPxtd6b4yHw4v7+20/Rdbn0jTtFj1WWFBGvmiWQMWBLh5Y5Fy4HytuDYAPpnxa+G1uvgzxNqdp4p8Z20dtpNxIbAa3LNbylImbDiXexDYwRuAI44yaAN/4v6Rea5qXw+tbFP9R4lt7+WRlbYkcEcsjZYZwSAQMjBJAyKn+PGtXXh74X6pqdhfSWFzDNabZ4zhlBuYg2OuflLZGDkZrwmy8La54w0z4caq3izxJG3iDU7gT2U2qSPHb26ibmFskq/2dHT5txYyHJHOfSvi58KNFfwVrOoHU/EjWulaXPcQaXLq809oZYopCkhWQs2RxwGAwo465APa65X4jeOdJ8CeH59Q1S4h+1NG5srIviS8lA4jQAE8sVBbBC7gTxWr4Ttr2z8K6NbarLJNqMNlDHcyytud5QgDsxyckkEk5P1Neb6rfaVqn7QZj1m4sDY+GNBN0i3m2P7PcySB2mUvjcFijQlxlVzyQaAOX8AfBV7j4farf+Jo9vxB1G5uL6LUGkkhlsbob1jPmRtyA5MhIGG3Dhtqmt7WvEvjS8+Gl5oniPwFrieINUspNMjn0+W2uYGmkhKCWQpIDChYkkkbVH8RrsvhJrtvr3haaaHVk1SWPUb5JJfOSRlH2qUxg7GIA2bNuDgrtI4xXa0AcT8MhY6L4GulzBY6bY6lqoy77Y4Yo7645LE8AAckntXKeGLbTfi14m1fxNqek3M3hiK0Ol6HPNcPGJ0fz4ryRYlcFN4ZUywDbVXoQQPO/G/xd0i08NeLPAFrFqFlqtxqt9Yy308SPaxJPfSmRmbcGA8t5CPlOOOTjNfRVnrvhy11SLw3Z6ppEOowoIo9LiuI1ljVU3BViByAEGcAcDnpQB53Zw+MPht4imstM0vU/E/w7js/Mt44pIWu9MK7z5EQdxJcKAFAByQpRVJKENxV3f6hY2Px11nxdYy6MuraVbPaQSlXkEckdza2+8RltrsVQEE8HOcDmvpSvmz9pPxVo+k+INY8Pa1Fct/bum6RtdFzGkcF/cPLvIIYZU8bQTn0oApX+g6/8Lm0NryO9ufDOpSaXdeINQnu/OFvqa36TzXD9SF2J5e4AA/JuJYDPiOl2Wr+FdQ0Y29nd3eoG50jV9OtxGS1whjkmAjAzuG9ivGecjGcivqz9ojWtN1r9n/xPd6HqVnqFtut4zNZzrKmftMOV3KSM4PT3ri9QudEs/2m/hiuk3dumgjw/HDZN537tl23UcKhmPJO4KM8knHU0AeKa9p91Z6DretWWnX0ukanpFjYz3ccBeKG4EenXDl23fJufIGRgkgLnnazwbDrnhnVLLSo9Fv7/U11DTPEUdjawF3mjhieUDIyVys2PutyCOCMHufA00Nx+yb42iv7l3RdbtllPmZdYd9koPfA2qQOo+XjOK7vTNf8NaL+1Nqd5fappdppU+gRCyuJJESAMyQFdkn3QDGhwc4I4HXkA+Z4PDGrD4eR+LNO+0vp8eptaXTR8C3lRI2ic4OefNYBsYB46sM9FfeB9S8PWF3pDWOoS+MBrUcdrZ26GUvFDbvK7qq5Df62Fu/GemTXffBzxH4d0v4EXttrep2MLp4ps7qa0llUyyW6zWhdhFyzrsV84Bztb0Namh+K/CV3+1xfeIbrWLcaVLaJJp96ZljgErWcSnzGbG35PMXBwQ+FPPFAHmOrySap4du5F07UYrN/7Pg+3GIKsVzp2lOkkJOcgln3DODhD3ztxdW0+/8AD+meI/Bl9Y3h1iPU4bpkWEkeVbQXO9+udu2VXBwQUBbIA57oT6DJ+y7o9pZalFbagniHzdUiSRhJl1ljyV67TCU5UFTtI5O6u28bNpVz8ZviNefa7aRLrwXc3Fi6TjE7taIMpg4kzErnjI2jPbNAHiPirw/qsGh/b9Lgv7vw28Onm5u428yGO5WygJSTYMKVa5KKWx94qCSGrsTpniXQb6DwtptlqWq6r4Y12XWJ7SDl5oYxZR28ihct90tjAO1Xz2OOo+FM2lD9mfWT4hcro58U2i3g3MMwCSy8wfL8x+QMcL83HHSu98O+KvCGi/tK+O7rW9TtLW7v7axj068llKwNEbVHkHmZ2DdtiILdcYB5wQD581LS5tWfwvrXhWS6n1S6lg0mL96IzFNBZWEaMrggqRNMQCTgbV6c19j6p8KdA1nwvoGjaubyUaTZxWAmt53t2uIE8vdHIFOGRzEmQckdVIPNfMvwy8Q+GNG8C+HZZ72K3uLS/e41BZ5FLhhqOlvvijGXYeREegyfLlx0r6f0H4ueBNY0W01JPE+k2a3CBvs97dxwzxHOCrozZBB78g9QSMGgDg/g3Bc+IvE3h65vrcx2HhHwzYWtmJE+/dXVrE8kqtx0jAjKnI5yMZNeleHPBWm6P4u17X4Ygt5f3Dugjd1jiSSK3Ev7sHZveSAOz7dx4yTivBvgf8bNJ0K3vtI8aS3C61d6vDC0yRosCIIIrcSO5Kqqr5A3ccBgQDzj3/wx448NeJdX1LTtC1mxvruzIZ0gnV9yFEO9CCdyguFJHRuDzQB09FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXO6noeoXN7oEsPiLUoUsLl5bhAkOL1TG6hZMIBwWBGBjrxu2svRV8xR/Gzxy66feXOg6hFp9xcs1tND4WmZbm28h3VwTd4LHaWKKcBFL7yAVIB9N7G/wCejfp/hSFGIwJXHuAP8K8L0j4k+P8AWpLaTS/D2ovp8kQkM83hgwklnjWPYH1AKykOSW3fKADgjcVv+HfFPxev9HtbnVPCNva3Ez7ysVrEwWEoCpKyX8bh92QUYLgHOcqVIB1vxot2m+HWoR/2ne2IaW3QzW23eczxrjJHGSRyP16GHU/hvdajc+dP8QPHEbbQu23vYIF4AGdqQgZ49K8v+JHiT4vt4dlXUvBWjjShcxGVpZEUnE0Zi/1d2SMvtBA6evUjZtNR+P8AYaVYQ/2D4UvpEVYXeWZjMdqL+8kPnKpJJIO3urcAYJAOs/4VPL/0UT4hf+DVP/jVNT4RKszzHx74+aV1VC/9rKCQMkDIjGQNx/M1kax4a+MWvrGbrxP4b0Ngr2rjSI7gh4ZdvmSEyHiVNgMZXB+ZvmXNRXvwl8aapplvput/FC51DToAu2F9L8pmZFIjdpY5lkdlYhxuY5ZFLbsUAHgv4WRat4C8PzXPjPxqsdzp1tK1vHqgESZjVtqqUOFB6DtgV0P/AAqj/qffH/8A4Of/ALCuE0n4Y+NvFfw08P2knxRurXSJtOt3S1g0pIyImhAETSJIrSKFbBDEhsZIzW/o/wAMfiNpEHk2vxhvpEznN3pCXTd/4pZWPf19PQUAas/wdtbiSGS48a+PJZIXMkTvrJzG5UruX5flO1mXIxwzDua574bfDtbkeK4r3xL4sEttr08KzQa3OjSRhYipkwQGcrwWxnB68AiPVfgz441aeCW/+L2rM0E73EZhsTAUdxtYrsmGPlJAA4AZgAMnPD/Dz4TeKtY/4Sb7B8Utd037FrdzZzeUsv8ApMqbd07YnHzNnnOTx1NAHtkXwr0xZxPL4g8YzXChlSWTXrneiMVLICGHykqpPrgZ6CpovhnYoG3eI/GcmWJG7xDdcD0GHHA/OvN3+A/jJ7mO4b4x+IDPGhjSTy5tyq20sAftHAJVSfXaPSups/APxLtLWGCP4uyskUYiQy+H4JHwMDLMzkseOWYknnJyaAKXg3wjby/Ff4gRvea8kVqNNSKVNUuVMn+ikHewf94R8p+bJH0JB9ggtY4Io40aYrGgQF5nckD1JJJPuck14JcfBTxrqeuX+pXXxZ1SG9LhPNs7VoNw8qIElI5VVSdiAgddiknPTqz4F+Jp/wCaut/4Tlt/8VQB23jbVLfwv4U13xCY4jNZWLyjzJNnmlFYxxluvLHAHq3HJrCvvCC6t8Ub/Ur06jFZLo9rbxyWmoXFqWkE9yzKTFIu7AZeDnGRjHfxz4vfDfxroXgLxLrF78S9U1uOZVFxp81uUhlV50yFBlZYsHB+VRwCowCRXoI8EfFFvEN9MPin5MDwQ7GXQ4GXO+UlBEWIXaCvz5JbcAfuCgD0vR/D+n6PAsOnrcxxK7ybWu5ZMs7s7sdzHJLOxJOSSfYYsT6XaXEFzBco88Fyhjlilld0dTnK7SSMHcQR6cdAK+evEfh3x94Bl8KWcHxWvdRk1LW4rZIbq0V5AHUo0h3ys8sa5XMedoLBuCAa7jUfBHxPurG6th8UotskDxq6aHFC7MwYffR8x44wy8jrjgZALfjnw/p58a/Dq0iS8ghF1cxKttfTwrFGllNhUCOAvO0ZAzgYzgkHrT4P0wj/AI+dd/8AB7e//Hq+fNV074j6R8WfCngyx8awate2tlLqVtf6lZ7SgfzY3Vzl2chVOCT1bHAFdhqnhr463lo1q3jDw/HFdgQzSWsJjkt1PDNG3lg5xnnIPTGDyAD3KGMQwpGhYqihQXYscD1JySfc8151rHwc8LeIPFuseIPEkE2o3l8yLEBcTQC2iWFYzGPLcbtxDkk/38Y4JPf6Yt2mnWq6lJDLfCJBcPCpWNpMDcVBJIBOcAnpVmgDxv4Q/D/w7P4budWhtrywvb3UL5bg6ZqV1Yo6x3k6RrshkVQFXgDHAro/FHwt0fWdEvLaK61pb1on+yT3Gt30628+1hHLtaYglSc/n61a+C6hfh7Z4zzdXrHJzkm7mJP5mu3oA+avA3w/8bar8RL688aeHrWx0LU0SXVGa4i33Mq2M1owQQOdvmNcyyHgezAjDenj4JfDsWK2o8NQBVuPtQmFxMLjzMY/12/zMd9u7bnnGea9GooA4m/+F/hjUIliv01q6jVt6pNr1+4DYxkAzdccZrxDxF8C9V1D4viFdPlHw92KonfUGmeKMRF2iAeXzADOXboQC+4ggYr6lps3+pf/AHTQB4l8V/gfoN74K1aPwZoIi1ueeOaCGK9kigVmlj8xhEZBEv7sNwF6AAcgV59qnwe0iy/aJ0LR7jRpI/Bl/bzG0hN47b2igLuAwk8xQJHVuSMknGRmvrCvMvHQz8cPhdwDiLVj9P3EVAHlHhz4DWem/C+xbxXopk8Sz6vZidEu5CI4Hu44yrCOTYf3bSHcBkBzyCM1paL+z5pf/C4fEB1Lw2v/AAgX2NBp6m+fJnxDuIxJ5vUTfe4547V9B63qMGl2cdxdb/Le5t7YbRk75ZkiX8NzjPtV+gD5L8HfBCC98BeCb9dBS519PEQTXC92Cq2cVxNHKhUvsYDYudoLHnGea0LP4H+GNQ8f/EmztNOlNtpdpDFplgJnAWeW2V1kEhkySHDDa/y/N6dPbfgyc+A4z66lqR/8n56r+CoivxT+I8vlYV5dPUSZ+9i2HGM9s+g698cAHhI+B1npvgn4dx61oKx+JrzxBDbav/pxw9qXmZl4k2A+Wqfc+bjjk86WvfCHQ7O5+LM91oN5Hpmj6RFN4elluLjy4z9lleXy2L/OBKMlSSBnoAefa/ia6re+CFPV/EUCr7nyZz/IGtP4mhD8NvFglZljOk3e5lXcQPJfJAyMn2yKAPmXwn8CJ7jwH4VutV8Lzf2zN4hgOpB7kq39lt9/KBwF6jOAHHtXaeGPgX4SvfHfxAtr3w8x0Kzks7fS8XkoMchthJMAfM3HmSM/Nkc4HQgfQ1n/AMekHX7i9RjtWB4VkL674yUsxEerRqAXyB/oNocAdhz046k96APmyy+CF5omrfCZLfSoZNdW4fUNfP2gMvkx3FucEM2w7Fl2kJ94/wB7rX0X4q+H3hrxHDqkl5omlNqd/bvA1/JZo8ykx7A27hsqAMYYHjgipdQI/wCFmaAOc/2RqPf/AKbWPaunoA5Pwl4PtdP+HemeGtetrPUgkC/bknU3EVxcFvMkc+YCWzKWfJHXnA6DQ8PeFdB8PzXL6HpFjYGSRnIt4QgUukSuFA4QMIYshcAlASCea3K53wlrI1e+8TRqpA0/VGs8lickQQsSM9OXPHTj8SAdFRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHj/7RnjfWfC3h1bfw4bm0u5YnuJNRW0eZIUTGI8hSqu7EDLYAUN3xXEeNviDr0n9oXVl4gu9LTTPDVpqlpH5Sx/bJ3kCu0iyLlhnK7eB3r6P1CytdRs5bPULaC7tJl2yQTxiRHHoyngj61SvvDmh6hLZyX+jabdSWYAtmmtUcwAdNhI+Xp2xQBb0ueW60yzuLiPyp5YUkeP+4xUEjn0NZd9qeqLd6AtroV08N1KTes8sINknlMRuHmfM28qPk3DAc5+7neryi8+Kk8ms6FbweCfGMaTzyB/PsRCzbYXOFBf5jnB5IGAepxQB6rvb/nm36f40b2/55t+n+NcJB8R5Z5pI18D+NVZOpfT0VT9CZMGrH/CeXH/QleLv/ASH/wCO0AW/iPDLeeF2t00q71IPdWrPb28kSOyrPG5wXdR0X1Gc9uolv/EOr29xst/B2s3Ue0HzEuLNRn0w04PH+fWsLVviILa1je88HeLY42uIIlJtYh87yoqD/W92ZR+NXf8AhPLj/oSvF3/gJD/8doAmfxRr4UlfAWuk+n2uwH/txVY+LPFOePhzrOP+wjY//Hqt2HjK4vLoQ/8ACI+J4MqW3z28KIMDPXzevtWkuuXTXd5bjw9rGbeN3Vz5AScrjCI3m43NnjdgdckYNAHJaF4l8XWeg6fbS/DW+SaG2jjZLa/skhVgoBCAzZCZHGecYqW+8YeN0KfYfhjqEwI+bztYsosH2w7Z/Sux8P6i2p6HYXwsby0FxCkoguQqyoCMgMAxwcds8d6tzTyRwyOlrNKyAkRoU3P7DLAc+5FAHng8YfEQ/wDNLmGfXxBbcfp/nB/Hi/hjrvjrTk8UvZfD8Xq3mv3lzJ/xOoI/JkLKrRcj5tpX7w4Oa9dm1/Uo7eORPCOuSuxYGJJbLcmMYJzcAc5OME/dOccZ5HwHrl/aabqRtfBHiKUT6tfzO4msh85uZAwIe6zkEbePlO3IyDkgEjeLviRn5PhfFjH8XiKAHr7If8ip7fxN8RZZEV/h1YQA9Wk8RIQvHfbCT+VbX/CUav8A9CJ4k/7/AOnf/JVH/CUav/0IniT/AL/6d/8AJVAGLa698Rxc6kJvBGjNGkv+j7dd270ESnGfJO4lgwBITqBjALnRg1fx1LGrSeEdFhJRW2PrzEgkcqcWxGR0649DVnxDrF5pfw+8ReIIbO4stQgsbm9S1vmSQxSRxHaCI3Zdp2A4Vu56EmvMPBXxf1ibQNd1fXfsN9plhosOpfbLW1kt1junX/jzO5iHbJA3Aj9eADW+O3inxToHw51uaXQdHFrKotvOXU5JXCu20sI/JTLbcnhvl68hSD1f2/4gtrc6JoHhxbJbaEqz6tLzKWk3gMIMkABOqL14LZITwDxd491r4g/De80TVrCO51myvmM8+mTxLalDZTyxkkyhsjYzHgr+7xy2FPuXw08W6lrw01r7R9WD3Oi2N1JeSyWwhYush8wIkm4byDjC9hkLgZAPKv2jNb8X6P4h8J6xLpmkw/2T9ov4TBevOrBZbdW8wNHGcfOowufvk8bRXuVzd+MxM/2TR/D7Q5+UzarMjH6gW7Afma4b41XEdzf3NkdF1i6uo/DeplZ7Rrd1jik8lXYxtMrNjaBjHOTtDYO3uv8AhJdV8t2/4QnxDlWChPOsMsDnkf6TjAwOpB5HB5wAePeKW8Tr+014bvodN0n7X/Zv2VImv5BGUdbx13sIiVb91JwFYZUc85HrZu/HmONE8MZ/7DE//wAi14Z+09qslt4mjaLRb6K5OlTRNcu6eXNG8VxCAAJOqfaJPfL8gjAP0nZXstzp0d09hdQSOm/7PI0RkHsSrlc/Rse9AE9m07WkDXkcUV0UUypE5dFfHzBWIUsAc4JAz6DpWNq1r4olvnfSNY0W1syBsiutJlnkHHOXW5QHnP8ACPx61t28jS28cjxPC7qGMUhUshI+6dpIyOnBI9CaxtU1zULO+kgtvC2s6hEoBFzbS2ixvkZ4Ek6Nx05Ue2aAPALm68RXXwL0uxsNX0xbXxPqT6RbQwabOJAZ7qXeTM1wcJtWQ8oTj5T3avXfCdz438QeFdG1n+2/Ddv/AGjZQ3nk/wBiTv5fmIH27vtYzjOM4GfSvKPhhJrMlt8KtNOg6i9jYLqWqsPMtdlwd2yORcy5AT7VyCAcsMBgCR6J8DbjXNN+F+n6brGj6hLfaWs1qT9ot38zy5HCxr+9OCqhUw23BGOmDQB1H2Hxx/0MPhv/AMEM/wD8mVDeReMbO0nurrxL4Zit4EaSSRtBnwqqMkn/AEzsBUsnibXFcgeBtccD+JbqxwfzuK5b4neItcn+HHimF/BOsQRy6XdRvNLd2WyJTCwLttnJIA5wATxQBD8PvE/jnxck3m3OjaU4t4b6AT6O0gntZ2k8iUGO/O0sIiSpxtPGW61e+Is3jjRfAXiHUh4g0RjbWE0g+zaJKkoIQ8qxu2CkdclWxjOD0OZpGs6po3irUbLQ/h7qu210TTreG2a+tFaOJHvBGGYzsu3qBjLcMWz8uanxd8S+J734deI7S78A6jZ2c9k0bXUmoWb+WWIGSiyEkYOeOc4GO4AO6WLxi11Jar4o8LNcxosjxDRJi6oxYKxH2zIBKOAe+0+hrg/GVp4qHxg+HS3GtaG960Wp/ZpY9HlWOPEUe/ehuiWyMYwy4I53Z45jS/G3i+f4/eIJE8DNPqUGkJZppq6jCkkUSvHLveUuUJPng4X+8o6hib8PjHxf4w8b6brujfD2aUeGJtQ0q7gbVbUE3DCEOoZ+m3b95eucZxuBAO18e2fjCLw/a/a9f0GZf7V0xR5eiyo2830AViTdEEBsEgAZGQCucjsbe08SiZjcazpTxYwix6W6MDxyxM5B79AOteX+OvFvjy40izju/hpLaQf2ppz+a2uWz/Ot7A0aYXn52ATPRd2TwDW8/jT4k7kEfwnbB+8X8RWoA/IGgCL4Fx6xc/DS2mi1a2KS3188TPp5R8fa5c7180jJbccDGAwXkjccjw3ofjafxn46hs/G9hBdrd2pnm/sNXz/AKOCqqpmwoCsoOdxO0HIyc4PwT8VePrX4c6XBpPw9Gr2PmXLpqD67DD5pa5kZsoylgQxYc9due9dJ4Wv/iPaeK/EN5L8PbRItYvYJGaTXogLcLBFESSqMXGE3cKDyQAaAG+MvCvxBlm8LxSeNrO8kXV1dJF0WKIxEQyHzCDNhwoVvlAyd564GH+PvDXj2HwJ4kl1D4hW1xZJpty08KaBGjSRiJtyhhL8pIyM9s1q3Xif4mNqFnHF8ONPWFbkiSVtfjYMmxxlT5YK87TnaxxkbcnK1fiprnjMeGvF9h/wh1kNG/su8B1X+2Vx5fkOd3leVv3dtvTP8WPmoA0h4U+I4jCL8SbMYGAR4ci9Ov8ArcVieHfDHj1tY8TiH4g20LjUUFw66DGTK/2S2+YZkwvy7VxyMrnviuzttZ8aP4ijsrnwjp0WmYUyakmtb1GQCwWPyQ7EEkDIUHHUZrCt9a8Q6PceK7oaPpM8kuv2tsIzqroo82C0hQ7jAf7yEjGeWA3YG4Aw7/w14+Hj3Q7d/iFAb06ZfSR3K6DEAqLNZ70ZPMIO4lORgjacdeN8eDfiESS/xTn+iaDaAdvXPvUMviK8u/2gNP0OKysi2n6BcT3EovSSqzzW+RtEf3lMK8EjKvuyMAHuvEMmupYqfDtrpk955i5F/cyRR7MjdykbHJGQOOCQecYIBy0HhDxmrQGf4l6lIFdjKE0myXeuBtC/uztIO7JOc5HAxznfBvStSstX8Zy3/iC81GIazPF5MsEEas2yE+axRAd+MLgEL1O3PI3tdm+IRW3Gg2HhRW8gec17e3BAmO3IULEPkGHHJycqflwQ3NfBQeLl1jxf/wAJJDoa2bapKztZPNv+07Is7Q64MW3GDkHcDwc8AHq9FFFABRRRQAUUUUAFFFFABRRRQAUVkeL5Yo/DGpie+tbAS28kKXF1II40dlKqSSR3Ir5x+HXhK4u/F+j3mgWVjo9zpf2drr7P4mF+14BPGJpAiu22MxeYu045kXpjNAH1LRRRQAV5b4q8X+GZ/HXge5h8R6I8MFxdmR11CIhA1s4BPzdM4GfcetepV554k0PQv+FheDbY6RaKxW9mXZBGEO2JVwwxz/rMj3FAHQ/8Jz4T/wCho0L/AMGEP/xVI3jrwiuN3inQRk4GdQh5P/fVfM3wn8M+J7/wLD4n0iyZwuj6gGkurn7V/aNzvkWExwsSEZCoGcDOO+TnW0nQfBuufDLVIfCmo6nJ41TQWub1XnnLpPG0bvuDfKj712DbjKs3UZNAHtviH4leD7PT4Zk8RaDebrq2Ty01CFsK88amT7x4QMXJ7BScjrV//hY/gf8A6HLw3/4NIP8A4qvlfUdR1PXore7SD7JaePbq2stMMShBZS21zAu9MfcLHzDkYz/L7Bi0TS4okjXT7TaihRmFScD1OKAMZfiN4IZgF8Y+GyTwANUg/wDiqB8RvBBPHjHw2e/GqQf/ABVbqaVp0bq6WForqQysIVBBHQjio5rTS9OtZ7l7O1hhhjZ5GSAcIAc8AZPGeKAIPCmraZq3hrS7/R5o2064to3gwRwm0YBHYjoR2IIrW82P++v51Q8NSWUvhzSpNKjSLT3tImto0TYqRFBsAXAwAMcYGK0aAG+bH/fX865rwFrGgavo1zdeG5oGtTf3QlKSq+ZvOYuxIY8NkOvPKOhGARXT1x/wnk83we8gVl3apqZwwwQft9x196AJ7r4g+ErSa3in8Q6crzsFQeaDgnH3iPu/eH3sfoapf8LV8EbVP/CR2XzZwPmzxjPGOOo/X0NdtRQBz8l7pfi3w1stYX1fRNWSW0meBwi+Ud0bkksrY4Zfly3p61W1HwzpF34cj8PXOh3Fxo2mRQG1txPhZvKH7uMHzAW27Fz5mFJIyTzi34buLibWfFUc8sjxwakkcCseET7HbMQvtuZz9Sa3qAPBPi5L4H8P38Al0620zxDq9jJHOHgkb7NC1pdBH2x7ot4kGwsuWwzc7eaf8JfiF4as9P03z724/deGdItH2WM7gSR/aA4+VDnB4z0ODgnBr1Dxe2PEPgcY66xIOuP+YfefnXnH7NmravqH9p2mvaamn3GlafZadEE3BZYoZryINhiWUhkdCD3ToM4ABleN/iLo8vjPXbywu7grD4Puo4DHaXMU3ntIW4bZ8gAjB3nAB5zxx6f/AMLR8J/8/wBef+Cy6/8AjdZnxJbTxZ/ECVLeX+17XwmxeYuQphcXRVQM9d0TEnHce9dZ4H8R23i7wjpWvWShIb+BZfLDbvLboyZ7lWBXPtQB8pftK+INK8ReK7i70uO4uoYdGt1mka3ki2KLt8/K4UgZdBuxjJxnJAr6T+E/ie2134d6HdxyX1xJHYQpcSy2swLyrGokwzL+8+bPKkgnOCa8g/aQ0tdR8Y3UYaSaafStOh+yW8jGSVDqLKysi8lS0iYP94DHOM+ofAwwWfhfVPD1pBcxW/h3WLzS42uJhK8qK/mI2QBgbZVGO2KAPQbaZbi3imjEgSRA6iSNkYAjPKsAVPsQCO9Y7a9MPEVzpSaFrDrDb+eL4Rxi2l6fu1cuCXzxggdOuOa3KwdU8Y+GNJv5LLVfEei2V7GAXt7m+ijkUEZBKswIyCDQB5Z8GtUnn1Pwdp02halBLZ+GZrhrlpIjEI7m4jMeQCTlvs5wCQwwQV6lek+EN60fiD4g6NJY6hayWutm9EVzLHIES5iSTClXYDLCR8dAJB33AZ3g7xp4FtvFd4+m+IdBtdIGg6ZDahruOJV2yXhKbWIKsA0e5ThhkZAqXw94i8JaV8VvGV+fFOjCLV7PTbhWe/iCNIoniIU7sE7UjJA/vL60AeqGVxIqiCUg9WBXA+vOa83+Onia50j4feI4T4d1K5tbizNobxZbdYVM+IhnMvmDmQDIQ8+2TXWXnjfwtZWcF1deItIjtp+YZTeR7ZOv3TnB6HpXH/GfWdEV/CNhquu6dY2kutQ3V2k8yYkggjlmwVP8JkjiXPqwHfBAKB1fxBB8bU1E+GNfjsb3w89uLHz7LdLJBcq3m8XG3AFxtGSD85wCMkT/ABk8R6i3w316KfwjrtvC8IQ3EktkUTLgAkLcFsdOinGecc4g8U/ED4fXXinwfrK+I9Kmm027uVaVLwAwxSWkxYlf4gWjjXGM7imOSAaPxh+JngPV/Ad/psPiPT7uSeS2JhhkZiyrcRs3K9PlBPXPFAGf4fub6H9oXxBrUHhrXJpLi2ltZrUNZhoWWLTju3faNpG0qcZz8wxnDBM/9m7xreXdhr00HhvU79tV1rUNSaW0aFUQkWxKfvZVwf3g6np03Yba/Rfi14Fg+KGq6pdaikEUtxdxLdGR3UqIrCNSFQEbZDE2Cf8AnkTxuwOM+Anjjwh4Svbd9R1WCxtlGpDBV3x5g03ZwAT83kyf98nPNAHvHj3WtRudDtUfwprcAGq6bJukmssErfQMF4uDySNo7ZPJA5rov+Ej1T/oTPEH/f6x/wDkmvOPG/xo+H+paPawWPiWGSZdU06YgQSriOO9hkc5KjgIrH8K3f8AhfPw13bV8TI7HACpZ3DEknGABHzQBkfALWtQtPhLoUEPhfWLyNfPxPbzWexszyHjfOrcZxyByK7Ox8XajcXupQp4L1/NrdLA7CWyHJijfPNwMgBx93P55A4jwV8XfhP4d8MabpGia1JBZ28RCW5s7qV0ydzbvkJzuYnrj04pfD3xs8FQ6t4nkvdcuPs8+oo9p/xL7pv3QtLZTwI8r+8WTg4PfoQaAN/xb4j1Rde8IY8I68Mao5C+dZfvj9iuhsX/AEjrj5ucDCnnOAU+Jevanc/D7xVav4P16GKXSrqM3DzWJRA0LAsQLndgZycDPHGawPFPxf8ABVzqXg6+h1S6NnbatLJJMdMulUAWNwhwTF8xDTRZAyQHBxjmk8ffGjwLqPgTxJZWGrzzXdxptzFDGdOukDu0TBRuMYA5I5JwKAPTE1zUGms0PhbWlWcKZJDLZ7bfLEEPifJwBuOwNweMnIrzbxFrN2bTxIy+HdVL/wDCXaVujD2wZSracVB/fYO/ChcE43ru24bb6LoPjPRte1S807Tnvze2ao1xFPptzbmIMMru8yNQCRyB1NeWeLPFen28msKYNTc3XjTS8Y0y5Bj8pLBmyDHncRGdqjlgwKg5oAxPDWr3q/tY+MbldF1K4nGiRJ9hjkt/NjBW0PJaUR9T2c9frXTQeMNcuPj1cRQaH4jewt9CMEulfabYBbgSxyGbYbgRn93Mi7wck5AyFbGD4HvYpv2wvGsyJcBJdHjVd9vIrAhLT7ylQVHynkgDp6jOv4U1DST+0Lr1/Hbamt9eC4tC7adcrlEg0zaGymFAbzDuOBhkOcOhYA9J/wCEm1bn/ih/EX/f/T//AJKrl/gncztJ4rR9E1OzS512+u3nuJLdkWQyKvlYjlZtwA9CvBwx4z30ms20dnd3LRX5jtXKSBbCdnYjGdiBN0g56qCDzjoa5v4Z+JPDWu2M7+E4782t1cXN4Z5bG5jimdpjvZZZFCNljwobIHGBtIAB21FFFABRRRQAUUUUAFFFFABRRRQBzPxHsp7/AMJ3Vva+HrLxFKzoRp15KscUmGByWYEcdfwrzX9n7w3qPhy+mttV8H6JpcywTk6paXsU08u+cOIWVeQoBAzn/lmvrXrfisA+FtYDI7j7FNlEl8pm+Q8B/wCE+/brXhv7M8OnJqED2ieBhcto67zpFxM9/wBYs+crDaBn72P4sUAfQ9FFFABXj9z8P/Cmg/E3wPBpehW0cZs9QjIZWlBChCC24nJ/eONx5wcZwAB7BXzf8ctP1fwpdaCnhzxN4pvfEV1b3v2Rri8i8uKOJI5Z2b5Bu/dqcL1JwQcjDAHpPwobw743+Flrew+GNO03TNTaQzaagWSMNHIYwSQq5OIlIOARx6ZrvbXTrK0VFtbO3hVEEaiOMKFUDAUADgAADHsK+b/gf4etLqCHwzL4g8a6XcpYWus2kdvevDb3FvNbwtL5ZA24W4kkBAweRyxDY1/jTDB8NtH0vUR4s8azzXWqRx+T/bLHEOQ0uFI+YBVIGf4nGcjigD0fx3aaF4o8HaPfS2FlqFlcX2mzW7XVsD+7luoAfldcruRiCCAcEg967eO3gijSOKGNI0AVVVQAoHQAV8/fDjQ9P8Z/Czw/e6FrviWSSym0+zu7I6jKsMMkM1uZdqdsINy4OBkYwRxJ8ZbTT/B+mT6fLrXjvUdQ1ywvhZQjUmlt4jFBljICynZ8wY/e4DZwBQB759ktsk/Z4ctjJ2DnH/6z+dZHjGws7nwxrf2i0t5fMspg++MNuHlkYORzXEeAPB39seBPDep3vibxa11e6bbXExXWJgC7xKzHr6k15r+0XpH9j2VjoOka7r9xqF7bXOoML3W55UjjtEE3+qzgswRirHgGM455AB7v8M7WCH4c+F0igjjX+y7Y7VQLyYlJ4+pJrfmktIJII53gjkuHMcKuQDI4Vm2qD1O1WbA7KT2Nct4a8AaboVtYR2uo+IZFtIxHGk+r3DJtCBQDHv2YGMgbcA9MAADyX9pjxTBpnjPwbp+7U0i0+VdX1CSzuJ43W2MghIQo4GSvnAnhgOjAMwYA+ifKj/uL+VeUfs1R6dbfCjRYY47OG8u5L64aNVVXmCXToXwOW2jylz2GwelepW0UQt4hC7vFsGxjKz7hjg7iST9c818WfCPxjpkXizwBpss2qWVrpkt0L+6XUJ/JkFyY3iDKGHloJxGrr9xiAzE5NAH2uYYmGDGhHoVFYV34J8KXk5nvPDOhzzHkyS2ETsfxK1p6lpsGo2b21xJdpG+Mm3u5YH4IPDxsrDp2Pt0NfNfwrudG+Ifxmu72yGvWumxaLNBDv1+8NxJsuk2yGTzBIqsrqfL3FQQTycEgHrXhfwX4WuNc8YRzeF9EaO31WOOIPYREKv2G1bCgrwMsxwO5NS+G9E+HXiW0tJLLwnoW+bT7bUhBNpUIeOG4D+Xu+Urk+W4IBONvoRnk9V8NWmnaB8WL6zv/ABDb3WmvLLbSprl7lWXTLaRWb99+8IY9WzwAvQADz39mmwk1rW76DWW1kW8lobWCSLXbmFojYmFGjxCyBkxdptySAVbAG40AetTeD/BX/Cxv7Kn8J6F9nW2tZ4I49PhVBM4vQ28Kg3ApGeGLLlAQARms5vDnhCD47N4euvC3h77Fd+HYrm2jl0+Hb50dzMHEYK43FZMtjnCAnpXMnRbTUf2nW0G1vtZFnp+lx3F0JNZvPMJCSBQknm78/wCkocbgADJ/eOdn4qeDtC8Japo3jiRdanisLu3ttQuJdaumktbKQTxtIjl2l4eeMlVJyFwAoZyQDF+Evhvw74w8e/FWy1vw1oL2FheLplpBDp8UIgiV7lSUKKCrsACXB3ZA5G1cdh4J+Huh6P8AEnx7pzaNpEmj3cNhqFraNao6wiUXEci/MDgFonIUfKA2AByK5P4I+Erd/iF8Ure8m1RETUxJC1vqd1AzI01yBvZXVnb5erE+uecnU8R+FNVsPj34YNnca7F4R1K0+x3kg1m43TXCR3kqIWMvm4ULuGDtGT/eOQDPt/BXhfVv2hdb0T+x9Mj0u00q3ma0hsoo0WWOaCVeNmCGDFW/vK209Bj0j4f6ToljrXjzS9OsNOt4U1SMPaQQRoFjextjgqB90sZDyMZLe9chpPgi3t/jlrMVxc6qbe505rmEx6xdiVUxaxgPIJA3LpLgFjkAf3QFyfGXiPQvhN8R9faO31C4/tLQI76dZL6d5Z545mihUSszMoKswJbOAq7ehVgD362t4bS2it7WKOG3hQRxxRqFVFAwFAHAAAxgVFfmyt4Zb7UPs0UMETPJcT7VWOMDLEseijGTnjipraFbe3ihjMhSNAimSRnYgDHLMSWPuSSe9eNftCeCPC+p6dHfXVnbx+JtZvbPRrS9kLttaSVVJ2525EfmHOO1AFz4GX48WTax4nt9LhsPD8ttZaZpdv5W3alusjSYG0LtDzsgK5GUYdhXQvcR6f8AGUWNzZotvrGiJ9mnZ1w0trNKzxhMZztug2emBx0Nch8Pvgx4A1XwD4Z1DUvDUEt9daXazTyedKpd2hUsSAwGScnpVH4mfCfwH4X0W01608Hpc2djexvqNvDPMXktnDRsVXLbijSJJj5ciM/MOhAPeFUKoVQAoGABwAK8e0zxSnxG+LukLoC6jDpPhN72W+knRRBdSuGtoWiKsdw4uCGIHAPfis74mfDnwZofhkaN4Z8G6ddeJNcka102MyKrpKsTOZi8jZCRqhYgZDHapHzZrudF+E3gjS9IsrE+GtIumt4Uia5ns42lmKqAXc7eWOMn3NAFX43re2nh3SPENgZynhzVoNWu47f/AFslqgdJ1XkA/u5HJBIBAPNbfxKgkufDEUcEZkk/tPTWCj0F9AT+gJqvdfDHwVPaXMCeGdJt/PhkgMsFqkciq6FG2sBkHDHmvI08PT6j+yunh421lY6099BpE+1EVUnXU0gy5QcnhSW5J6nJ5IA34ffZbjxb8N/ElpZXlp/wk2o6/qEsFxJvMbyoCCCFX5SsCkDH8Wcmp/2cIY7e58PRoiJKdN1CWUKhXBkXSZFzkDPyOnPTGMEjFXfHnhjwR8M/B/g281vwxpupmwmS1upILCBWvHFlPl5Aw+fLJu2lvvYOSQK8y0vwJe+Ip9Gg8C23h+xvWtPPkbVLOGdGiGn6QxBzC+X3zs2do5eQ8bmBAPrjXPsP2KP+1REbf7Vb7fNGR5vnJ5X4+Zsx74rQr5ts7rSdHt9GsPiP8IoNLj/0a2v9djtbUW63SyxEPI0QVVgbdGxbdt3F49rBWpupeLfDd9Fa2nw6+EK3HiC9MclsdQ8PRwwfZSygXBZefLbOFbIA6kjADAH0NoTWL6HpzaSIBpptozaiBQsYi2jZtA4C7cYA7Vh+Df8AkY/Hf/Yaj/8ATdZ14F4J8CePdc0PTtbsNH8E2GnfZ7RLPSdV0+C4W4h+zKGuGmSMyjLYcKzbslgxwo3zeHvD/ivQZde0v/hW/hvxpe22pRPdamwtLaNC1tbSSQRxFFPCtw4AGW3FTypAPfPFib9f8FtgnZq8jZ9P9Aux/WsH4/8AiTT/AA38KNfbU2lzqNrLplska7mkmmjdVHoABuYk9lOMnAPjmv8AjnwVfXOkTaH8KdTLWOqywTwSaDDEk84tLhFtGKbv3nmPGxUgkBS2CQBWofg7aad4Gn8X+PoFu9estLuZbjSbVLa3shlJcLiKIfOquPnBJDqCGIC0AbF7q3xa+IGrXV/4BLeD9BtVW2SDxDapHNcyjcZJApikZdpKr12nbwc7gOF1TRPFvh7xnodle+KLnWfDMHjPS7SUX7b7uW+MEEhl3FSRFtPyrv4GBg8sfpA+AvB5OT4U0DP/AGDof/ia+cfiJ4e0Of4Y/E7VbPQ7K1vdJ8VBLVooEBRUFtGRwozGQ8jbD8uWzyeaAPSvDbxt+1J4nMUQjf8AsoxzMpIEpVbFlLDoSBKRn0IHam+D9dt7r4zXkmJYzd6hrFnEXX77QRabG3QYAzA2D/s+pxXK/DXS/D2ufHrxdBP4X06KyiW7t7e2ktUaELbSWkO5V2heWRmGBwSwz1zV8IaFodxJ8LfGcPh21tdMuNY1Jbl47NSEaeaRLLzAq5wHEao2AqEr0yKAPc/ir4nk8G/DzXNegRXuLSD9yrDK+a7BEyO43MuR3rJ+AukHQPhdp2kNOlw1hdX1sZUGA5S8mXOO3TpVX4jeCfC8PhIW1t4e0m1hutU0yCYW9okJeN7+3VlJQA8g4rQ+Fdh4Xis9Rm8NaVYWc1pqF5YzPBarE6ss3zJuwCV+VOhxgKP4cAA7uiiigAooooAKKKKACiiigAooooAz/EU7Wvh/U7iNrdHhtZZFa4/1QIQnL4/h9favHPgDrMmr6uJp9aS7lm03zntI/DI09YmLRk4uBxIBnGP4s7u1e2X9ql7Y3NpKWEc8bRMVxkBhg4zkd65LwL4BTwfOrW/ibxLqdslsLWKz1K7SWGJQVwVVUXBAXA56E0AdpRRRQAV8i6No/iXx78YdU0m78dXdxcaMNRhivZNNjAVvLgtpwkW/aqt5hHBx8u4AFzj66r5Y+Gej+LfBPxpvXufD2oajeX+jy3MglvrZWnleaAzzghtigyDAX72Cuc9aANfQNC8ZadqXw80+68f3WlXmpaHNFZwHQ4c2vlx2rtaspHJCqx3PgjysDBYg+XfFF/EniTSNfuPE3iY6oPD11qNlApsIItyw3Wnxk5QDBfz1bvjy8A/Ma9++JTeN/EWhwnRfBFzZa/YXEV1p942qW37p1cbgQHG5WTcpU5U5GRwMeXeBPCF5ZaleeENT8E3uq266eZtRtn1iBXM0/wBiZyTHIPLXzLQlRksykE4AIoA6HTPAfjbwp4yufDmgeNb2FL+2tdTE8ekwR28hjnjgn4JIEixmJztH7zOHPdvN/iXY+LfGb+C/7S8RNrRntrCR3NpbwCwm1AjZHhCC+fJzkjgBem6vZfihqfxAOq+Gdf0bwpd2L6fdJa3ETajakXcM89v+5zklN0kUS7h0BOeM1yPwXs7rVdMn1KbwTeas8cmkeW0erQJFG1nZQmBgN6ncfMLspyo3hSMq1AGl4O0/xl4f0XxZpM3xJutPtvBjOPsw0q3unNkIvNhkDPz8ybgE3Hbs28ACuG8R6V4g8U60/iG88RaldxjTVtba9uNJghMsU+lXd28QVCVyEIRiOcy9fkUnufivrOsafr13I/hm7sNR8X6RJ4dism1K2KXVwzosMuFJO5FmkBZuMFBlc5NH4X6J4rh+EE9rP4Ln1S5ufOu7C5k1OFVUtZfZELKXBx5e5dp6A9iAQAP8N/8ACXaP8ItZ1DS/iTd28Xhl7vT/AOz59GgdkkgcrFCXfccspiwAWC7woJ24qro3ww1rWvGd1NeeNrqS91yHWbe8muLCObdFbXsVvsCuSqhgwYbQNm0BeKd8XbnxBb/23oGmeEbzSbjxlBFPFEupw+Ws1oWlupgFcqC0IgU/d3bf4j16r4P654juvBWk63F4KudX1DGoNFff2nBCJRcXhlkXaWGPmRMkrxsOMZwQDA0W98Wad8O/hpeaR8Q7n+ztZurLRlgTSLVvsu6NlKhmXLbGj2ZPoTz0PAeDPhXe6lqMWiRasVbV/BP9rGOOCMeYZLjfDCWYcDzFict975SoIGCOr8ajxnoOp6Ja6joEOneEbDxFB4hgeS4Rxblpo/MgDxLwglupMAoWweNwTn0L4aJ4gg8P+GNZt/AdnLqMegWumx3z60EeS2VVZRs2EKCfmx15wTxQBjan4q8T6bD4GvdU8Z6pBaa5olzql2lvp9mXhNvYxTMEDRHJLGVjnsQo243VwfhbwfrVtc+Hde0LWNUsbaG9020vp4TDC+24h0orGVVRuBM8pIcSL+7G4FmZnrfEKx+I2g+EvDsPiHw5B9m0O1vdFt78X0LiaK7hEKDYpDZRAVBxyQCR1z7ZqXh7xVfeF9X0PS/Cul6EL5Y3W7h8RzBopokijiddtuSNqwxcAjITnBJoA5/4raX4ttJNb0jTfEeq38evW1w6Wa2toS4L2FrsY+SDjbcS5IK4VUOchi2NZfDLVPDXwu17XbPxZ4i0zUrBtYvEiWNIFkTDpll2h8yLBE4bOFyCgBw1eeaZrHjnxj8TfC2rzLNNePfR6a2nzztB5ctiLSa5aVVTEaO+HICkg5G07Vz9m6tYQ6vpV5puoQLNZXkL288fmMu+N1KsMjBGQSMgg0AeOfCr4f3OqgfES78ReIrDxFr0LMWU2Uh+yMymAMDAybjFHCSVC+mByK3J/Cupaz4s8S6BqHjXxLJp8ujWglULZqXWaS8R1wLfC8IPmUBueScLt9IsLOPTNMtrHTreKK2tYVggiDkKiKoCrnB4AAFeezy+Ml+J2vPo2meHmzpdgp+16jMuUEt4Vb5YDgklwR2CqcnJAAOf8AeALrw/8QvGOm6d4p8R2kPkWV2J2a0nluTK1yWd2khb+MSdgepORtxo/Fbw9qel+GofEEvjDxXdDQryHUSsFvZGRYwSkrKEgTOIpJc7iVxnKkcVuWdr48g1m41R9K8MNc3SQwTqNVm2CKJnI2f6Lu3EyvnLEcDAHOcz4hP8QLnwT4mhuNJ8KrYy6fdI+zU7hpBGY2BxmBQWx7gZ7igDE8L2V/e/GPxlpcnivxILywjhEd5/oTfunht2KBGtyq/MSTtCg8HG7JPJftN+AC/9g6k+savf6rqd1Doaz3Bt1RFZmkjUpHGmfnBOc8e/ArQ+Ger+LPFnjHxr4u8H2Phie3u5La1S6ur25WIMkMe9UHkq7DhSS6Jgn5SwzW18WNP+IGo+CLm91qw8JK2hKNYgntb65LxTwRu3mKjQ7X6khGOOzE0Ae3wI0UEcbyvM6qFMjgBnIHU4AGT7AD2FeIeP/AXirxp8Y7I3N3rlh4KtEWdbi1voV2XKRttkiTlkOWxkoTw2CARt9b8HanLrfhHRNVuViWe+sYLqRYs7AzxqxC5J4yeOatzx6iwvfIurRC6Ytd9szeU23q+JBvG7nA2ccZ70AeN+BPhOL/wN4du18feP7VZ9OtpRBa6wI4og0Snai7OFGcAegFa158E4L20mtbz4gfESe2mRopYpdaDJIjDBVgY8EEEgg11ngfSNc0jwd4V02e8sEawsILe7j+ys5coirhHEgAIAxuIOTzgdKn8Y+OdF8IXWnW2rteG51ATNbRWtpJcO4iUNIcICcAMCfbJ7GgDipfgbYXGpWmoXnjbx7c3tpv8As00urgvBvGH2MEyuRwcEZAxWknwlhXOfHHxAb669J/QVo3/xT8L28GlvZ3F3qsmp25u7WDTbOW4leEHBkKKuVUEEfNjkEdjguPip4TttP1e8uL+aKHSobW4uhJbSKypcgGEhSMnO4ZA5HQ4oAoN8J4COPGvj5fpr0teU698LvEWlePNQnj1XVrPwH/bemzxQHVpne+luLq2WTO2Tcux2dvMbD5CEFj8y+qazeap4s8YXum+DPHbaQ2nWsDXdsmkR3KgyhnR/MfuyFflGfu571iePPCfjcaZbvP8AEWWa3Oo6aoh/sa2QrIbuECTcP7rkOFxg7QDkZyAYX7RHw2l1Hw7pUGiN4h1G4vdfgWRJtRubqK2jeN1JCuzJGoYj5yMrvIzg4rq/DfgvStO+KVzc2lxrG+IXOFm1S4lBPk6cOSzksMdmzn5c8IgXRh8IePPlE/xPuWAPPl6HaKSOPUH0bt1PtiuD8Oab42X486xoeqeJ9YjsRprXlrqS2Fqn2pytmkuN0RTAIUYAyNo55O4A6v4k/D/Rn8NGK5uNdu7e61XTYZILvXLyWIxyXtvG6bGlIIILHJyQTkEYGOntPh1oNnaw2tnN4ggtoUWOKKLxDqCpGgGAqqJ8AAAAAVh+N/DmsxaNbNL421uYf2npyhWtrIAE3sIB+WAHgnI5xkDORkHon8Na03l48ca6gCgNttrHLHuebc4oA574eeCtLufAHhmeS68QB5dMtXYR6/fxqCYlJwqzBVHsAAO1XtJ+G2mWt/rU0l/r7Ld3azxhNev0KqIIo8MRMC5zGTuOTghc4UAUvhZourP4C8G3i+K9VFudKtJGtGt7UxkGJTs3eSHwAQB82eBkk5rr9I03Ube81t7zV7i5iubkPaqVjBto/JjUqMJyd4c85GCO+SQDndX8AaE+oaK0154m8xLxmix4gvW+byJhyWmJX5S3KYbtnaWBwPjH4a0fQvhd4m1D7V4jZorJ1QNr19KN7fIuUeYqwywyCCMZ4PSuo1Hwtr0l5pz23jnXUiS4Zp1aGyyU8qQALi367in3sjAPGcEcT+0DoeoWnwd8ST3HivW72JIo90E8VmEkzKgwSkCtjvwwoA9A/wCED0j/AJ/PEn/hR6j/APH6+atd8JXWs6frmj6DLqEuoXvi/VbaOKfVZzHMsNm7qrBnKs5Kgb35OAGbb0+mP+Ea1XJP/Cb+IuTkDyNP49v+PWvM/hn4Aur+41nUrrxNrUFxZeKNSmtXtzZPuYloGlceS2HZdwKnAHUKODQB4eNH8S6Pe6EkkfiLRfEXiKxS2W+NzcxCG/udUYgzPvyN1vEcrySQGKlgWHveofDew8OfDXw7YSz6oLu3vNHt7gW+tXogMjXtusrJH5gVcszMCFBUkEbSBjf1P4bXmsa002reMtdubWE2dzaK0VlvhuYZZXEg/wBH2r95RlQCRuViy4Ag+I3hDxVP4Suf7B8Ua5quqQT211b2dwunxJI8U8cg+YW64I2ZGTjIGQRkEAf4+8HadZaHay2974iDtqumxHd4gv3G176BG4aYjO1jg9QeRggGsP8AZrtbSW38Y6la3OoTx/8ACQ3sNuZr2eSN4G8qRH2O5UsQwPmEbznknNeZ6r421jxr8TPBXh3wr4y1e+0S/NpqExnjs4p4JY5GkdWKRKpKJGDsIZSwH3uK739kW3U+CtUvLbUL14X1Bw9rLHEIxIYICZAQu8kjHUgc8qSNxAPeKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvKI/7Xb9oq01GfRr+DTZvDc1lE8k1uQHS4SR5NqykhfnjXOMkkcbQWHq9eeeJfGPhvSfHPh6+1LXdNt7OTSr9Ume4XYxM1pgA55J2t/wB8n0NAHeRzSPndbTJg4+YpzwPRj6/ofbPl3w7kuZPjb8UpprO4WItp8UZd4z5e235GA5IDhlYYHQc4PFdB/wALb8Af9Ddo/wD4ECmL8V/h6jOyeK9FVnO5iJ1G44AyfXgAfhQB0PiTUmsILUnTNSu45bqCMtaMgMRaVFVmy6nbkjOM8ZyMZrxz9lbULq38FahZppd/domsyW7zxyQlYNkFuuG3SgkdcbA3A+ldL4x+MXhSG20tdG8U6TI8up2qXBWYMUt/MBkb2G0HJPYnvirPhjxx8LPC+nyWOh+JdJtrV5nnZGvmk+dvvHLsSOnQcUAXdc0+XWPHmg61e+FNVmTQ4Lv7MWktdpmlMIV1/wBI7Kkn3h/EDwQK5X4a+INT8LfA6zub7w1q89vBp9xqf2mOe1MfkuZJ06zb+EZR93PHSu0/4W34A/6G7R//AAIFcZ4j8b+ArP4N6r4Z0jxbply8GgS6dbBrhS8pW2MaZx1Y4HQdTQB0fxI13U38A+JmTwlrltMNJu1S6aWy/c5ib5srcFsAgE7QT8vAPFN+GOu6hB8NvCkUPhHWpo10m1CyxSWSpJ+5X5gDcAgHryAeeQKvr8XPAMikr4o01xjJwxPHvxVb/hbXw60ixtoIdds4bSNBHDFa28jIiKAAqqiEAAYAHSgDmv2gfEF6fhPrD3XhbV7OKN7djPcyWrJH+/jGSI7gsTzxgHnGeORv/DzxPqo+H3hfb4N166B0u1PnQTWIST9ynzKHuVYA9sgH1ArN8R/Fb4WeJNEutI1jW3n0+6UJNEtvdxF1BBxuRA2OOQDyMg8E1S+Hvxi8CaV4A8Maffa75N3a6Xawyx/Y522OsKgjIQg4I7E0AHxg8SXdxaeFLfUPB+uW8M3iKxUCaWzPnMGLLGvl3JwxIGC2F4OSK7//AISjV/8AoRPEn/f/AE7/AOSq4nX/AIqfCfX001tW1drgafeRahagWl4pSePOx8KgJxk/Kcj1Fap+Onw7DAf8JA5J9NPujj/yHQB53p97rt58ZtPvk0HW5WsNQ1e4ltlubRnaN7eziEeTcBfkLxkjdjlcZIbb7ro+sX1+0wuvDeraYEXKm7ktWEh9F8qZ+frgV578JviD4b1J9fWzmmea61a9ug0NjcsrxpsHmFtmAdhiyMjG5RjkV6vHOjrlRIB/tRsP5igBVkYqCYnUkdCVyP1rktGvJ5vif4jjk027gSPTLBVkkaIrIBLd4Zdrk4OTjIB+U5A4z1/mL6N/3ya5zStT0u68b67BbW16mqW1naJczSwSRo8Ze4MYTdgNg+bllGDuA3EghQDo97f882/T/GuV+KxZvhd4wURsCdHvBklQP9Q/U5rqvMX0b/vk0eYvo3/fJoA8f+A/hvUfh7o1zoM2i6tItx/xM3mc2wWGRl2G3yJjuP7oEMOMON23vs/EPWda1PwB4msIPA/iQTXWm3MCHfZPy0TKDtS4ZjyeiqWPYE8Vs2Os5+KOs6e7XpiGkWUscf2eUxowmvA5zt2qSAgGSN23jO3jq3uESJpCsu1QWIETE8egAyfoKAML4cWtxY/DzwvaXsLwXUGl2sU0TjDRusKhlI9QQRU+q6xqNncXEdp4b1K/SJUKSQTWyiYnOQoeVSMcZ3AdeM1r20y3FvFNGJAkiB1EkbIwBGeVYAqfYgEd65jxR4vm8P3UqP4Y129tYo/Ne9tfswgVcHJLSTIVxg5yAB16c0AQeHPEviG6tdKTU/BeqW0s0cQuJo7qzaGJiBuYDz95QHJ6bsDoTxWZ8SvAN74w8Y+D9Qg1F7Cw0pb5bqS3mMdyRPEqL5R2kdVIbOODxzWnpHjO71PSLDUNO8H+ILiyvLaK5hlWSxXcjoGHDXIIOD3FWm8TasBx4H8Rn6T6f/8AJVAHHSfDjVfCnifTtX+G50hIYNKGkS2OqvKE8sSGQSK6Bju3HkEYPPrxV8WfCjUvFPjvQ9Y1S7sBpz2UUOu28JdftM0Qco0akEbd7D7xBAUda7n/AISjV/8AoRfEn/f/AE//AOSqlPiPVNxH/CGeIMDv51hg/wDkzQB5J8O9H+IXwzh1a0Xwaviq8upY2Opw6tBbRyRxxIkaBZPn+UA5JA5J6jDHU8eeLfH0mi26XXw2e2QalpzrIuu27hnW9hKR4AyN7BUz0G7J4Br0j/hI9U/6EzxB/wB/rH/5JrF8Xa/fvpcCzeEfEiIL+yIaKazyWF1EVHy3BOCcA8YwTkgZIAMuXxp8TFbCfCcOPUeJLYdvdf8AOK5yfxf48l+Junbvh5bpqUOjXJFkfEEJLRPPb5k3bMDa0YGMc7uvHPp0niXVUJ2+CfEL/wC7NYe3rcj1/SuLtNY1G5/aCTztD1W3jXw55YglmtmKbrtcy4WZgF4x/eOw4BwKAKXjDxT8QJ9Jtkvfh1b2cX9pWDCU+IIXy4vISiYEf8TBVz23Z5xiuxj1zx6/2BT4K0pHuN5mLa/8lqAqld5FuSSSWX5AwBXrg5pPHl7d3MVtYNoOrfZhq2mt9uQ27RfLdwvnb5wk25UKTs4znBAzW9qes3tkJTD4d1W9WM8GCS1G4YByN8y8ckc46HtgkA534UTauvw58Dxtp9l9mbSrdZZFvGLRqIF2NtMYBJwMjPyk8FhzW54c1HU73VfEcF/b2McVlfrb2xguC7NGbeGTMgx8rZkJxxwRwQAzZ3h/xZe6jo+kXVr4S1t7W8tYZkmWezKKrqCMlpwxwD/dzWXoGu39v4g8X+R4R12536spcxTWQCkWdsozvuB1UKwx2YZwcgAEnjPxBrll8T/Aei2UVqumajLdS3DmZhJJ5UD5QjZgKN6sOSWZQPlAycz9ps3B+CfiFIo428w20ZzIRgG4jGRgc8kcEgfXoc3xbq2rXfxb8A3Q8I65G1jDqUv2d57LfMrRxISmLnb8pdc7iDhuM84i+Puu6je/CrV7e58J65YRPLabrm4lsiiYuojyEuGbk8cDqRnAyQAekW0/i86Jctc6foC6wHxBHHfzNAVwOXcwhgc54CnjHNZOiT+O00K78zQvDVvqH22YwxjUJViMZlclm2wtyeCD/FuyQhylX/8AhKNX/wChE8Sf9/8ATv8A5KqlpPivX3tXN54D8QCQXE4AjnscbBK4T71yDnbtz2znBIwSAcro+p/EaT4ieJbZbXw5JJDZ2LPbS6nc+REGM+Gj/cn5m2nd8o+6vJ7dR9p+JWf+QT4OA/7Cdyf/AG3rmfDXie8k+K/jR7fwpr8twtnpsVxb+ZZBrdh9oYZP2jawZXBG0k8MCBxnuB4l1UpuPgnxCD/dM1hn/wBKcUAeeeH/AIda34f8Sza7pPhPwNbanK8khuf7RvJNrSH5zGjRlY88j5ccHHAOKyvgHp2veC/Ht74Y1mzsbO21TRYdZS0s7h5I7WWMpA6/MT87ZBYgsMqMEjp6u3ibVgoI8EeImJ7CfT+P/Jql8F67q+rWNmNZ8Malo85tElllnkt2hMmFyihJWk6kkblXgc4PFAHT0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVxvi74keHfCepmw1ae58+OBbq4MFs8q20LPsEkpUHaC3HrQB2VZ97dWdrqVu11eRQSGGTakkyoGXfEC20nnDMgz2LgfxDN5HWRFeNgyMMqynII9RXNan4b8MXmt6bb3+l6ZNcR2twbe2lt1ZfL3w+YwQjHDGPnGRu9zkA1P+Eh0X/oL6d/4Ep/jQfEGjA4OraeO/Nyn+NUB4G8JAYHhfQsf9g+H/4mkXwJ4RQEL4V0Fckk406Hr/3zQBz3xH1zRJ18MQtq1p82u2jho5o22lC0nzfNwp2Yz7iux/4SHRf+gvp3/gSn+NcF8QPB3hS3uPCzHRNCs4Bq6vO5tIEUxpbzyMGztBX5MnngDODjFdCnh3wC8F1Omj+FmhtC63EgtbcrCUGXDnHy7QRnPTPNAG5/wkOi/wDQX07/AMCU/wAa5b4meJ9BHgLxNbDXNL+1S6TdeXF9rj3v+6cfKM5PPHFaM/hjwPab2n0Pw1Bsj81i9pAu1M53HI4GV6+3tXP+NT4Bi8E6/YRXXh2x/wCJTOR9mWFpIo5IXIdI1IJyCWAGN3brQB1P/Cc+E/8AoaNC/wDBhD/8VR/wnPhP/oaNC/8ABhD/APFVjy6/8M4pCkureDUdTtKtc2oIPp1600eI/hgSQNY8Fkjri6tf8aANr/hOfCf/AENGhf8Agwh/+Krmvhr408MW3w28KRXviPRbeeLSLRZY5L6JGRhCmQQW4I9KtN4j+F6/e1nwWPrdWv8AjXPfDnxD8Oofh54WTUNY8JJeR6XapMJ7m3EiyLCgYMCchgeoPINAHbH4h+Ch18YeHByV51ODqOo+970+Lx74Pljlki8V+H3jiAaRl1GEhAehJ3cVlDxV8MxkDXvBvzADi8tuQOg61Yi8c/D2G3a3h8UeFI4GBDRrqFuFIPXI3Y5oAg+F13pbWetCx1nTr97jV766KW06v5StOwAOD6AHP+13GCe382P++v51wPhb4ieAf7KcWfiDQtOiF1ck282oQIwbz5N74DkbXbc4IOCGB71rf8LH8D/9Dl4b/wDBpB/8VQB1Hmx/31/Osa38T6HPrd5psOsac99bIpmgW4UvGfnOGGeDhScdQOT2rPb4keB1UsfGXhvAGeNThJ/LdXP6Z8SfCEnjjXjN4g8MQW6WlnHDe/2lFuueZ2Zd27BCF+AORuJJ5AAB3Flr+j31lJeWOrafc2cW7fPDco8abRlssDgYHX0qax1bTb+0S6sdQs7m2fO2aGZXRsEg4YHHBBH4Vhf8LH8D/wDQ5eG//BpB/wDFUyb4l+BoYXlfxj4eKoCTs1GFzwM8AMSTx0HWgDGg8Z+FLX4ja9PceJdDhQ6XYxF5NQiUbkmu9y8t1HmLkdtw9RW4fiN4IHXxl4b/APBpB/8AFVz1l8QfBy/EDWp28W+HxbvpdiiSnUYdjMst2WUNuwSAykgcjcueorof+Fj+B/8AocvDf/g0g/8AiqAOltbiG8tYbm0mjnt5kEkUsTBkdSMhlI4IIOQRXM/Em9tj8P8AxjCtzCZ4NJuTLGJBujzA5G4ZyMjmumtLmC8tIbqzmintpkWSKWJwySIRkMpHBBBBBFc38VmK/C7xiykhho14QQeQfIegDz34f/Gf4eaV4D8NadeeJYYrm0022t5UaCYlXSJQwJCY4INbjfHr4aBwp8URZPpazkfn5eK6HwjqumaJ4C8Lx6rqNhZH+zYFXzrlFVikaBtpJwQCQMjPUVpP4u8Npjf4h0dc8DN7EM8Z/vegJ/CgDin+Pnw0WTZ/wkoZsFvksbluAMnpH6ClT49fDeRmVPEEjMvBA027JH/kKuuXxx4Ta4FuvijQjOekY1CLd0z03Z6c1H/wn/g3cV/4Szw/uGcj+0ocjHX+KgDmU+Ofw9d1RNcuGdmChRpd2SSegH7rryKr3/x5+H8EIZdWu5j5saFU025BAZ1Usd0YGBnJ5zgHAJwD1v8AwsLwX/0N/h3/AMGcP/xVcz8QPHnhC60O2itvFXh6aVdV02UoupQkhEvoHdsBuiqpY+wNAFi1+NHga7DG01O+n2lQ3l6ReNgsQoziLuSAPcisfTPiB4em+KerXcT6u6votnEqrpN6WJWe5LExiLOBvXDEY5IB4bHXzfEvwNEjO3jHw6QASduowsePYNk1xtp8UvBEPxG8RX1x4n0sWkemWMEcqzblkYS3JYLjO4r5iZ2jgNz04ANPxn8QNOktNLt9Nm1u3uZ9Y0+LJ0i7hV1N1GHQu8YABXcMZyegBzW34r8c6Zpenaupi1U3NrBITjSbpkyFzneI9pHOSQcYzXAfE/4seB77TtCisfEVncvHrmm3EnlEny4lmSVnPHQKDnuDwea1PHvxZ8Caj8PvEcFl4n06We40+6giiDne7mLaAFxnkuuD06/3TgA6v4YX8A+G3hJY0u2X+zLSJWNtJz+6UZPy9OOvTv0IrN0jxVZ6brXjBpbHXJt+tCMC20m5mPy2dqrMdqHC5Bwf4hyuQQaw/Anxg8A2Hgjw9Z3niWxgubfTreKWIh/3brEoK9OxBFVtA+M/gCw1PxddXfiWBYLjVElgIilcugs7aMlVCk43o46dienNAFzXPGNlN8UfCd0mm+IvLt7DUVdTod2H+ZrbBCGPcw+XBIBAyucbhnoda+I2i2tnHJd6T4keM3MEYDaBdgb2mRUPzRgZDFSAOSRhQWwDyGp/G74dL430q6k1m2kt4LK8i+2pFcMY5GlgHl7VXBVgjHcQR8gwRn5jxt8b/AVzpCxab4nVri31SweTy4JwTGl5E0pU7PmXy0fO3ORxzkAgHef8J/pmSP7L8Ucf9S9ff/Gq4X4MfEZpfhzYS67aeKb+/L3Ej3SaTc3KzbriUgK6IRwMLjgDGBwK1T+0F8MQcf8ACTf+SF1/8brhfgh8Z/Afhv4X6JpOu66bXUbcS+bEbOd9paZ2HKowPDDvQBoeEPHsNv8AE74g6mnhnxbcNef2YhtotKczwbYGz5iEjZ97I9eoyOa7o/FAb41XwP46YvgcaQQFyAeSWGMZx+B7c1xnhj4v/C2x8XeKtVXxJKtzrN1b5aaynWMpHbxou07DgZ35LbTnPGAGPXzfHD4cRbN/iq0O9gg2RytyfXC8D3PFAFtviPKJLVD4H8a5uSApGnoQucffPmfJ1/ix39DVn4ceMbnxRpOlyXeg6pYST6dFdvcyxKLZ2ZUJWNg5Y53ZGQOAc81iN8e/hmsUUh8URbZSQoFpcEjBxyPLyv44o+CXj/wx4h8NaFoGjaotzq9jpMH2i3EMimPy0jR8sygHDOo4PPOM4OAD0+iiigAooooAKKKKACiiigAooooAKKKKACvH/iX8M9d8QeINdu9BvNNjtde0yLTbz7YXDwbJN3mRhVIfK8bSV55z2r2CigCvp1olhp9raREtHbxLEpbqQoAGfyryeX9nf4eNq1tNHoSrYJBKktv9suSZJC0ZR93mZG0LIMd949BXsFFAHlX/AAz58MP+hZ/8n7r/AOOUf8M+fDD/AKFn/wAn7r/45XqtFAHkdx+zz8OHmtWg0BYo0kLTKbu6YypsYBQfNG07irZ54UjHORP/AMM+fDD/AKFn/wAn7r/45XqtFAHlX/DPnww/6Fn/AMn7r/45UV5+z18N5LSdLXw8sFwyMscrXl04RiOGK+aM4POMjNetUUAeVf8ADPnww/6Fn/yfuv8A45R/wz58MP8AoWf/ACfuv/jleq0UAeVf8M+fDD/oWf8Ayfuv/jlQWH7PPw5isbaO90BLi7SNVmmS7uo1kcD5mC+adoJycZOPU165RQB5V/wz58MP+hZ/8n7r/wCOUf8ADPnww/6Fn/yfuv8A45XqtFAHjmifs5/D6009YdU0j+0boSSMbj7TcQ5VpGZF2iXHyqVXPfbk8mr3/DPnww/6Fn/yfuv/AI5XqtFAHlX/AAz58MP+hZ/8n7r/AOOVRtv2c/h7Hqt9cT6QZrKZYxBa/arhfs5UNvO8SZbdleD028da9jooA8q/4Z8+GH/Qs/8Ak/df/HKP+GfPhh/0LP8A5P3X/wAcr1WigDyRP2efhuLyV28PqbZo0VIvtl0CrAtuYt5vIIKjGONp5OeJv+GfPhh/0LP/AJP3X/xyvVaKAKulafbaTpdnp2nx+VZ2cKW8Ee4tsjRQqjJJJwAOSSa4vxr8IvBXjPUbnUdd0jzNTniERuo55I3AAwrABtpI7Eg9BnIGK76igDzBfgL8NFdWHheLK4xm6nI49R5nNTf8KN+G/mrJ/wAIta7lXaB5suMe434J9zzXpNFAHnf/AApT4df9CpYfm/8A8VUtt8G/h5bXCTR+E9NLocgSIZF6Y5ViQfxFd/RQBwZ+D/w+NxcTf8IlpW+dGRx5XygMMHaucIfQqAR2xUV18Gfh3dSM8nhPTlLbciNWjHyjAwFIA9/U8nJr0GigDgbz4O/D27uXnl8JaWrvjIijMS8ADhVIUdOw96rj4JfDkOzf8IrZZIAPzyY49t2BXo1FAHm83wO+HEuzd4VtBtYMNksq8j1w3I9jwa0Lz4TeBLnSZtPHhXR4EkgNuJorOMTICu3cshUneOobk55ruKKAOMtfhd4Ft7WGAeEdCkEaKm+WwiZ2wMZYleT6nvUdl8KPA1pc303/AAi+jTfapxNsmsYWWHEaJsjG35V+Tdjn5mY98V29FAHDN8JvArasL8+F9HBEDW/2cWUQhwzBi+zb9/5cBuwJAxk1NqHwt8D3sCxHwnoUIWWKXdBp8KMdjq+0kL91tu1h3Ukd67OigDlf+FceB/8AoTfDf/grg/8Aiao6J8J/AukaVbWEfhbRrpYV2ia8sop5n5zlnZck8/0ruKKAOMtfhd4Gt57yUeE9CkNzKJSsmnwsseEVNqAr8q/JnA/iZj3qz/wrjwP/ANCb4b/8FcH/AMTXVUUAcr/wrjwP/wBCb4b/APBXB/8AE1a8MeC/DXhYRHw/oWm2EyQC2+0Q26rM8Yxw8mNzZKgkknJGTzXQUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pressure waveforms with ventricular tachycardia (VT). Top left: Right atrial (RA) pressure tracing shows prominent \"v\" wave. Top right: With restoration of sinus rhythm, there is a slight reduction in the mean RA pressure; the \"v\" wave is attenuated and a normal RA pressure waveform is seen. A similar response can be seen in the pulmonary capillary wedge (PCW) pressure tracing. Bottom left: During sinus rhythm, the mean PCW pressure is 18 mmHg and there is a \"v\" wave of 24 mmHg. Bottom right: During ventricular tachycardia, the mean PCW pressure increases to 24 mmHg with \"v\" waves of 40 mmHg.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton Kern, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_37_20055=[""].join("\n");
var outline_f19_37_20055=null;
var title_f19_37_20056="Work and pregnancy";
var content_f19_37_20056=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Work and pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/37/20056/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/37/20056/contributors\">",
"     Josephine R Fowler, MD, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/37/20056/contributors\">",
"     Larry Culpepper, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/37/20056/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/37/20056/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/37/20056/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/37/20056/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/37/20056/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women accounted for 40.4 percent of the salaried global labor force in 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20056/abstract/1\">",
"     1",
"    </a>",
"    ]. In the United States, three-fifths of women are in the salaried labor force and three-fourths of these women are of reproductive age; many work multiple jobs [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20056/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Thus, issues about work and pregnancy commonly arise.",
"   </p>",
"   <p>",
"    Factors influencing a woman's ability to work during pregnancy include [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20056/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pregnancy-related physiological changes (eg, back pain, sleep disruption, nausea)",
"     </li>",
"     <li>",
"      Comorbid maternal medical conditions",
"     </li>",
"     <li>",
"      Obstetrical complications",
"     </li>",
"     <li>",
"      Occupational issues:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Environmental toxins and hazards (chemical, biological, radiation)",
"     </li>",
"     <li>",
"      Physical demands and ergonomic factors",
"     </li>",
"     <li>",
"      Exposure to excessive noise or vibration",
"     </li>",
"     <li>",
"      Shift work issues (length, scheduling)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHYSICAL CHANGES IN PREGNANCY THAT MIGHT AFFECT WORK",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first trimester of pregnancy can be a difficult time for pregnant women, especially for those experiencing their first pregnancy. Common discomforts of early pregnancy include nausea and vomiting, fatigue, urinary frequency, bloating, cramping, breast tenderness, emotional lability, and lightheadedness. Pregnant women, especially those with nausea",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vomiting, may have difficulty tolerating any odors. The majority of these changes can be managed by taking a brief break, as needed, but sometimes a short-term absence from work is required.",
"   </p>",
"   <p>",
"    During the early second trimester, by comparison, women tend to have a burst of energy as nausea and vomiting resolve, the feeling of fatigue lessens, and they are less stimulated by the smell of foods and noxious odors. However, by the end of the second trimester and continuing through term, physical and physiologic changes bring on discomforts such as heartburn, urinary frequency, constipation, dyspnea, back pain, varicose veins, hemorrhoids, urinary incontinence, nasal and sinus congestion, itching, and physical discomfort from the enlarging uterus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32340?source=see_link\">",
"     \"Respiratory tract changes during pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/1/2074?source=see_link\">",
"     \"Musculoskeletal changes and pain during pregnancy and postpartum\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20105?source=see_link\">",
"     \"Maternal cardiovascular and hemodynamic adaptations to pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/60/9160?source=see_link\">",
"     \"Maternal gastrointestinal tract adaptation to pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35816?source=see_link\">",
"     \"The skin, hair, nails, and mucous membranes during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both the woman and her employer should develop strategies to deal with the physical and emotional changes associated with pregnancy, as well as lost work time and interruptions in work flow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MATERNITY LEAVE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increasing number of pregnant women in the workforce has prompted change in workforce policies related to working mothers. Women of reproductive age should be familiar with pregnancy discrimination and parenting leave statutes, such as the Pregnancy Discrimination Act of 1978 and the Family and Medical Leave Act of 1993, discussed below.",
"   </p>",
"   <p>",
"    The Family Medical Leave Act (FMLA) mandates 12 weeks of unpaid leave for childbearing or family care in a 12-month period for eligible employees [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20056/abstract/5\">",
"     5",
"    </a>",
"    ]. Eligibility criteria include working at least 12 months for the current employer, for at least 1250 hours over the previous 12 months, in a facility that has at least 50 employees. For women in smaller organizations, or who have worked less than 12 months, an arrangement between employer and employee should be made early in the pregnancy, allowing time for workload to be distributed appropriately and allowing opportunity for the employee to plan for leave and return to work. However, paid leave is not mandated and is at the discretion of the employer. According to one study, fewer than 40 percent of pregnant women received wages during maternity leave [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20056/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women of reproductive age in the workforce should consider evaluating policies on maternity leave when searching for employment. They should also evaluate the company's policies on issues related to child care, such as flexible schedules, part time work, working from home, leaving early for child related needs, sick",
"    <span class=\"nowrap\">",
"     children/snow",
"    </span>",
"    days, dependent care spending accounts, child care assistance, resource and referral programs, etc.",
"   </p>",
"   <p>",
"    Estimating the effects of maternal employment on children's development is difficult to study due to selection bias and missing data (eg, quality of child care, home environment, maternal sensitivity, paternal factors). The literature is conflicting, and generally shows any adverse effects of maternal employment on child development are small [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20056/abstract/7-9\">",
"     7-9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     WORKPLACE DISCRIMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Federal law prohibits discrimination due to pregnancy under the Pregnancy Discrimination Act (PDA) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20056/abstract/10\">",
"     10",
"    </a>",
"    ]. The PDA is an amendment to the Title VII of the Civil Rights Act of 1964. The PDA protects the pregnant woman from firing discrimination, peer and employer misjudgments when suffering pregnancy related conditions, insurance payment unfairness, and fringe benefit discrimination.",
"   </p>",
"   <p>",
"    In 1991, the Supreme Court ruled that a rigid policy that banned women of reproductive age from certain jobs discriminated against women on the basis of their sex. Although several toxic substances found in the workplace also could harm men of reproductive age, men were not banned from jobs on that basis. Therefore, it is illegal for an employer to ban a woman from certain jobs because she might become pregnant while working there.",
"   </p>",
"   <p>",
"    During the fiscal year 2005, the Federal Equal Employment Opportunity Commission received more than 4000 complaints about pregnancy discrimination. More than half were related to unfair dismissal during pregnancy or immediately following maternity leave [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20056/abstract/11\">",
"     11",
"    </a>",
"    ]. Pregnancy-related complaints occurred more frequently than sexual harassment and sexual discrimination complaints. According to the Equal Opportunity Commission, the number of workforce discrimination charges has increased 67 percent in the last 15 years for all women and 76 percent for ethnic and racial minorities, although it is considered illegal [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20056/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Before considering pregnancy, women in the workplace should familiarize themselves with state laws about maternity leave, inquire about coverage under the Family Medical Leave Act (FMLA), understand their rights in the workplace and benefits granted during maternity leave, and know standard duration in the workplace, along with expectations about return. Women who have concerns about unfair treatment during pregnancy should consider seeking legal services.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DISABILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Pregnancy Discrimination Act also requires employers offering medical disability benefits to treat pregnancy-related disabilities just like all other disabilities. Pregnant workers must be provided the same insurance benefits, sick leave, seniority credits, and reinstatement privileges awarded workers disabled by other causes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DEMANDS OF WORKPLACE AND PERINATAL OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;A woman with an uncomplicated pregnancy who is employed where there are no greater potential hazards than those encountered in routine daily life may continue to work without interruption until the onset of labor. However, the physical demands of the woman's job should be considered, especially in women at higher risk of preterm delivery.",
"   </p>",
"   <p>",
"    Studies on the effect of work on pregnancy outcome have shown wide variations in results. This is likely due, in part, to \"healthy worker\" effects whereby healthier workers are more likely to continue to work and work in more demanding jobs, thus biasing outcomes. A meta-analysis of 21 studies including 146,457 women identified a high cumulative work fatigue score as the strongest (OR 1.63) work-related risk factor for preterm birth [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20056/abstract/13\">",
"     13",
"    </a>",
"    ]. The results of this analysis are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef51860 \" href=\"UTD.htm?29/10/29867\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There is a general consensus that working during pregnancy should be limited or contraindicated in some women:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vaginal bleeding",
"     </li>",
"     <li>",
"      Short or dilated cervix before 36 weeks of gestation",
"     </li>",
"     <li>",
"      Uterine malformation",
"     </li>",
"     <li>",
"      Pregnancy-induced hypertension",
"     </li>",
"     <li>",
"      Fetal growth restriction",
"     </li>",
"     <li>",
"      Multiple gestation with complications",
"     </li>",
"     <li>",
"      Prior history of preterm birth",
"     </li>",
"     <li>",
"      Polyhydramnios",
"     </li>",
"     <li>",
"      Maternal medical disorders that are unstable or associated with impaired placental perfusion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relationship between physical",
"    <span class=\"nowrap\">",
"     activity/work",
"    </span>",
"    and preterm labor is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35898?source=see_link&amp;anchor=H19#H19\">",
"     \"Risk factors for preterm labor and delivery\", section on 'Physical activity and work'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Frequent air travel is a component of some jobs, and is generally safe for pregnant women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=see_link&amp;anchor=H28#H28\">",
"     \"Initial prenatal assessment and patient education\", section on 'Airline travel'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     WORKPLACE SAFETY DURING PREGNANCY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether or not a woman continues to work during her pregnancy depends on her health, the health of the baby, and the presence of workplace hazards that may affect the woman or her unborn child. Employers are mandated by law to provide information regarding work exposures that might affect reproductive outcomes.",
"   </p>",
"   <p>",
"    There are several potential environmental exposures that a pregnant woman might encounter in the workplace that could have an adverse effect on the pregnancy (",
"    <a class=\"graphic graphic_table graphicRef51370 graphicRef64742 \" href=\"UTD.htm?11/21/11614\">",
"     table 2A-B",
"    </a>",
"    ). Such exposures should be avoided, but all do not necessarily warrant leaving the job. Environmental exposures that may put pregnancy at risk include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Exposure to metals, chemicals, solvents",
"     </li>",
"     <li>",
"      Exposure to pharmaceutical agents",
"     </li>",
"     <li>",
"      Exposure to extreme heat",
"     </li>",
"     <li>",
"      Exposure to infections",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Providers should inform women to minimize exposures and encourage them to ask employers for information regarding potential workplace risks. The Occupational Safety and Health Administration (OSHA) sets and enforces standards requiring employers to provide a workplace free from recognized hazards likely to cause serious physical harm. Every employer is mandated to have a Material Safety Data Sheet (MSDS) that contains information on the chemical properties and health effects of the substances used in the workplace. The sheet gives valuable information about the ingredients of a particular chemical, its appearance and odor, flammability, health hazards, reactivity data, precautions, spill and exposure procedures, pregnancy risk, preventive measures and first aid measures. Additional information can be obtained from the Organization of Teratology Information Specialists (",
"    <a class=\"external\" href=\"file://www.otispregnancy.org/\">",
"     www.otispregnancy.org",
"    </a>",
"    or telephone 866-626-6847).",
"   </p>",
"   <p>",
"    Selected environmental exposures will be discussed below. These issues are reviewed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4746?source=see_link\">",
"     \"Occupational and environmental risks to reproduction in females\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/13/14553?source=see_link\">",
"     \"Overview of occupational and environmental health\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16823?source=see_link\">",
"     \"Information and educational resources for occupational and environmental health issues in the United States\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, simple precautions that can help reduce excessive fatigue and potentially reduce the risk of pregnancy complications include minimizing lifting, bending, and prolonged standing; using proper lifting techniques; taking regular breaks every few hours and a longer break after five hours; and drinking plenty of fluids [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20056/abstract/13-16\">",
"     13-16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Lead",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal occupational exposure to lead has been linked to a variety of adverse outcomes (",
"    <a class=\"graphic graphic_table graphicRef51370 graphicRef64742 \" href=\"UTD.htm?11/21/11614\">",
"     table 2A-B",
"    </a>",
"    ). Lead is the third most common occupational exposure in women. It enters the body via inhalation and ingestions and accumulates in the soft tissues, bones, blood, liver, and kidneys. Lead that is stored in the bones may mobilize during pregnancy and lactation due to bone demineralization [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20056/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Under federal and state law, employers should have written lead standards and air monitoring results. Symptoms of lead toxicity (fatigue, muscle and joint pain, abdominal cramps, headaches, and irritability) appear when lead levels are between 60 to 120",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    in the blood. The Occupational Safety and Health Administration (OSHA) recommends a level less than 30",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    to prevent reproductive problems. Neurologic, hematologic, and reproductive effects may occur at lower levels [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20056/abstract/19\">",
"     19",
"    </a>",
"    ]. In pregnant women, blood lead elevations of 20",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    are of high concern because of the potential for adverse effects on the developing fetus, which is more susceptible to lead's toxic effects. Even lead levels less than 10",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    may be of concern in pregnancy in light of studies demonstrating intellectual impairment in children with blood lead concentrations below 10",
"    <span class=\"nowrap\">",
"     mcg/dL.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12922?source=see_link\">",
"     \"Adult lead poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=see_link\">",
"     \"Childhood lead poisoning: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4746?source=see_link\">",
"     \"Occupational and environmental risks to reproduction in females\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women working in known areas of lead exposure should always wear protective clothing, change work clothing and shoes before going home, use respiratory equipment to avoid inhalation, and wash hands before handling food and drinks [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20056/abstract/20\">",
"     20",
"    </a>",
"    ]. Women with symptoms of lead toxicity should have their lead levels checked and be removed from exposure. Chelating agents are not recommended during pregnancy. To reduce their risk if exposed to lead, pregnant women can be counseled to eat a well balanced diet that would increase iron, calcium, and zinc stores. As nutritional deficiencies in iron, calcium and zinc may increase lead absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20056/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Mercury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mercury is found in numerous manufactured products. Inhaling metallic mercury over time can affect all systems in the body, but the brain and kidneys are the most likely to be affected at lower levels. In pregnancy, exposure to mercury can be associated with adverse effects (",
"    <a class=\"graphic graphic_table graphicRef51370 graphicRef64742 \" href=\"UTD.htm?11/21/11614\">",
"     table 2A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34295?source=see_link\">",
"     \"Epidemiology and toxicity of mercury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4746?source=see_link\">",
"     \"Occupational and environmental risks to reproduction in females\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mercury can be found in elemental, organic and inorganic forms. Elemental mercury is inhaled through vapors and fumes and is the least absorbed form of mercury. Women working with dental amalgam are at risk of exposure to elemental mercury. Inorganic mercury is found in fungicides, antiseptics and disinfectants and may be absorbed in toxic levels through the skin. Organic mercury is consumed by eating fish with high levels of methyl mercury. The major source of mercury exposure occurs in the workplace. Persons working in light bulb manufacturing facilities, dental facilities, and gold mining industries in undeveloped countries where mercury fumes are high have the greatest risks of elemental exposures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Solvents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occupational exposure to solvents ranges from exposure to known toxic chemicals in the workplace to routine household solvents used for cleaning. Household solvents are usually not a major risk since exposure is episodic and air levels are low. However, women with industrial exposure appear to be at some risk [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20056/abstract/23-25\">",
"     23-25",
"    </a>",
"    ], which depends on dose and duration of exposure.",
"   </p>",
"   <p>",
"    We advise women working with occupational solvents to request information regarding the solvent from their employers, work in well ventilated areas, and wear protective gear such as masks, gloves, and clothing while using these solvents [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20056/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pharmaceutical agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Healthcare workers may be exposed to hazardous pharmaceutical agents. Exposure can occur through direct or indirect contact with these substances [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20056/abstract/27\">",
"     27",
"    </a>",
"    ]. Although healthcare facilities recommend universal precautions, employees should ask for Material Safety Data Sheets (MSDS) when they work in areas exposed to hazardous materials. Hazardous materials should be prepared in well ventilated areas, handlers should wear protective clothing (double gloves, gowns, eye protective gear) and all spills should be cleaned immediately and cleaning material discarded properly. Employers should provide training sessions to employees about hazardous materials in the workplace. It is important to have guidelines and procedures on storage, use, preparation, cleaning spills, decontamination, and patient wastes.",
"   </p>",
"   <p>",
"    Occupational exposures to chemotherapeutic agents have been linked to adverse pregnancy outcomes. A systematic review that tested the hypothesis that oncology health care workers are at an increased risk of reproductive complications found no significant association between exposure to cytotoxic drugs and congenital malformations (OR 1.64; 95% CI, 0.91-2.94) or stillbirths (OR 1.16, 95% CI: 0.73-1.82), but did identify an association between exposure to chemotherapy and spontaneous abortions (OR 1.46, 95% CI 1.11-1.92) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20056/abstract/28\">",
"     28",
"    </a>",
"    ]. A subsequent systematic review found that nurses with occupational exposure to anesthetic gases were at increased risk of having a child with a congenital malformation (OR 1.33, 95% CI 1.06-1.68) and with spontaneous abortion (OR 1.27, 95% CI 0.99-1.63); this review did not find a statistically significant association between chemotherapy and spontaneous abortion (OR 1.21, 95% CI 0.80-1.83) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20056/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Healthcare workers are exposed to infections daily, and often repetitively. The likelihood of adverse sequelae if a pregnant woman becomes infected depends on several factors, including the type of infection and the trimester during which the exposure occurred (see individual topic reviews on each infection) (",
"    <a class=\"graphic graphic_table graphicRef65355 \" href=\"UTD.htm?8/36/8780\">",
"     table 3",
"    </a>",
"    ). Pregnant women working in health care facilities should always use universal precautions when coming in contact with children or adults who may have an infectious disease and should have appropriate immunizations before and during pregnancy (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=see_link\">",
"     \"Immunizations during pregnancy\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A report by the United States Nuclear Regulatory Commission lists limits for prenatal radiation exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20056/abstract/30\">",
"     30",
"    </a>",
"    ]. Women should not be exposed to more than 5 mSv during the nine months of pregnancy and no more than 0.5 mSv during any gestational month. Women working in an environment with radiation exposure should wear a dosimeter badge, which is processed every two to four weeks. They should also be encouraged to wear proper shielding (eg, lead apron) if exposure is expected, minimize the time of exposure, and maximize their distance from the source of radiation. The risks of radiation exposure in pregnancy are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=see_link\">",
"     \"Diagnostic imaging procedures during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Heat",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heat is a workplace hazard for those working in agricultural industries, construction work, farming, and, in some areas, outside jobs. The human fetus' temperature is about 1 degree Celsius higher than the maternal temperature. Animal studies suggest that perinatal risks (eg, CNS, vascular disruption and neural defects [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20056/abstract/31\">",
"     31",
"    </a>",
"    ]) increase with maternal heat exposure. Similar findings were found in human studies related to febrile illnesses, sauna use, and hot tub use [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20056/abstract/32-34\">",
"     32-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The National Institute of Occupational Safety and Health guidelines address protection of workers in hot environments [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20056/abstract/35\">",
"     35",
"    </a>",
"    ]. Employers of facilities with risk for high temperature should institute measures to minimize environment and metabolic heat exposure (eg, good ventilation to draw steam and heat from work areas, cooling fans, heat shields, labor saving devices, rest periods in cooler areas, hydration) and provide training to employees on how to recognize heat-related illnesses. In areas where heat is unavoidable, employees should take precautions to avoid heat stress and heat related complications. Pregnant women should be encouraged to increase fluid intake, request periodic breaks from the heated area, and to dress in light clothing to avoid over heating.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Noise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent occupational noise stress does not appear to cause fetal structural anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20056/abstract/36\">",
"     36",
"    </a>",
"    ]. The effect of noise on birth weight and length of gestation is unclear, as studies have reported discordant findings [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20056/abstract/37\">",
"     37",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Environmental noise, if sufficiently loud, may damage fetal hearing, although data in humans are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20056/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. By the 20th week of gestation, the structures of the fetal auditory system are well-developed, enabling the fetus to detect sounds after the late second trimester of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20056/abstract/42\">",
"     42",
"    </a>",
"    ]. Low-frequency sounds penetrate the maternal tissues and amniotic fluid more effectively than higher frequency sounds: external noise is minimally reduced for frequencies below 0.5 kHz, but reduced by 40 to 50 dB for frequencies above 0.5 kHz [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20056/abstract/43\">",
"     43",
"    </a>",
"    ]. In one report, children with hearing loss at 4 to 10 years of age were more likely to have been born to women exposed to hours of occupational noise of 85 to 95 dB during their pregnancy than to women exposed to levels below 85 dB; low frequency noise increased the risk of hearing loss [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20056/abstract/39\">",
"     39",
"    </a>",
"    ]. However, this study has been criticized for methodological shortcomings, such as absence of a matched control group, retrospective noise evaluation, and multiple confounders.",
"   </p>",
"   <p>",
"    Most countries have regulations about occupational noise exposure, but these standards typically do not specifically address pregnant women and fetal safety. The American Conference of Governmental Industrial Hygienists noted that eight hours total work exposure of 115 dB or a peak exposure of 155 dB to pregnant workers beyond the fifth month of pregnancy may cause hearing loss in the fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20056/abstract/44\">",
"     44",
"    </a>",
"    ]. The US Navy suggests that pregnant workers be vigilant about wearing hearing protection whenever environmental noise exceeds 84 dB to minimize the effects of potentially unhealthy maternal physiological changes on the fetus, and recommends that extended exposures (more than 12 minutes) above 104 dB should be avoided after 20 weeks of gestation, even with the use of maternal hearing protection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20056/abstract/45\">",
"     45",
"    </a>",
"    ]. There is no method for shielding the fetus from environmental noise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Video display terminals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Video display terminals emit very low frequency (VLF) and extremely low frequency (ELF) electromagnetic fields. They do not emit detectable levels of ionizing radiation. Literature reviews have generally concluded that there is no evidence of a significant association between a woman's use of a video display terminal (VDT) and fetal loss or other adverse reproductive outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20056/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. However, ergonometric issues related to use of computers in the workplace (eg, carpal tunnel syndrome, low back pain) may be more problematic for pregnant women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Environmental tobacco smoke may have an adverse effect on the fetus, but there are few data. The effects of passive and active smoking on pregnancy are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22505?source=see_link\">",
"     \"Secondhand smoke exposure: Effects in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27482?source=see_link\">",
"     \"Smoking and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Air travel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Frequent business-related air travel is common and generally safe during pregnancy. Issues related to air travel are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=see_link&amp;anchor=H28#H28\">",
"     \"Initial prenatal assessment and patient education\", section on 'Airline travel'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31614482\">",
"    <span class=\"h2\">",
"     Shift work",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review that evaluated the influence of shift work among nurses found it moderately increased the risk of spontaneous abortion (OR 1.44, 95% CI 1.06-1.95) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20056/abstract/29\">",
"     29",
"    </a>",
"    ]. In another systematic review of epidemiologic studies on shift work and selected pregnancy outcomes, shift was associated with no or minimal increase in risk of preterm delivery, low birth weight, small for gestational infant, and preeclampsia (pooled RR 1.03-1.27 with wide confidence intervals) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20056/abstract/48\">",
"     48",
"    </a>",
"    ]. These results are consistent with previous analyses that observed only modest associations between shift-night work and preterm birth (OR 1.24, 95% CI 1.06-1.46) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20056/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Cosmetologists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cosmetologists in hair salons are potentially exposed to hundreds of chemicals. There is no good evidence of teratogenic effects, but it is prudent for workers in hair salons to wear gloves when possible and attempt to work in well-ventilated areas since data are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20056/abstract/49-55\">",
"     49-55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Pesticides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic studies have reported adverse reproductive or developmental effects associated with mixed pesticide exposure in occupational settings, particularly when personal protective equipment was not used [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20056/abstract/56\">",
"     56",
"    </a>",
"    ]. Every class of pesticide (organophosphates, carbamates, pyrethroids, herbicides, fungicides, fumigants, organochlorines) appears to have at least one agent capable of affecting a reproductive or developmental endpoint in animals or humans. Counseling patients who are concerned about reproductive and developmental effects of pesticides involves helping them assess their degree of exposure, weigh risks and benefits of this exposure, and adopt practices to reduce or eliminate exposure and absorption.",
"   </p>",
"   <p>",
"    One systematic review of childhood leukemia and parental occupational pesticide exposure determined that there was no overall association between childhood leukemia and any paternal occupational pesticide exposure (OR 1.09; 95% CI 0.88&ndash;1.34) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20056/abstract/57\">",
"     57",
"    </a>",
"    ]. However, childhood leukemia was associated with prenatal maternal occupational pesticide exposure (OR 2.09; 95% CI 1.51&ndash;2.88); this association was slightly stronger for studies with high exposure-measurement-quality scores (OR 2.45; 95% CI 1.68&ndash;3.58) and farm-related exposures (OR 2.44; 95% CI 1.53&ndash;3.89). The risk was also elevated for prenatal maternal occupational exposure to insecticides (OR 2.72; 95% CI 1.47&ndash;5.04) and herbicides (OR 3.62; 95% CI 1.28&ndash;10.3).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/15/8434?source=see_link\">",
"       \"Patient information: Activity during pregnancy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Every woman should be counseled about any risks associated with her job and the impact of the demands of her job on pregnancy. Employees should be advised to inquire about substances in the workplace that may pose risk to the unborn child. Employers, in turn, should be knowledgeable about these risks and exposures, offer ongoing education to all employees, and assist in minimizing these risks.",
"     </li>",
"     <li>",
"      Simple precautions that can help reduce excessive fatigue and potentially reduce the risk of pregnancy complications include minimizing lifting, bending, and prolonged standing; using proper lifting techniques; taking regular breaks every few hours and a longer break after five hours; and drinking plenty of fluids.",
"     </li>",
"     <li>",
"      Discussing leaves and interim absences early in pregnancy can limit misunderstandings. Although women may not totally avoid discrimination in the workplace, identifying advocates in the workplace, knowing expectations of employers before becoming pregnant, and knowing rights and responsibilities can minimize stress related to workplace discrimination.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Global trends for women. Global Employment Trends for Women, March 2009.",
"    </li>",
"    <li>",
"     Chao, EL, Utgoff, KP. Women in the Labor Force: A Databook, US Department of Labor, Bureau of Labor Statistics, Report 1973, February 2004.",
"    </li>",
"    <li>",
"     Women's Safety and Health Issues at Work. From the National Institute for Occupational Safety and Health. DHHS (NIOSH) Publication Number 2001-123.",
"    </li>",
"    <li>",
"     Health-related Maternity leave in the Uncomplicated Pregnancy and Birth. Alberta Perinatal Health Program. February 2008. www.aphp.ca (accessed July 2008).",
"    </li>",
"    <li>",
"     www.dol.gov/esa/whd/fmla/ (Accessed March 22, 2006).",
"    </li>",
"    <li>",
"     O'Connell, M. Maternity leave arrangements: 1961-85. In: Work and family patterns of American women, Government Printing Office, Washington DC 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20056/abstract/7\">",
"      Brooks-Gunn J, Han WJ, Waldfogel J. Maternal employment and child cognitive outcomes in the first three years of life: the NICHD Study of Early Child Care. National Institute of Child Health and Human Development. Child Dev 2002; 73:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20056/abstract/8\">",
"      Hill JL, Waldfogel J, Brooks-Gunn J, Han WJ. Maternal employment and child development: a fresh look using newer methods. Dev Psychol 2005; 41:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20056/abstract/9\">",
"      Zoritch B, Roberts I, Oakley A. Day care for pre-school children. Cochrane Database Syst Rev 2000; :CD000564.",
"     </a>",
"    </li>",
"    <li>",
"     www.eeoc.gov/abouteeoc/35th/thelaw/pregnancy_discrimination-1978.html (Accessed March 22, 2006).",
"    </li>",
"    <li>",
"     The U.S. Equal Employment Opportunity Commission. Pregnancy Discrimination Charges_EEOC &amp; FEPAs Combined: FY 1992 - FY 2005, January 2006.",
"    </li>",
"    <li>",
"     The Us Equal Employment Opportunity Commission. Pregnancy and Discrimination Charges, 1997-2007. file://www.eeoc.gov/stats/enforcement.html.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20056/abstract/13\">",
"      Mozurkewich EL, Luke B, Avni M, Wolf FM. Working conditions and adverse pregnancy outcome: a meta-analysis. Obstet Gynecol 2000; 95:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20056/abstract/14\">",
"      Saurel-Cubizolles MJ, Zeitlin J, Lelong N, et al. Employment, working conditions, and preterm birth: results from the Europop case-control survey. J Epidemiol Community Health 2004; 58:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20056/abstract/15\">",
"      Fortier I, Marcoux S, Brisson J. Maternal work during pregnancy and the risks of delivering a small-for-gestational-age or preterm infant. Scand J Work Environ Health 1995; 21:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20056/abstract/16\">",
"      El-Metwalli AG, Badawy AM, El-Baghdadi LA, El-Wehady A. Occupational physical activity and pregnancy outcome. Eur J Obstet Gynecol Reprod Biol 2001; 100:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20056/abstract/17\">",
"      Thompson GN, Robertson EF, Fitzgerald S. Lead mobilization during pregnancy. Med J Aust 1985; 143:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20056/abstract/18\">",
"      Gomaa A, Hu H, Bellinger D, et al. Maternal bone lead as an independent risk factor for fetal neurotoxicity: a prospective study. Pediatrics 2002; 110:110.",
"     </a>",
"    </li>",
"    <li>",
"     Substance Data Sheet for Occupational Exposure to Lead -1926. 62 App A. US Department of Labor. Occupational Safety and Health Administration, 57 FR 26627, May 4, 1993, as amended at 58 FR 34218, June 24, 1993.",
"    </li>",
"    <li>",
"     Lead OSHA standards. US Department of Labor, Occupational Safety and Health Administration. Toxic and Hazardous Substances. Employee standard Summary 1910.",
"    </li>",
"    <li>",
"     Hertz-Picciotto, I, Schramm, M, Watt-Morse, M, Chantala, K, et al. Patterns and determinants of blood lead during pregnancy. American Journal of Epidemiology 152:829.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20056/abstract/22\">",
"      Aimo L, Oteiza PI. Zinc deficiency increases the susceptibility of human neuroblastoma cells to lead-induced activator protein-1 activation. Toxicol Sci 2006; 91:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20056/abstract/23\">",
"      Laslo-Baker D, Barrera M, Knittel-Keren D, et al. Child neurodevelopmental outcome and maternal occupational exposure to solvents. Arch Pediatr Adolesc Med 2004; 158:956.",
"     </a>",
"    </li>",
"    <li>",
"     Rouvet, JF, Westall, C, Koren, G, Till, C. Maternal Occupational Exposure to Organic Solvents during Pregnancy and Infant Visual Processing. University of Toranto. Workplace Safety and Insurance Board of Ontario, November 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20056/abstract/25\">",
"      Taskinen H, Kyyr&ouml;nen P, Hemminki K, et al. Laboratory work and pregnancy outcome. J Occup Med 1994; 36:311.",
"     </a>",
"    </li>",
"    <li>",
"     Mercury OSHA standards. US Department of Labor, Occupational Safety and Health Administration. Toxic and Hazardous Substances. Employee standard Summary 1910.",
"    </li>",
"    <li>",
"     Preventing Occupational Exposure to Antineoplastic and other Hazardous Drugs in Healthcare Settings. National Institute for Occupational Safety and Health. DHHS (NIOSH) Publication Number 2004-165.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20056/abstract/28\">",
"      Dranitsaris G, Johnston M, Poirier S, et al. Are health care providers who work with cancer drugs at an increased risk for toxic events? A systematic review and meta-analysis of the literature. J Oncol Pharm Pract 2005; 11:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20056/abstract/29\">",
"      Quansah R, Jaakkola JJ. Occupational exposures and adverse pregnancy outcomes among nurses: a systematic review and meta-analysis. J Womens Health (Larchmt) 2010; 19:1851.",
"     </a>",
"    </li>",
"    <li>",
"     Instruction Concerning Prenatal Radiation Exposure. US Nuclear Regulatory Commission, Regulatory guide 8.13, DG-6014, June 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20056/abstract/31\">",
"      Cadwell-Smith, J, Upfold, J, Edwards, M, et al. Neural Tube and other Developmental Anomalies in the Guinea Pig following Maternal Hyperthermia during Early Neural Tube Development. Teratogenesis Carcino. Mutagen 1992; 12:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20056/abstract/32\">",
"      Graham JM Jr, Edwards MJ, Edwards MJ. Teratogen update: gestational effects of maternal hyperthermia due to febrile illnesses and resultant patterns of defects in humans. Teratology 1998; 58:209.",
"     </a>",
"    </li>",
"    <li>",
"     Graham, JM, Edwards, MJ, Lipson, AH, et al. Gestational Hyperthermia as a Cause for Moebius Syndrome. Teratology 37:461.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20056/abstract/34\">",
"      Edwards MJ. Review: Hyperthermia and fever during pregnancy. Birth Defects Res A Clin Mol Teratol 2006; 76:507.",
"     </a>",
"    </li>",
"    <li>",
"     www.cdc.gov/niosh/86-113.html (accessed April 5, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20056/abstract/36\">",
"      Kurppa K, Rantala K, Nurminen T, et al. Noise exposure during pregnancy and selected structural malformations in infants. Scand J Work Environ Health 1989; 15:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20056/abstract/37\">",
"      Noise: a hazard for the fetus and newborn. American Academy of Pediatrics. Committee on Environmental Health. Pediatrics 1997; 100:724.",
"     </a>",
"    </li>",
"    <li>",
"     www.Reprotox.org (Accessed September 22, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20056/abstract/39\">",
"      Lalande NM, H&eacute;tu R, Lambert J. Is occupational noise exposure during pregnancy a risk factor of damage to the auditory system of the fetus? Am J Ind Med 1986; 10:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20056/abstract/40\">",
"      Daniel T, Laciak J. [Clinical observations and experiments concerning the condition of the cochleovestibular apparatus of subjects exposed to noise in fetal life]. Rev Laryngol Otol Rhinol (Bord) 1982; 103:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20056/abstract/41\">",
"      Nurminen T, Kurppa K. Occupational noise exposure and course of pregnancy. Scand J Work Environ Health 1989; 15:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20056/abstract/42\">",
"      Gerhardt KJ, Pierson LL, Huang X, et al. Effects of intense noise exposure on fetal sheep auditory brain stem response and inner ear histology. Ear Hear 1999; 20:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20056/abstract/43\">",
"      Gerhardt KJ, Abrams RM. Fetal exposures to sound and vibroacoustic stimulation. J Perinatol 2000; 20:S21.",
"     </a>",
"    </li>",
"    <li>",
"     ACGIH: 2003 TLVs and BEIs. Publication No. 103.",
"    </li>",
"    <li>",
"     Navy and Marine Corps Public Health Center",
"Technical Manual NMCPHC-TM-OEM 6260.01C. Reproductive and developmental hazards: A guide for occupational health professionals. file://www.nmcphc.med.navy.mil/downloads/occmed/Repro2010d2.pdf (Accessed on April 12, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20056/abstract/46\">",
"      Shaw GM. Adverse human reproductive outcomes and electromagnetic fields: a brief summary of the epidemiologic literature. Bioelectromagnetics 2001; Suppl 5:S5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20056/abstract/47\">",
"      Robert E. Intrauterine effects of electromagnetic fields--(low frequency, mid-frequency RF, and microwave): review of epidemiologic studies. Teratology 1999; 59:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20056/abstract/48\">",
"      Bonzini M, Palmer KT, Coggon D, et al. Shift work and pregnancy outcomes: a systematic review with meta-analysis of currently available epidemiological studies. BJOG 2011; 118:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20056/abstract/49\">",
"      Blackmore-Prince C, Harlow SD, Gargiullo P, et al. Chemical hair treatments and adverse pregnancy outcome among Black women in central North Carolina. Am J Epidemiol 1999; 149:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20056/abstract/50\">",
"      Burnett C, Goldenthal EI, Harris SB, et al. Teratology and percutaneous toxicity studies on hair dyes. J Toxicol Environ Health 1976; 1:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20056/abstract/51\">",
"      Holly EA, Bracci PM, Hong MK, et al. West Coast study of childhood brain tumours and maternal use of hair-colouring products. Paediatr Perinat Epidemiol 2002; 16:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20056/abstract/52\">",
"      Gallicchio L, Miller S, Greene T, et al. Cosmetologists and reproductive outcomes. Obstet Gynecol 2009; 113:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20056/abstract/53\">",
"      Kersemaekers WM, Roeleveld N, Zielhuis GA. Reproductive disorders due to chemical exposure among hairdressers. Scand J Work Environ Health 1995; 21:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20056/abstract/54\">",
"      Efird JT, Holly EA, Cordier S, et al. Beauty product-related exposures and childhood brain tumors in seven countries: results from the SEARCH International Brain Tumor Study. J Neurooncol 2005; 72:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20056/abstract/55\">",
"      McCall EE, Olshan AF, Daniels JL. Maternal hair dye use and risk of neuroblastoma in offspring. Cancer Causes Control 2005; 16:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20056/abstract/56\">",
"      Frazier LM. Reproductive disorders associated with pesticide exposure. J Agromedicine 2007; 12:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20056/abstract/57\">",
"      Wigle DT, Turner MC, Krewski D. A systematic review and meta-analysis of childhood leukemia and parental occupational pesticide exposure. Environ Health Perspect 2009; 117:1505.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 439 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.181.191-9843F0D5B8-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_37_20056=[""].join("\n");
var outline_f19_37_20056=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHYSICAL CHANGES IN PREGNANCY THAT MIGHT AFFECT WORK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MATERNITY LEAVE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      WORKPLACE DISCRIMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DISABILITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DEMANDS OF WORKPLACE AND PERINATAL OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      WORKPLACE SAFETY DURING PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Lead",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Mercury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Solvents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pharmaceutical agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Radiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Heat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Noise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Video display terminals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Smoking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Air travel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31614482\">",
"      Shift work",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Cosmetologists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Pesticides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/439\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/439|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/10/29867\" title=\"table 1\">",
"      Work and pregnancy outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/25/31133\" title=\"table 2A\">",
"      Occupational agents causing adverse pregnancy outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/36/41547\" title=\"table 2B\">",
"      Chemical and physical agents that are reproductive hazards",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/36/8780\" title=\"table 3\">",
"      Infection related reproductive hazards in the workplace",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12922?source=related_link\">",
"      Adult lead poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=related_link\">",
"      Childhood lead poisoning: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=related_link\">",
"      Diagnostic imaging procedures during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34295?source=related_link\">",
"      Epidemiology and toxicity of mercury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=related_link\">",
"      Immunizations during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16823?source=related_link\">",
"      Information and educational resources for occupational and environmental health issues in the United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=related_link\">",
"      Initial prenatal assessment and patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20105?source=related_link\">",
"      Maternal cardiovascular and hemodynamic adaptations to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/60/9160?source=related_link\">",
"      Maternal gastrointestinal tract adaptation to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/1/2074?source=related_link\">",
"      Musculoskeletal changes and pain during pregnancy and postpartum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4746?source=related_link\">",
"      Occupational and environmental risks to reproduction in females",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/13/14553?source=related_link\">",
"      Overview of occupational and environmental health",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/15/8434?source=related_link\">",
"      Patient information: Activity during pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32340?source=related_link\">",
"      Respiratory tract changes during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35898?source=related_link\">",
"      Risk factors for preterm labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22505?source=related_link\">",
"      Secondhand smoke exposure: Effects in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27482?source=related_link\">",
"      Smoking and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35816?source=related_link\">",
"      The skin, hair, nails, and mucous membranes during pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_37_20057="Schizophrenia: Epidemiology and pathogenesis";
var content_f19_37_20057=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Schizophrenia: Epidemiology and pathogenesis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/37/20057/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/37/20057/contributors\">",
"     Bernard A Fischer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/37/20057/contributors\">",
"     Robert W Buchanan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/37/20057/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/37/20057/contributors\">",
"     Stephen Marder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/37/20057/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/37/20057/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/37/20057/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H31673341\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Schizophrenia is a psychiatric disorder involving chronic or recurrent psychosis. It is commonly associated with impairments in social and occupational functioning. [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/1\">",
"     1",
"    </a>",
"    ]. It is among the most disabling and economically catastrophic medical disorders, ranked by the World Health Organization as one of the top ten illnesses contributing to the global burden of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Characteristics of schizophrenia typically include positive symptoms such as hallucinations or delusions, disorganized speech, negative symptoms such as a flat affect or poverty of speech, and impairments in cognition including attention, memory, and executive functions. Antipsychotic medications are first-line treatment for schizophrenia. Evidence-based psychosocial interventions in conjunction with pharmacotherapy can help patients achieve recovery.",
"   </p>",
"   <p>",
"    This topic discusses the epidemiology and pathogenesis of schizophrenia. Clinical manifestations, assessment, diagnosis, and course of schizophrenia are discussed separately. Anxiety and depression in schizophrenia are discussed separately. Pharmacologic and psychosocial treatments for schizophrenia are discussed separately. Other psychotic disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34552?source=see_link\">",
"     \"Schizophrenia: Clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29241?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44760?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Side effect management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/9/30871?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Long-acting injectable antipsychotic drugs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8904?source=see_link\">",
"     \"Psychosocial interventions for schizophrenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/21/25944?source=see_link\">",
"     \"Depression in schizophrenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/3/2105?source=see_link\">",
"     \"Anxiety in schizophrenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28583?source=see_link\">",
"     \"Overview of psychosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31673348\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Schizophrenia occurs throughout the world. The prevalence of schizophrenia (ie, the number of cases in a population at any one time point) approaches 1 percent internationally. The incidence (the number of new cases annually) is about 1.5 per 10,000 people [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/3\">",
"     3",
"    </a>",
"    ]. Slightly more men are diagnosed with schizophrenia than women (on the order of 1.4:1) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/4\">",
"     4",
"    </a>",
"    ], and women tend to be diagnosed later in life than men. There is also some indication that the prognosis is worse in men [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of risk factors have been associated with the development of schizophrenia, including living in an urban area [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/7,8\">",
"     7,8",
"    </a>",
"    ], immigration [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/9,10\">",
"     9,10",
"    </a>",
"    ], obstetrical complications [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/11\">",
"     11",
"    </a>",
"    ], and a late winter-early spring time of birth (perhaps reflecting exposure to influenza virus during neural development). Advanced paternal age at conception has been associated with increased risk of schizophrenia in epidemiologic studies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/12\">",
"     12",
"    </a>",
"    ], and may be associated with an increased risk of de novo mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31673355\">",
"    <span class=\"h2\">",
"     Co-occurring conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;People with schizophrenia have higher rates of several psychiatric disorders than people without schizophrenia, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Depressive disorders (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/21/25944?source=see_link\">",
"       \"Depression in schizophrenia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anxiety disorders: social anxiety disorder, posttraumatic stress disorder, and obsessive-compulsive disorder (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/3/2105?source=see_link\">",
"       \"Anxiety in schizophrenia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Alcohol and other substance abuse and dependence (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36521?source=see_link\">",
"       \"Dual diagnosis: Severe mental illness and substance use disorders\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    People with schizophrenia are also at greater risk for co-occurring conditions such as metabolic and neurological problems. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34552?source=see_link&amp;anchor=H17284595#H17284595\">",
"     \"Schizophrenia: Clinical manifestations, course, assessment, and diagnosis\", section on 'Associated physical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rate of suicide among people with schizophrenia is much higher than in the general population. Approximately five percent of people with schizophrenia commit suicide over their lifetime [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/14\">",
"     14",
"    </a>",
"    ]. About 10 percent of all completed suicides are among people with schizophrenia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31673362\">",
"    <span class=\"h2\">",
"     Cost",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cost of schizophrenia is staggering. The overall cost of schizophrenia in the United States in 2002 was estimated at about $63 billion [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/17\">",
"     17",
"    </a>",
"    ]. This figure includes direct healthcare costs and indirect costs associated with loss of productivity. A recent study examining US insurance claims found that the annual health-related expenses of someone with chronic schizophrenia averaged more than $15,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H296339\">",
"    <span class=\"h2\">",
"     Deficit schizophrenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deficit schizophrenia, characterized by primary, enduring negative symptoms, seems to be a specific disease process within the larger syndrome of schizophrenia. Approximately 15 to 20 percent of the total schizophrenia population has the deficit form of schizophrenia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/19-22\">",
"     19-22",
"    </a>",
"    ]. They are more likely to be male and more likely to have relatives with schizophrenia than people with nondeficit schizophrenia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/23-27\">",
"     23-27",
"    </a>",
"    ]. As opposed to the excess of late winter-early spring births observed in schizophrenia in general, there is a disproportionate rate of summer births in the deficit group [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/19,28\">",
"     19,28",
"    </a>",
"    ]. Examples of negative symptoms include decreased expressiveness, apathy, flat affect, and a lack of energy. People with deficit schizophrenia are less likely to have addictions, depression, suicidality, or delusions with high emotional content (such as jealous delusions) compared to nondeficit schizophrenia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34552?source=see_link&amp;anchor=H2265295#H2265295\">",
"     \"Schizophrenia: Clinical manifestations, course, assessment, and diagnosis\", section on 'Deficit schizophrenia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31673369\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the pathogenesis of the disorder is unknown, it is almost certain that schizophrenia represents a syndrome comprised of multiple diseases that present with similar signs and symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/32\">",
"     32",
"    </a>",
"    ]. This heterogeneity complicates the elucidation of the etiological and pathophysiological factors that underlie the group of disorders. Schizophrenia appears to be a uniquely human condition, which limits the utility of animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/33\">",
"     33",
"    </a>",
"    ]. There is little doubt that schizophrenia proceeds from a complex interaction between genes and the environment, but even the attempt to differentiate genetic from environment risk factors may be artificial, since environmental factors can influence gene expression just as a person&rsquo;s genetic make-up can influence response to environmental stressors.",
"   </p>",
"   <p>",
"    Research studies have found the following genetic and environmental risk factors in schizophrenia, which may act through disrupted neurotransmitter system function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31673376\">",
"    <span class=\"h2\">",
"     Genetic risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies in monozygotic twins have demonstrated a strong genetic component to schizophrenia. However, schizophrenia is not a completely genetic illness. If schizophrenia were completely genetic-based, monozygotic twins, which share 100 percent of their DNA, would always be concordant for the diagnosis of schizophrenia. If schizophrenia was independent of genes, the concordance rate would be closer to the 1 percent rate observed in the general population. The observed concordance rate is about 40 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. Thus, although there is a strong genetic component to schizophrenia, environmental factors are also probably required. One non-genetic explanation for high monozygotic twin concordance rates is shared environment. However, dizygotic twins, who also share a common environment starting in utero, but share only half of their genes, are only concordant for schizophrenia in about 5 to 10 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. Other first degree relatives share an elevated risk of schizophrenia with prevalence rates of about 5 to 10 percent.",
"   </p>",
"   <p>",
"    Despite advances in research techniques, including genome-wide association studies (GWAS) and the evaluation of copy number variants (CNVs), the genetics of schizophrenia remain murky. Findings vary based on the participant ethnicity, sample size, and the technique used. Few findings have been reliably replicated, the effect of reliably replicated genes is small, and none are universally associated with increased schizophrenia risk. More than half of all people with schizophrenia have no family history of the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/37\">",
"     37",
"    </a>",
"    ] and a similar phenotype may be caused by mutations in many different genes coding for multiple steps along complex metabolic or developmental pathways. If mutations in multiple genes with additive small effects are required, the picture becomes even more complicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/38/3689?source=see_link\">",
"     \"Genetic association studies: Principles and applications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several specific genes have been identified as candidates for a role in the development of schizophrenia (",
"    <a class=\"graphic graphic_table graphicRef69865 \" href=\"UTD.htm?36/25/37276\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31673383\">",
"    <span class=\"h2\">",
"     Environmental risk",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31673390\">",
"    <span class=\"h3\">",
"     Obstetrical complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various perinatal problems, grouped together for analysis as &ldquo;obstetrical complications&rdquo;, increase the risk of later development of schizophrenia two-fold [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/11\">",
"     11",
"    </a>",
"    ]. These perinatal problems include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemorrhage",
"     </li>",
"     <li>",
"      Pre-term labor",
"     </li>",
"     <li>",
"      Blood-group incompatibilities",
"     </li>",
"     <li>",
"      Fetal hypoxia",
"     </li>",
"     <li>",
"      Maternal infection (See",
"      <a class=\"local\" href=\"#H31673397\">",
"       'Infections'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The accuracy of these data, based on maternal recall many years after childbirth, has been questioned, but studies suggest that the risk does not appear to be influenced by inaccurate memories [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. The association between obstetrical complications and the development of schizophrenia has also been observed in data from medical records, which do not rely on recall [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pregnancy during famines in the Netherlands (1944 through 1945) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/40\">",
"     40",
"    </a>",
"    ] and in China (1959 through 1961) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/41,42\">",
"     41,42",
"    </a>",
"    ] has been associated with a two-fold risk of schizophrenia in the offspring, in studies based on subsequent hospital records. This may indicate maternal nutrition is a factor in the development of schizophrenia. Other, related factors associated with an increased risk of subsequently developing schizophrenia include being the product of an unwanted pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/43\">",
"     43",
"    </a>",
"    ] and the prenatal death of the father [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increased maternal stress has been proposed as the common pathophysiological mechanism underlying risk factors, such as famine, bereavement, and antenatal infection. An animal model provides some support for this theory [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31673397\">",
"    <span class=\"h3\">",
"     Infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several infectious agents have been studied as potential risk factors for the development of schizophrenia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Numerous epidemiological studies have found a rise in schizophrenia prevalence in cohorts born during influenza epidemics [",
"      <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The increased risk for schizophrenia among those born in the late winter-early spring; possibly reflecting increased maternal exposure to influenza virus during prenatal neural development.",
"     </li>",
"     <li>",
"      High maternal IgG antibodies to the parasite toxoplasma gondii have been found to increase the relative risk of developing schizophrenia in offspring by about 60 to 70 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/47,48\">",
"       47,48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Studies have varied on whether herpes simplex virus type 2 maternal infection increases the risk for schizophrenia; some studies have found increased risks between 60 percent to more than 400 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/49,50\">",
"       49,50",
"      </a>",
"      ], while other studies have found no increased risk [",
"      <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other infectious agents associated with schizophrenia appear to have an influence outside the model of perinatal exposure of the affected individual. As examples:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Higher maternal levels of IgG to toxoplasma gondii are related to the later development of schizophrenia in the mother herself [",
"      <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Measles antibodies are higher in people with schizophrenia, especially in those with recent-onset of psychosis, than controls [",
"      <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mechanism by which infections increase the risk of schizophrenia is unclear. There is little evidence to suggest that the risk is associated with direct damage to the CNS by the infectious agent. A study comparing individuals hospitalized for meningitis as children to a control group who were hospitalized with gastroenteritis as children found no difference in the risk of later hospitalization for schizophrenia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/54\">",
"     54",
"    </a>",
"    ]. A more likely explanation is that infection by certain agents triggers an immune response in a mother that is passed through the placenta to the developing fetus, which comprises the blood brain barrier and allows antibodies, which cross-react with CNS proteins, to enter into the developing nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/55\">",
"     55",
"    </a>",
"    ]. Early childhood infections could also initiate an immune response and lead to a general state of increased inflammation. (See",
"    <a class=\"local\" href=\"#H31673404\">",
"     'Inflammation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31673404\">",
"    <span class=\"h3\">",
"     Inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased immune system activation leads to higher levels of circulating cytokines; increased cytokine levels have been frequently observed in schizophrenia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/56\">",
"     56",
"    </a>",
"    ]. Cytokines can alter the blood-brain barrier, or be produced locally in the CNS by activated microglia, and may be responsible for psychosis, its exacerbation, or cognitive impairments [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/57\">",
"     57",
"    </a>",
"    ]. The actions of antipsychotic drugs may be partially mediated by the anti-inflammatory effects of these agents [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to associations between schizophrenia and some infections, there is other evidence for abnormal immune activation in people with schizophrenia. (See",
"    <a class=\"local\" href=\"#H31673397\">",
"     'Infections'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Autoimmune disorders that have been associated with a higher prevalence of schizophrenia include [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acquired hemolytic anemia",
"     </li>",
"     <li>",
"      Bullous pemphigoid",
"     </li>",
"     <li>",
"      Celiac disease",
"     </li>",
"     <li>",
"      Interstitial cystitis",
"     </li>",
"     <li>",
"      Thyrotoxicosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (A notable exception is rheumatoid arthritis, in which schizophrenia rates are lower than expected based on rates in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/61\">",
"     61",
"    </a>",
"    ]. People with schizophrenia are also more likely to have circulating antibodies to proteins common in most Western diets, such as gluten [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/62,63\">",
"     62,63",
"    </a>",
"    ] and casein [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].)",
"   </p>",
"   <p>",
"    Clinical trials are investigating several anti-inflammatory agents in the treatment or prevention of psychosis, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Omega-3 fatty acids [",
"      <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/66\">",
"       66",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"       Minocycline",
"      </a>",
"     </li>",
"     <li>",
"      Statins",
"     </li>",
"     <li>",
"      Non-steroidal anti-inflammatory drugs [",
"      <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/67,68\">",
"       67,68",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Inflammation in people with schizophrenia may also be responsible for some of the disorder&rsquo;s associated conditions such as heart disease (through decreased elasticity of inflamed blood vessels) and diabetes (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34552?source=see_link&amp;anchor=H17284616#H17284616\">",
"     \"Schizophrenia: Clinical manifestations, course, assessment, and diagnosis\", section on 'Metabolic disturbances'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15986866\">",
"    <span class=\"h3\">",
"     Cannabis use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiological studies suggest that cannabis use is a risk factor for the development of psychosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/69-71\">",
"     69-71",
"    </a>",
"    ]. Initial findings from retrospective studies were inconclusive because people with psychotic disorders, even before they were diagnosed, could be using cannabis. This would indicate that psychosis was a risk factor for using cannabis rather than the reverse. Well-controlled, prospective studies following hundreds of people have subsequently supported the hypothesis that cannabis use is the risk factor and psychosis the result [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. The increased risk posed by cannabis use depends on other risk factors, such as family history, but is generally reported with odds ratios of 2.2 to 2.8 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/70,72,73\">",
"     70,72,73",
"    </a>",
"    ]. Acute infusions of delta-9-tetrahydrocannabinol have provoked psychotic-like symptoms in people with and without schizophrenia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/74,75\">",
"     74,75",
"    </a>",
"    ], providing further evidence for cannabis as a risk factor for psychosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/28/4554?source=see_link&amp;anchor=H30#H30\">",
"     \"Cannabis use disorders: Treatment, prognosis, and long-term medical effects\", section on 'Psychotic disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31673411\">",
"    <span class=\"h3\">",
"     Immigration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous studies in multiple countries have observed a higher prevalence of schizophrenia in immigrant populations compared to native-born populations [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. This increased relative risk can be as high as four-fold, depending on the study. An increased risk appears to extend to second-generation immigrants as well [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several possible explanations for the association between immigrants and schizophrenia have been proposed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Schizophrenia may be overdiagnosed in immigrant populations; however, further research suggests that this cannot entirely explain the increase in risk observed [",
"      <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In people with either a genetic or neurodevelopmental biological risk for schizophrenia, stress can play a role in the ultimate development of the disorder. In this way, the stress of immigration, becoming part of an outsider group, may contribute to the development of schizophrenia. Studies have found associations between the amount of social discrimination experienced by immigrant groups and the rates of schizophrenia in the group; that is, immigrant groups experiencing more discrimination have higher rates of schizophrenia than immigrant groups experiencing lower rates of social discrimination. This finding has been observed in several immigrant groups in several countries:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Ethiopian immigrants to Israel [",
"      <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/77\">",
"       77",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Moroccan immigrants to Holland [",
"      <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Caribbean immigrants to the United Kingdom [",
"      <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/78\">",
"       78",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The increased risk of schizophrenia in immigrants may be related to vitamin D deficiency, especially among individuals who move to more northern latitudes [",
"      <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31673460\">",
"    <span class=\"h2\">",
"     Neurotransmitters",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31673425\">",
"    <span class=\"h3\">",
"     Dopamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;All drugs with antipsychotic properties block the dopaminergic D2 receptor, a finding that has led to the dopamine hypothesis of schizophrenia, in which excess dopamine in the mesolimbic tract has been hypothesized to cause positive psychotic symptoms. However, if dopamine were the sole neurotransmitter disrupted in schizophrenia, then antipsychotics would be universally and completely effective for these symptoms. However, despite adequate antipsychotic treatment, many people with schizophrenia continue to exhibit positive symptoms. Therefore, it is likely that dysfunction in other neurotransmitter systems is required to explain why many people with the illness exhibit only a partial reduction in positive symptoms, and why",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    , the most efficacious antipsychotic in schizophrenia, is a weak D2 antagonist.",
"   </p>",
"   <p>",
"    Decreased dopamine in the prefrontal cortex (largely affecting the D1 receptor) may be responsible for some of the cognitive and negative symptoms observed in schizophrenia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34552?source=see_link&amp;anchor=H17284539#H17284539\">",
"     \"Schizophrenia: Clinical manifestations, course, assessment, and diagnosis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31673432\">",
"    <span class=\"h3\">",
"     Glutamate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glutamate is the major CNS excitatory neurotransmitter. Hypofunction of the N-methyl-D-aspartate (NMDA) glutamate receptor has been hypothesized to contribute to the pathology of schizophrenia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/82\">",
"     82",
"    </a>",
"    ]. Evidence comes from:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Clinical observations of people who have misused phencyclidine (a NMDA receptor antagonist)",
"     </li>",
"     <li>",
"      Challenge studies using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"       ketamine",
"      </a>",
"      (a NMDA receptor antagonist) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/83-85\">",
"       83-85",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Genetic findings [",
"      <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/82\">",
"       82",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Post-mortem studies [",
"      <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/86\">",
"       86",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Studies measuring the level of endogenous NMDA receptor antagonists in the CNS of people with schizophrenia [",
"      <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/87,88\">",
"       87,88",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical trials with agents that enhance glutamatergic neurotransmission have had varied results depending on the mechanism of the agent used [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29241?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31673439\">",
"    <span class=\"h3\">",
"     Gamma-amino-butyric acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gamma-amino-butyric acid (GABA) is the major CNS inhibitory neurotransmitter GABAergic interneurons are important for regulation of prefrontal cortical function, through their modulation of glutamatergic pyramidal cells. Several lines of evidence suggest that these interneurons are dysfunctional in people with schizophrenia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/91-96\">",
"     91-96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Postmortem studies in people with schizophrenia have found decreased levels of glutamic acid decarboxylase (GAD67) mRNA expression in the prefrontal cortex [",
"      <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/97\">",
"       97",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with decreased GAD67, there is a decrease in the density of chandelier cell connections with the pyramidal cell axon initial segment [",
"      <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/97\">",
"       97",
"      </a>",
"      ] and in the immunoreactivity of the GABA plasma membrane transporter-1 in chandelier cell axon terminals [",
"      <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/97\">",
"       97",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There appears to be a decrease in GABA reuptake transporter mRNA levels [",
"      <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/97\">",
"       97",
"      </a>",
"      ] and an increase in GABAA &alpha;2 subunit density on the axon initial segment [",
"      <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/97\">",
"       97",
"      </a>",
"      ], both of which may be compensatory shifts.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31673446\">",
"    <span class=\"h3\">",
"     Acetylcholine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increased smoking behaviors observed in people with schizophrenia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/98-101\">",
"     98-101",
"    </a>",
"    ] has led to the hypothesis that nicotine, which stimulates a subset of acetylcholine receptors, is correcting a fundamental neurochemical problem in schizophrenia. Treatment with nicotine or a nicotinic cholinergic drug can normalize some eye-tracking and EEG abnormalities observed in people with schizophrenia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/102-106\">",
"     102-106",
"    </a>",
"    ] and may acutely improve some aspects of cognition [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/107,108\">",
"     107,108",
"    </a>",
"    ]. However, nicotinic acetylcholine receptors can affect many other neurotransmitter systems (for example, nicotine can enhance current mediated by glutamate receptors in dopamine neurons of the rat ventral tegmentum [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20057/abstract/109,110\">",
"     109,110",
"    </a>",
"    ]), and so it is not clear whether the cholinergic system is primarily disrupted in schizophrenia or the disruption is secondary to other pathological characteristics of the illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1475992\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Schizophrenia has a worldwide prevalence approaching 1 percent, with an incidence of about 1.5 new cases annually per 10,000 people. (See",
"      <a class=\"local\" href=\"#H31673348\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      People with schizophrenia have higher rates of depression, several anxiety disorders, substance use disorders, and suicide compared to people without schizophrenia. (See",
"      <a class=\"local\" href=\"#H31673355\">",
"       'Co-occurring conditions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately 15 to 20 percent of patients with schizophrenia have the deficit form of schizophrenia, characterized by primary, enduring negative symptoms such as decreased expressiveness, apathy, flat affect, and a lack of energy. (See",
"      <a class=\"local\" href=\"#H296339\">",
"       'Deficit schizophrenia'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34552?source=see_link&amp;anchor=H2265295#H2265295\">",
"       \"Schizophrenia: Clinical manifestations, course, assessment, and diagnosis\", section on 'Deficit schizophrenia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although the pathogenesis of the disorder is unknown, schizophrenia is likely a syndrome comprised of multiple diseases that present with similar signs and symptoms. The disorder appears to proceed from a complex interaction between genes and the environment. (See",
"      <a class=\"local\" href=\"#H31673369\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several neurotransmitter systems are involved in the pathology of schizophrenia including dopamine, glutamate, GABA, and acetylcholine. These represent the current best targets for pharmacological intervention in the disorder. (See",
"      <a class=\"local\" href=\"#H31673460\">",
"       'Neurotransmitters'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29241?source=see_link\">",
"       \"Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22853334\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Michael Jibson, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR), American Psychiatric Association, Washington, DC 2000.",
"    </li>",
"    <li>",
"     Murray CJL, Lopez AD. The Global Burden of Disease, Harvard University Press, Cambridge, MA 1996. p.21.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/3\">",
"      McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 2008; 30:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/4\">",
"      Abel KM, Drake R, Goldstein JM. Sex differences in schizophrenia. Int Rev Psychiatry 2010; 22:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/5\">",
"      Grossman LS, Harrow M, Rosen C, et al. Sex differences in schizophrenia and other psychotic disorders: a 20-year longitudinal study of psychosis and recovery. Compr Psychiatry 2008; 49:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/6\">",
"      Usall J, Ochoa S, Araya S, et al. Gender differences and outcome in schizophrenia: a 2-year follow-up study in a large community sample. Eur Psychiatry 2003; 18:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/7\">",
"      Krabbendam L, van Os J. Schizophrenia and urbanicity: a major environmental influence--conditional on genetic risk. Schizophr Bull 2005; 31:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/8\">",
"      Pedersen CB, Mortensen PB. Evidence of a dose-response relationship between urbanicity during upbringing and schizophrenia risk. Arch Gen Psychiatry 2001; 58:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/9\">",
"      Werbeloff N, Levine SZ, Rabinowitz J. Elaboration on the association between immigration and schizophrenia: a population-based national study disaggregating annual trends, country of origin and sex over 15 years. Soc Psychiatry Psychiatr Epidemiol 2012; 47:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/10\">",
"      Bourque F, van der Ven E, Malla A. A meta-analysis of the risk for psychotic disorders among first- and second-generation immigrants. Psychol Med 2011; 41:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/11\">",
"      Clarke MC, Harley M, Cannon M. The role of obstetric events in schizophrenia. Schizophr Bull 2006; 32:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/12\">",
"      Miller B, Messias E, Miettunen J, et al. Meta-analysis of paternal age and schizophrenia risk in male versus female offspring. Schizophr Bull 2011; 37:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/13\">",
"      Kong A, Frigge ML, Masson G, et al. Rate of de novo mutations and the importance of father's age to disease risk. Nature 2012; 488:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/14\">",
"      Hor K, Taylor M. Suicide and schizophrenia: a systematic review of rates and risk factors. J Psychopharmacol 2010; 24:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/15\">",
"      Arsenault-Lapierre G, Kim C, Turecki G. Psychiatric diagnoses in 3275 suicides: a meta-analysis. BMC Psychiatry 2004; 4:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/16\">",
"      Suominen K, Isomets&auml; E, Heil&auml; H, et al. General hospital suicides--a psychological autopsy study in Finland. Gen Hosp Psychiatry 2002; 24:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/17\">",
"      Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005; 66:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/18\">",
"      Nicholl D, Akhras KS, Diels J, Schadrack J. Burden of schizophrenia in recently diagnosed patients: healthcare utilisation and cost perspective. Curr Med Res Opin 2010; 26:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/19\">",
"      Kirkpatrick B, Buchanan RW, Ross DE, Carpenter WT Jr. A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry 2001; 58:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/20\">",
"      Kirkpatrick B, Buchanan RW, Breier A, Carpenter WT Jr. Case identification and stability of the deficit syndrome of schizophrenia. Psychiatry Res 1993; 47:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/21\">",
"      Amador XF, Kirkpatrick B, Buchanan RW, et al. Stability of the diagnosis of deficit syndrome in schizophrenia. Am J Psychiatry 1999; 156:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/22\">",
"      Carpenter WT Jr, Heinrichs DW, Wagman AM. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 1988; 145:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/23\">",
"      Kirkpatrick B, Mitchell BD, DeLisi LE. Concordance of the deficit/nondeficit categorization in affected siblings. Schizophr Bull 2007; 33:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/24\">",
"      Kirkpatrick B, Castle D, Murray RM, Carpenter WT Jr. Risk factors for the deficit syndrome of schizophrenia. Schizophr Bull 2000; 26:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/25\">",
"      Dollfus S, Ribeyre JM, Petit M. Family history and deficit form in schizophrenia. Eur Psychiatry 1996; 11:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/26\">",
"      Kirkpatrick B, Ross DE, Walsh D, et al. Family characteristics of deficit and nondeficit schizophrenia in the Roscommon Family Study. Schizophr Res 2000; 45:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/27\">",
"      Ross DE, Kirkpatrick B, Karkowski LM, et al. Sibling correlation of deficit syndrome in the Irish study of high-density schizophrenia families. Am J Psychiatry 2000; 157:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/28\">",
"      Messias E, Kirkpatrick B, Bromet E, et al. Summer birth and deficit schizophrenia: a pooled analysis from 6 countries. Arch Gen Psychiatry 2004; 61:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/29\">",
"      Fenton WS, McGlashan TH. Antecedents, symptom progression, and long-term outcome of the deficit syndrome in schizophrenia. Am J Psychiatry 1994; 151:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/30\">",
"      Kirkpatrick B, Amador XF, Flaum M, et al. The deficit syndrome in the DSM-IV Field Trial: I. Alcohol and other drug abuse. Schizophr Res 1996; 20:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/31\">",
"      Kirkpatrick B, Buchanan RW, Breier A, Carpenter WT Jr. Depressive symptoms and the deficit syndrome of schizophrenia. J Nerv Ment Dis 1994; 182:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/32\">",
"      Fischer BA, Carpenter WT Jr. Will the Kraepelinian dichotomy survive DSM-V? Neuropsychopharmacology 2009; 34:2081.",
"     </a>",
"    </li>",
"    <li>",
"     Taylor A, Taylor S, Markham J, Koenig J. Schizophrenia Research Forum: Animal Models of Schizophrenia. [pdf] 2009. file://www.schizophreniaforum.org/res/models/Animal_Models_04_09.pdf (Accessed on September 29, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/34\">",
"      Kringlen E. Twin studies in schizophrenia with special emphasis on concordance figures. Am J Med Genet 2000; 97:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/35\">",
"      Cardno AG, Marshall EJ, Coid B, et al. Heritability estimates for psychotic disorders: the Maudsley twin psychosis series. Arch Gen Psychiatry 1999; 56:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/36\">",
"      Cannon TD, Kaprio J, L&ouml;nnqvist J, et al. The genetic epidemiology of schizophrenia in a Finnish twin cohort. A population-based modeling study. Arch Gen Psychiatry 1998; 55:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/37\">",
"      Tiwari AK, Zai CC, M&uuml;ller DJ, Kennedy JL. Genetics in schizophrenia: where are we and what next? Dialogues Clin Neurosci 2010; 12:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/38\">",
"      Buka SL, Goldstein JM, Seidman LJ, Tsuang MT. Maternal recall of pregnancy history: accuracy and bias in schizophrenia research. Schizophr Bull 2000; 26:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/39\">",
"      Walshe M, McDonald C, Boydell J, et al. Long-term maternal recall of obstetric complications in schizophrenia research. Psychiatry Res 2011; 187:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/40\">",
"      Susser E, Neugebauer R, Hoek HW, et al. Schizophrenia after prenatal famine. Further evidence. Arch Gen Psychiatry 1996; 53:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/41\">",
"      St Clair D, Xu M, Wang P, et al. Rates of adult schizophrenia following prenatal exposure to the Chinese famine of 1959-1961. JAMA 2005; 294:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/42\">",
"      Xu MQ, Sun WS, Liu BX, et al. Prenatal malnutrition and adult schizophrenia: further evidence from the 1959-1961 Chinese famine. Schizophr Bull 2009; 35:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/43\">",
"      Myhrman A, Rantakallio P, Isohanni M, et al. Unwantedness of a pregnancy and schizophrenia in the child. Br J Psychiatry 1996; 169:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/44\">",
"      Huttunen MO, Niskanen P. Prenatal loss of father and psychiatric disorders. Arch Gen Psychiatry 1978; 35:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/45\">",
"      Koenig JI, Elmer GI, Shepard PD, et al. Prenatal exposure to a repeated variable stress paradigm elicits behavioral and neuroendocrinological changes in the adult offspring: potential relevance to schizophrenia. Behav Brain Res 2005; 156:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/46\">",
"      Brown AS, Derkits EJ. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry 2010; 167:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/47\">",
"      Mortensen PB, N&oslash;rgaard-Pedersen B, Waltoft BL, et al. Toxoplasma gondii as a risk factor for early-onset schizophrenia: analysis of filter paper blood samples obtained at birth. Biol Psychiatry 2007; 61:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/48\">",
"      Brown AS, Schaefer CA, Quesenberry CP Jr, et al. Maternal exposure to toxoplasmosis and risk of schizophrenia in adult offspring. Am J Psychiatry 2005; 162:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/49\">",
"      Buka SL, Cannon TD, Torrey EF, et al. Maternal exposure to herpes simplex virus and risk of psychosis among adult offspring. Biol Psychiatry 2008; 63:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/50\">",
"      Buka SL, Tsuang MT, Torrey EF, et al. Maternal infections and subsequent psychosis among offspring. Arch Gen Psychiatry 2001; 58:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/51\">",
"      Brown AS, Schaefer CA, Quesenberry CP Jr, et al. No evidence of relation between maternal exposure to herpes simplex virus type 2 and risk of schizophrenia? Am J Psychiatry 2006; 163:2178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/52\">",
"      Pedersen MG, Stevens H, Pedersen CB, et al. Toxoplasma infection and later development of schizophrenia in mothers. Am J Psychiatry 2011; 168:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/53\">",
"      Dickerson F, Stallings C, Origoni A, et al. Antibodies to measles in individuals with recent onset psychosis. Schizophr Res 2010; 119:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/54\">",
"      Weiser M, Werbeloff N, Levine A, et al. CNS infection in childhood does not confer risk for later schizophrenia: a case-control study. Schizophr Res 2010; 124:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/55\">",
"      Benros ME, Nielsen PR, Nordentoft M, et al. Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. Am J Psychiatry 2011; 168:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/56\">",
"      Miller BJ, Buckley P, Seabolt W, et al. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011; 70:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/57\">",
"      Monji A, Kato T, Kanba S. Cytokines and schizophrenia: Microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci 2009; 63:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/58\">",
"      Kato TA, Monji A, Mizoguchi Y, et al. Anti-Inflammatory properties of antipsychotics via microglia modulations: are antipsychotics a 'fire extinguisher' in the brain of schizophrenia? Mini Rev Med Chem 2011; 11:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/59\">",
"      Chen YJ, Wu CY, Lin MW, et al. Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study. Br J Dermatol 2011; 165:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/60\">",
"      Eaton WW, Byrne M, Ewald H, et al. Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. Am J Psychiatry 2006; 163:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/61\">",
"      Eaton WW, Hayward C, Ram R. Schizophrenia and rheumatoid arthritis: a review. Schizophr Res 1992; 6:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/62\">",
"      Dickerson F, Stallings C, Origoni A, et al. Markers of gluten sensitivity and celiac disease in recent-onset psychosis and multi-episode schizophrenia. Biol Psychiatry 2010; 68:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/63\">",
"      Samaroo D, Dickerson F, Kasarda DD, et al. Novel immune response to gluten in individuals with schizophrenia. Schizophr Res 2010; 118:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/64\">",
"      Severance EG, Dickerson FB, Halling M, et al. Subunit and whole molecule specificity of the anti-bovine casein immune response in recent onset psychosis and schizophrenia. Schizophr Res 2010; 118:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/65\">",
"      Severance EG, Lin J, Sampson HA, et al. Dietary antigens, epitope recognition, and immune complex formation in recent onset psychosis and long-term schizophrenia. Schizophr Res 2011; 126:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/66\">",
"      Amminger GP, Sch&auml;fer MR, Papageorgiou K, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2010; 67:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/67\">",
"      Laan W, Grobbee DE, Selten JP, et al. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2010; 71:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/68\">",
"      Akhondzadeh S, Tabatabaee M, Amini H, et al. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res 2007; 90:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/69\">",
"      Andr&eacute;asson S, Allebeck P, Engstr&ouml;m A, Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 1987; 2:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/70\">",
"      van Os J, Bak M, Hanssen M, et al. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 2002; 156:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/71\">",
"      Kristensen K, Cadenhead KS. Cannabis abuse and risk for psychosis in a prodromal sample. Psychiatry Res 2007; 151:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/72\">",
"      Kuepper R, van Os J, Lieb R, et al. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ 2011; 342:d738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/73\">",
"      McGrath J, Welham J, Scott J, et al. Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults. Arch Gen Psychiatry 2010; 67:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/74\">",
"      D'Souza DC, Perry E, MacDougall L, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 2004; 29:1558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/75\">",
"      D'Souza DC, Abi-Saab WM, Madonick S, et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 2005; 57:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/76\">",
"      Selten JP, Hoek HW. Does misdiagnosis explain the schizophrenia epidemic among immigrants from developing countries to Western Europe? Soc Psychiatry Psychiatr Epidemiol 2008; 43:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/77\">",
"      Youngmann R, Pugachova I, Zilber N. Patterns of psychiatric hospitalization among ethiopian and former soviet union immigrants and persons born in Israel. Psychiatr Serv 2009; 60:1656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/78\">",
"      Coid JW, Kirkbride JB, Barker D, et al. Raised incidence rates of all psychoses among migrant groups: findings from the East London first episode psychosis study. Arch Gen Psychiatry 2008; 65:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/79\">",
"      McGrath JJ, Eyles DW, Pedersen CB, et al. Neonatal vitamin D status and risk of schizophrenia: a population-based case-control study. Arch Gen Psychiatry 2010; 67:889.",
"     </a>",
"    </li>",
"    <li>",
"     Fischer BA, Kirkpatrick B, Carpenter WT. The neurobiology of negative symptoms and the deficit syndrome. In: The Handbook of Neurochemistry and Molecular Neurobiology: Schizophrenia, 3rd ed, Javitt DC, Kantrowitz JT.  (Eds), Springer Science and Business Media LLC, New York 2009. Vol 27, p.507.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/81\">",
"      Goldman-Rakic PS, Castner SA, Svensson TH, et al. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl) 2004; 174:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/82\">",
"      Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/83\">",
"      Lahti AC, Weiler MA, Tamara Michaelidis BA, et al. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 2001; 25:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/84\">",
"      Newcomer JW, Farber NB, Jevtovic-Todorovic V, et al. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 1999; 20:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/85\">",
"      Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/86\">",
"      Geddes AE, Huang XF, Newell KA. Reciprocal signalling between NR2 subunits of the NMDA receptor and neuregulin1 and their role in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/87\">",
"      Schwarcz R, Rassoulpour A, Wu HQ, et al. Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 2001; 50:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/88\">",
"      Erhardt S, Schwieler L, Nilsson L, et al. The kynurenic acid hypothesis of schizophrenia. Physiol Behav 2007; 92:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/89\">",
"      Buchanan RW, Javitt DC, Marder SR, et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 2007; 164:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/90\">",
"      Patil ST, Zhang L, Martenyi F, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 2007; 13:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/91\">",
"      Hashimoto T, Volk DW, Eggan SM, et al. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J Neurosci 2003; 23:6315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/92\">",
"      Guidotti A, Auta J, Davis JM, et al. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch Gen Psychiatry 2000; 57:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/93\">",
"      Pierri JN, Chaudry AS, Woo TU, Lewis DA. Alterations in chandelier neuron axon terminals in the prefrontal cortex of schizophrenic subjects. Am J Psychiatry 1999; 156:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/94\">",
"      Woo TU, Whitehead RE, Melchitzky DS, Lewis DA. A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia. Proc Natl Acad Sci U S A 1998; 95:5341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/95\">",
"      Volk D, Austin M, Pierri J, et al. GABA transporter-1 mRNA in the prefrontal cortex in schizophrenia: decreased expression in a subset of neurons. Am J Psychiatry 2001; 158:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/96\">",
"      Volk DW, Pierri JN, Fritschy JM, et al. Reciprocal alterations in pre- and postsynaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia. Cereb Cortex 2002; 12:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/97\">",
"      Kinon BJ, Zhang L, Millen BA, et al. A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol 2011; 31:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/98\">",
"      U&ccedil;ok A, Polat A, Bozkurt O, Meteris H. Cigarette smoking among patients with schizophrenia and bipolar disorders. Psychiatry Clin Neurosci 2004; 58:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/99\">",
"      de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res 2005; 76:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/100\">",
"      Williams JM, Gandhi KK, Lu SE, et al. Higher nicotine levels in schizophrenia compared with controls after smoking a single cigarette. Nicotine Tob Res 2010; 12:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/101\">",
"      Olincy A, Young DA, Freedman R. Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. Biol Psychiatry 1997; 42:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/102\">",
"      Avila MT, Sherr JD, Hong E, et al. Effects of nicotine on leading saccades during smooth pursuit eye movements in smokers and nonsmokers with schizophrenia. Neuropsychopharmacology 2003; 28:2184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/103\">",
"      Olincy A, Johnson LL, Ross RG. Differential effects of cigarette smoking on performance of a smooth pursuit and a saccadic eye movement task in schizophrenia. Psychiatry Res 2003; 117:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/104\">",
"      Sherr JD, Myers C, Avila MT, et al. The effects of nicotine on specific eye tracking measures in schizophrenia. Biol Psychiatry 2002; 52:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/105\">",
"      Adler LE, Hoffer LD, Wiser A, Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry 1993; 150:1856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/106\">",
"      Olincy A, Harris JG, Johnson LL, et al. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 2006; 63:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/107\">",
"      Hong LE, Schroeder M, Ross TJ, et al. Nicotine enhances but does not normalize visual sustained attention and the associated brain network in schizophrenia. Schizophr Bull 2011; 37:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/108\">",
"      Freedman R, Olincy A, Buchanan RW, et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 2008; 165:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/109\">",
"      Mao D, Gallagher K, McGehee DS. Nicotine potentiation of excitatory inputs to ventral tegmental area dopamine neurons. J Neurosci 2011; 31:6710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20057/abstract/110\">",
"      Jin Y, Yang K, Wang H, Wu J. Exposure of nicotine to ventral tegmental area slices induces glutamatergic synaptic plasticity on dopamine neurons. Synapse 2011; 65:332.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14804 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-197.136.42.3-9A7ECFAA8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_37_20057=[""].join("\n");
var outline_f19_37_20057=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1475992\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31673341\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31673348\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31673355\">",
"      Co-occurring conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31673362\">",
"      Cost",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H296339\">",
"      Deficit schizophrenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31673369\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31673376\">",
"      Genetic risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31673383\">",
"      Environmental risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31673390\">",
"      - Obstetrical complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31673397\">",
"      - Infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31673404\">",
"      - Inflammation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15986866\">",
"      - Cannabis use",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31673411\">",
"      - Immigration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31673460\">",
"      Neurotransmitters",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31673425\">",
"      - Dopamine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31673432\">",
"      - Glutamate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31673439\">",
"      - Gamma-amino-butyric acid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31673446\">",
"      - Acetylcholine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1475992\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22853334\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/14804\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14804|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/25/37276\" title=\"table 1\">",
"      Some genes of interest in schizophrenia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/3/2105?source=related_link\">",
"      Anxiety in schizophrenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/28/4554?source=related_link\">",
"      Cannabis use disorders: Treatment, prognosis, and long-term medical effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/21/25944?source=related_link\">",
"      Depression in schizophrenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36521?source=related_link\">",
"      Dual diagnosis: Severe mental illness and substance use disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/38/3689?source=related_link\">",
"      Genetic association studies: Principles and applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28583?source=related_link\">",
"      Overview of psychosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29241?source=related_link\">",
"      Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/9/30871?source=related_link\">",
"      Pharmacotherapy for schizophrenia: Long-acting injectable antipsychotic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44760?source=related_link\">",
"      Pharmacotherapy for schizophrenia: Side effect management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8904?source=related_link\">",
"      Psychosocial interventions for schizophrenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34552?source=related_link\">",
"      Schizophrenia: Clinical manifestations, course, assessment, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_37_20058="Antimicrobial therapy of native valve endocarditis";
var content_f19_37_20058=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Antimicrobial therapy of native valve endocarditis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/37/20058/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/37/20058/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/37/20058/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/37/20058/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/37/20058/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/37/20058/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/37/20058/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the availability of antimicrobial therapy, infective endocarditis (IE) was invariably fatal. Although approximately 80 percent of patients with endocarditis now survive their infections, one of every six patients with IE does not survive the initial hospitalization, and up to one-third of patients infected with highly virulent organisms (such as Staphylococcus aureus) may die as a direct or indirect result of their valvular infection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/1\">",
"     1",
"    </a>",
"    ]. An adverse outcome in these patients can occur despite having received appropriate antimicrobial therapy in a timely manner, and despite the skillful use of modern diagnostic techniques.",
"   </p>",
"   <p>",
"    The major issues related to the antimicrobial therapy of IE will be reviewed here. The pathogenesis of vegetation formation and the complications and indications for surgery in this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17718?source=see_link\">",
"     \"Pathogenesis of vegetation formation in infective endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18249?source=see_link\">",
"     \"Complications and outcome of infective endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22297?source=see_link\">",
"     \"Surgery for native valve endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Soon after the discovery of sulfonamides and penicillins, it was realized that only bactericidal, not bacteriostatic, therapy was effective in treating endocarditis. Thus, following the establishment of a diagnosis using microbiologic and echocardiographic methods, or by clinical deduction, antimicrobial therapy should be administered in a dose designed to give sustained bactericidal serum concentrations throughout much of the entire dosing interval. In vitro determination of the minimum inhibitory concentration or other susceptibility testing of the etiologic cause of the endocarditis should be performed in all patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31094?source=see_link\">",
"     \"Infective endocarditis: Historical and Duke criteria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Empiric therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, therapy for infective endocarditis (IE) should be targeted to the organism isolated from blood cultures; cultures are positive in over 90 percent of patients with IE. For patients with suspected IE who present without acute symptoms, empiric therapy is not always necessary, and therapy can await blood culture results. Results of blood cultures are usually available within one to three days, and an accurate diagnosis is a critical first step in designing a management strategy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=see_link\">",
"     \"Diagnostic approach to infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For acutely ill patients with signs and symptoms strongly suggestive of IE, empiric therapy may be necessary. Such empiric therapy should be administered ONLY after at least two (preferably three) sets of blood cultures have been obtained from separate venipunctures, and ideally spaced over 30 to 60 minutes. The choice of empiric therapy in such cases should take into consideration the most likely pathogens. In general, empiric therapy should cover staphylococci (methicillin-susceptible and resistant), streptococci, and enterococci.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     Vancomycin",
"    </a>",
"    (30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per 24 h IV in two divided doses) is an appropriate choice for initial therapy in most patients.",
"   </p>",
"   <p>",
"    Early consultation with a cardiac surgeon should be obtained for all cases in which complications are observed or expected (such as in infections involving prosthetic valves or complicated by moderate to severe heart failure). In addition, consultation by specialists in infectious diseases or cardiology may be useful if the treating clinician does not have experience in managing this life-threatening illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with IE become afebrile three to five days after treatment is begun with an appropriate antibiotic. Patients with S. aureus endocarditis may respond somewhat more slowly, remaining febrile for five to seven days after the institution of therapy. Patients with right-sided endocarditis and septic pulmonary emboli may remain febrile for an even longer duration of time.",
"   </p>",
"   <p>",
"    The initial microbiologic response to therapy should be assessed by obtaining repeat blood cultures 48 to 72 hours after antibiotics are begun. Thereafter, regular careful serial examinations should be performed to search for signs of heart failure, emboli, or other complications.",
"   </p>",
"   <p>",
"    The duration of therapy must be sufficient to eradicate microorganisms growing within the valvular vegetations. Although early clinical trials showed that a few patients with streptococcal endocarditis could be cured with low doses of penicillin administered for as short as six days, longer therapy was necessary to ensure cure in the majority of patients. As an example, the results of two landmark treatment trials performed in the 1940s and early 1950s revealed that approximately 20 percent of patients with viridans streptococcal endocarditis relapsed when penicillin was administered for only 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By contrast, in a later study of 74 patients with viridans streptococcal endocarditis, none of 66 consecutive patients who survived a four-week course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    relapsed, and no patient treated with this regimen died of active infection. Similarly, four to six weeks of bactericidal therapy with a single drug was shown to be highly effective as treatment for endocarditis due to other streptococcal species and for staphylococci. Prolonged therapy was presumed to be necessary because bacterial concentrations within vegetations are as high as 10",
"    <sup>",
"     9",
"    </sup>",
"    to 10",
"    <sup>",
"     11",
"    </sup>",
"    <span class=\"nowrap\">",
"     CFUs/gram",
"    </span>",
"    of tissue, and because organisms deep within vegetations are not accessible to phagocytic cells and often are in a state of reduced metabolic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17718?source=see_link\">",
"     \"Pathogenesis of vegetation formation in infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Duration of therapy in patients with native valve endocarditis ranges from two to six weeks, depending on the pathogen and site of valvular infection. Short (two-week) therapeutic regimens are effective in a small number of carefully selected patients with right-sided endocarditis and in some patients with endocarditis due to highly susceptible viridans streptococci treated with synergistic antimicrobials. Most patients are treated parenterally with regimens given for&nbsp;either four or six weeks. In general, longer (six week) treatment regimens are used in patients with highly virulent or more resistant pathogens, those with secondary cardiac or extracardiac complications, and in patients with infections of long duration prior to diagnosis.&nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Combination antimicrobial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for prolonged therapy in treating endocarditis and the problem of increasing antimicrobial resistance among pathogens that cause IE have stimulated interest in using combination therapy to treat endocarditis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Combination therapy using a beta lactam agent, such as penicillin, with an aminoglycoside has been shown to be highly effective in streptococcal and enterococcal endocarditis, and of equivocal efficacy in patients with staphylococcal endocarditis (see below).",
"     </li>",
"     <li>",
"      Combination therapy with a penicillin and an aminoglycoside, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      and an aminoglycoside for two weeks is highly effective in carefully selected patients with streptococcus viridans endocarditis [",
"      <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Combination therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"       nafcillin",
"      </a>",
"      and an aminoglycoside for two weeks has been shown to be effective in patients with right-sided endocarditis due to Staphylococcus aureus [",
"      <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/6\">",
"       6",
"      </a>",
"      ]. In contrast, combined therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      and an aminoglycoside administered for two weeks does not appear to be effective in these patients. In addition, combined therapy with nafcillin and an aminoglycoside is not effective in",
"      <strong>",
"       left-sided",
"      </strong>",
"      endocarditis if treatment is given for only two weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are small differences, described under each specific microorganism below, in recommended treatment guidelines between the American Heart Association (AHA), British Society for Antimicrobial Chemotherapy (BSAC), and the European Society for Cardiology (ESC) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/7-10\">",
"     7-10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Oral antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several reports have appeared that describe the successful use of oral regimens for selected patients with IE [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/11\">",
"     11",
"    </a>",
"    ]. However, these and other reports on the use of oral therapy in patients with IE have involved only small numbers of patients and generally patients with a history of drug abuse who have right-sided IE due to S. aureus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40215?source=see_link\">",
"     \"Infective endocarditis in injection drug users\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, oral regimens should",
"    <strong>",
"     NOT",
"    </strong>",
"    be used as initial therapy but may be used in highly selected cases if the following criteria are met:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The causative organism is known",
"     </li>",
"     <li>",
"      The antimicrobial susceptibility has been carefully studied",
"     </li>",
"     <li>",
"      In vitro studies show high levels of susceptibility",
"     </li>",
"     <li>",
"      There is a compelling reason to give oral therapy rather than conventional intravenous therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As an example, a randomized prospective study of right-sided endocarditis in 44 injection drug users (IDUs) showed that combination oral therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    was as effective as parenteral therapy for staphylococcal endocarditis in patients in whom oral therapy could be closely supervised [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/11\">",
"     11",
"    </a>",
"    ]. In this trial, all patients received parenteral therapy for the first five days; thereafter, 19 patients completed one month of therapy with oral rifampin and ciprofloxacin and 25 received one month of parenteral therapy. There was no significant difference in treatment failures among patients receiving oral versus parenteral therapy (1 of 19 for oral versus 3 of 25 for parenteral therapy).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Home antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Until recently, most patients with IE received the entire duration of their antimicrobial therapy while in the hospital. However, the development of systems and equipment that permit prolonged and safe administration of intravenous therapy in the home has made it acceptable to treat most patients with endocarditis as outpatients during much or even all of their therapy.",
"   </p>",
"   <p>",
"    Patients selected for outpatient therapy should be hemodynamically stable, compliant, and capable of managing the technical aspects of intravenous therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/7\">",
"     7",
"    </a>",
"    ]. Such patients still require careful and regular monitoring, and must have ready access to full medical care should complications, such as drug allergy, emboli, or cardiac failure, occur [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/7,12\">",
"     7,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     VIRIDANS STREPTOCOCCI AND STREPTOCOCCUS BOVIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The various species of streptococci that make up the viridans group and Streptococcus bovis (renamed S. gallolyticus and S. infantarius) account for approximately 40 to 60 percent of all cases of native valve endocarditis in community practice. Members of the viridans group include S. mitis, S. mutans, S. oralis, S. sanguinis, S. sobrinus, and the S. milleri group (S anginosus, S. constellatus, and S. intermedius). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29926?source=see_link&amp;anchor=H5#H5\">",
"     \"Microbiology, pathogenesis, and epidemiology of Streptococcus bovis infection\", section on 'Bacteremia and endocarditis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/33/22041?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of Streptococcus bovis infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most viridans group streptococci are highly penicillin-susceptible, defined as a minimum inhibitory concentration (MIC) &le;0.12",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"    Occasional strains have \"intermediate\" susceptibility to penicillin (MIC &gt;0.12",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    and &le;0.5",
"    <span class=\"nowrap\">",
"     mcg/mL),",
"    </span>",
"    and rare strains are considered to be fully resistant with a penicillin MIC &gt;0.5",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment regimens recommended for native valve endocarditis are identical to those recommended for prosthetic valve endocarditis (PVE); however, a total duration of six rather than four weeks is recommended for PVE. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34712?source=see_link\">",
"     \"Antimicrobial therapy of prosthetic valve endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endocarditis due to viridans group streptococci and S. bovis organisms can usually be microbiologically cured if one of four different regimens is used (",
"    <a class=\"graphic graphic_table graphicRef73007 \" href=\"UTD.htm?6/53/7006\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef53990 \" href=\"UTD.htm?22/16/22797\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For treatment of penicillin-susceptible strains (MIC &le;0.12",
"      <span class=\"nowrap\">",
"       mcg/mL),",
"      </span>",
"      the American Heart Association (AHA), British Society for Antimicrobial Chemotherapy (BSAC), and European Society for Cardiology (ESC) all recommend a regimen consisting of aqueous crystalline",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"       penicillin G",
"      </a>",
"      at a dose of 12 to 18 million units daily (either continuously or in four to six equally divided doses) for four weeks as reliably effective in patients with endocarditis due to highly penicillin-susceptible streptococci (",
"      <a class=\"graphic graphic_table graphicRef73007 \" href=\"UTD.htm?6/53/7006\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/7,8,10\">",
"       7,8,10",
"      </a>",
"      ]. Penicillin, or an equally effective regimen consisting of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      given intravenously or intramuscularly as a 2 g daily dose for four weeks, remain the preferred treatments for elderly patients, or in other patients in whom aminoglycoside therapy is considered risky or contraindicated.",
"     </li>",
"     <li>",
"      Selected patients with native valve endocarditis due to penicillin-susceptible strains who do not have evidence of intracardiac or extracardiac complications, or preexisting renal or otic disease, may be treated with shorter courses of combination therapy (",
"      <a class=\"graphic graphic_table graphicRef73007 \" href=\"UTD.htm?6/53/7006\">",
"       table 1",
"      </a>",
"      ). The AHA guidelines recommend a regimen that includes",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      plus either aqueous crystalline",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"       penicillin G",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      for two weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/7\">",
"       7",
"      </a>",
"      ]. The BSAC guidelines recommend a regimen of gentamicin plus penicillin or ceftriaxone for two weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/10\">",
"       10",
"      </a>",
"      ], while the ESC guidelines recommend monotherapy with penicillin G for two weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/8\">",
"       8",
"      </a>",
"      ]. Gentamicin, if used, should be given either as a single dose of 3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day or in two to three equally divided doses adjusted to give a peak serum level of 3 to 4",
"      <span class=\"nowrap\">",
"       mcg/mL.",
"      </span>",
"      We prefer to administer the gentamicin in two to three equally divided doses for hospitalized patients when serum concentrations can be followed and as a single daily dose in outpatients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     Gentamicin",
"    </a>",
"    is more commonly used in clinical practice than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    due to the wider availability of gentamicin serum levels, and because dosing regimens for gentamicin are more familiar to most clinicians than for streptomycin. When streptomycin is used to treat endocarditis, the suggested dose in patients with normal renal function is 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day IM or IV in divided equally into two doses a day for two weeks. Dosage intervals need to be prolonged in patients with renal insufficiency.",
"   </p>",
"   <p>",
"    Patients with prior histories of penicillin allergy can usually be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    , if their prior history of penicillin allergy consists of rash without other signs of immediate-type hypersensitivity. Patients with histories of immediate-type hypersensitivity may either be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in two equally divided doses) for four weeks, or desensitized to penicillin and treated with a standard regimen. In patients with streptococcal endocarditis and a history of significant penicillin allergy, some favor treatment with a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    with either vancomycin or teicoplanin [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We believe that penicillin is preferable to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    ; we are unaware of controlled treatment trials comparing the efficacy of vancomycin to penicillin in cases of suspected drug hypersensitivity. Thus, when expertise is available to safely supervise desensitization protocols, we advise desensitization to penicillin rather than substitution of vancomycin. The healthcare provider should inform the patient who undergoes desensitization that the tolerance induced persists only as long as the patient continues to receive the drug. Once antibiotic therapy is stopped for a period of more than 24 hours, repeat desensitization is required if the particular drug is to be used again. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link\">",
"     \"Allergy to penicillins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For treatment of endocarditis due to \"intermediate\" susceptibility viridans streptococci (MIC &gt;0.12 and &le;0.5",
"      <span class=\"nowrap\">",
"       mcg/mL),",
"      </span>",
"      and patients with endocarditis due to streptococci with nutritional deficiencies that hinder their growth in routine laboratory culture media, the AHA guidelines recommend aqueous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"       penicillin G",
"      </a>",
"      (24 million units daily either continuously or in four to six equally divided doses) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      (2 g IV or IM once daily) for a total of four weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/7\">",
"       7",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"       Gentamicin",
"      </a>",
"      should be added to this regimen for the first two weeks (dosed as above). As for other patients with streptococcal endocarditis who have had an immediate-type hypersensitivity reaction to beta-lactams,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      is an acceptable alternative to penicillin (",
"      <a class=\"graphic graphic_table graphicRef53990 \" href=\"UTD.htm?22/16/22797\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2012 BSAC guidelines recommend that streptococcal endocarditis associated with strains with penicillin MICs &gt;0.12 and &le;0.5",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    be treated with benzylpenicillin for four to six weeks combined with an aminoglycoside for the first two weeks of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/10\">",
"     10",
"    </a>",
"    ]. Regimens used to treat enterococcal endocarditis are recommended for streptococcal endocarditis due to strains with MIC &gt;0.5",
"    <span class=\"nowrap\">",
"     mg/L.",
"    </span>",
"    Both the ESC and the BSAC guidelines recommend that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    be used for the treatment of streptococcal endocarditis due to strains with MICs &gt;4",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    although they acknowledge that there are no controlled trials to support these consensus opinions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endocarditis due to strains of viridans streptococci and streptococcal-like organisms (eg, Abiotrophia defectiva, Granulicatella spp, and Gemella spp) that have penicillin MICs &gt;1",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      and are considered fully resistant to penicillin should be treated with regimens used to treat enterococcal endocarditis, as recommended by the AHA (",
"      <a class=\"graphic graphic_table graphicRef50418 \" href=\"UTD.htm?30/24/31117\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/7,10,14,15\">",
"       7,10,14,15",
"      </a>",
"      ]. A review of 29 patients with endocarditis due to penicillin-resistant viridans streptococci seen over a 39 year period concluded that current treatment guidelines should be successful in most patients. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Enterococci'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     OTHER STREPTOCOCCAL SPECIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other streptococcal species (eg, groups A, B, C, and G, and Streptococcus pneumoniae) are occasional causes of endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Therapy should always be based on the results of susceptibility testing. Since most of these organisms are highly sensitive to penicillin, regimens used to treat endocarditis due to viridans streptococci are typically effective.",
"   </p>",
"   <p>",
"    Many strains of Group B, C, and G streptococci are more resistant to penicillin than S. pyogenes. For this reason, some experts recommend adding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    to a penicillin or cephalosporin for the first two weeks of a four to six week course of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pneumococcus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumococcal endocarditis typically follows pneumonia in alcoholic patients and may be complicated by concurrent meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/16\">",
"     16",
"    </a>",
"    ]. However, increasing numbers of isolates of S. pneumoniae have become relatively or highly resistant to penicillin. These organisms may be simultaneously resistant to other beta lactams and other antimicrobial agents. Therapy in these cases usually requires the input of an infectious disease specialist or a microbiologist.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     Penicillin G",
"    </a>",
"    (24 million units per day either continuously or in four to six equally divided doses) remains the therapy of choice for patients with endocarditis due to penicillin-susceptible strains of S. pneumoniae and Streptococcus pyogenes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/7\">",
"     7",
"    </a>",
"    ]. The 2012 British Society for Antimicrobial Chemotherapy (BSAC) guidelines recommend that the therapy of pneumococcal endocarditis be guided by the same susceptibility breakpoints used to determine the therapy of endocarditis due to other streptococcal species [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Viridans streptococci and Streptococcus bovis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A few strains of Streptococcus pneumoniae only respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/5/81?source=see_link\">",
"     \"Resistance of Streptococcus pneumoniae to beta-lactam antibiotics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pneumococcal endocarditis is usually fulminant and causes severe valve damage and embolic complications. The potential complications of pneumococcal endocarditis are illustrated by a case series from France [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/18\">",
"     18",
"    </a>",
"    ]. Transesophageal echocardiography (TEE) was performed in 28 of 30 patients with pneumococcal endocarditis; valvular vegetations, valve perforation, ring abscess, and other complications were detected in 97, 20, 13, and 20 percent, respectively. Early valve replacement may be necessary in patients with pneumococcal endocarditis to prevent complications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22297?source=see_link\">",
"     \"Surgery for native valve endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ENTEROCOCCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enterococci have a narrower spectrum of susceptibility than streptococcal species. In particular, members of the genus Enterococcus are all resistant to, at the least, low concentrations of penicillin. They are also relatively resistant to expanded spectrum penicillins, resistant to cephalosporins, and typically resistant to aminoglycosides at concentrations achieved after standard dosing regimens. However, many strains of enterococci are killed both in vitro and in vivo if penicillin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    is given in synergistic combination with an aminoglycoside such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    There are also a number of additional trends in the resistance pattern of enterococci. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/56/26506?source=see_link\">",
"     \"Mechanisms of antibiotic resistance in enterococci\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rare strains of Enterococcus faecalis have acquired genetic material that allows them to produce beta lactamase [",
"      <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/19,20\">",
"       19,20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other strains have acquired high level resistance to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"       streptomycin",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      . The latter is accompanied by high level resistance to synergy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"       tobramycin",
"      </a>",
"      , netilmicin, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"       amikacin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      High level resistance to penicillin and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      (MIC &ge;128",
"      <span class=\"nowrap\">",
"       mcg/mL)",
"      </span>",
"      that is not mediated by penicillinase has increased in some enterococci, primarily strains of Enterococcus faecium.",
"     </li>",
"     <li>",
"      Increasing numbers of enterococci have acquired high level resistance to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      as well as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      . Some, but not all, of these highly resistant strains, are also resistant to the glycopeptide antibiotic, teicoplanin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These patterns of resistance have a direct impact on the guidelines for treatment of enterococcal endocarditis (",
"    <a class=\"graphic graphic_table graphicRef50418 \" href=\"UTD.htm?30/24/31117\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef64258 \" href=\"UTD.htm?9/4/9294\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef66444 \" href=\"UTD.htm?42/0/43021\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Susceptible strains",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of cases of enterococcal endocarditis are caused by strains of E. faecalis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/21\">",
"     21",
"    </a>",
"    ]. The American Heart Association (AHA) and British Society for Antimicrobial Chemotherapy (BSAC) recommend that therapy for E. faecalis with typical low level penicillin resistance consist of a combination of intravenous aqueous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef50418 \" href=\"UTD.htm?30/24/31117\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/7,10\">",
"     7,10",
"    </a>",
"    ]. In addition, the BSAC recommends either a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    and gentamicin and teicoplanin as alternatives to penicillin or ampicillin in the penicillin-allergic patient if the isolate is susceptible (MIC &le;4",
"    <span class=\"nowrap\">",
"     mcg/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/10\">",
"     10",
"    </a>",
"    ]. The European Society for Cardiology (ESC) recommends combination therapy with either penicillin G plus gentamicin for four weeks or vancomycin plus gentamicin for six weeks (",
"    <a class=\"graphic graphic_table graphicRef50418 \" href=\"UTD.htm?30/24/31117\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    is about one dilution more potent then penicillin in vitro, there is no evidence that this is necessary or beneficial for synergism in most instances. Because of the possibility of increased allergic reactions to ampicillin, some experts prefer penicillin rather than ampicillin for synergistic therapy.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     Gentamicin",
"    </a>",
"    therapy is usually given at doses of 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every eight hours to achieve peak serum levels of approximately 3 to 4",
"    <span class=\"nowrap\">",
"     mcg/mL,",
"    </span>",
"    and trough serum concentrations &lt;1",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"     Tobramycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    are usually avoided.",
"   </p>",
"   <p>",
"    In one study, patients with symptoms of endocarditis for less than three months were usually treated successfully with four weeks of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/23\">",
"     23",
"    </a>",
"    ]. By contrast, six weeks of therapy is preferred in patients with symptoms of more than three months duration prior to the initiation of treatment, with a relapsed infection, or with prosthetic valve infection.",
"   </p>",
"   <p>",
"    The AHA recommends four to six weeks of treatment based upon the length of time the patient reports symptoms at presentation (",
"    <a class=\"graphic graphic_table graphicRef50418 \" href=\"UTD.htm?30/24/31117\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/7\">",
"     7",
"    </a>",
"    ]. The BSAC recommends at least four weeks of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/10\">",
"     10",
"    </a>",
"    ], while the ESC recommends only four weeks of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with a history of penicillin allergy should be treated with a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    (3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) for six weeks or considered for desensitization. As stated previously, we believe that penicillin is preferable to vancomycin. Thus, when expertise is available to safely supervise desensitization protocols and when the nature of the penicillin allergy is doubtful or otherwise inconclusive, we advise desensitization to penicillin rather than substitution of vancomycin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link\">",
"     \"Allergy to penicillins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    is elected, the AHA and ESC recommend a duration of therapy of six weeks rather than four weeks, because vancomycin has decreased activity against enterococci as compared to penicillin (",
"    <a class=\"graphic graphic_table graphicRef50418 \" href=\"UTD.htm?30/24/31117\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/7,22\">",
"     7,22",
"    </a>",
"    ]. The BSAC recommends at least four weeks of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Gentamicin-resistant strains",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enterococcal endocarditis caused by strains that are susceptible to penicillin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    but resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    can be treated with one of two combinations. The preferred treatment regimen is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    or penicillin plus streptomycin (15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in two equally divided doses). In the penicillin-allergic patient, the alternative treatment is vancomycin (30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in two equally divided doses) plus streptomycin [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/7\">",
"     7",
"    </a>",
"    ]. Patients who have enterococcal endocarditis due to ampicillin-susceptible (MIC of 4",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    or less) and high-level gentamicin and streptomycin resistant (MIC &gt;128",
"    <span class=\"nowrap\">",
"     mg/L)",
"    </span>",
"    enterococci may be treated with ampicillin monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     High-level penicillin resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The AHA recommends that enterococcal endocarditis due to strains with intrinsic high-level penicillin resistance (MIC &gt;16",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    be treated with a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    plus either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1160?source=see_link\">",
"     ampicillin-sulbactam",
"    </a>",
"    (12 g per day in four equally divided doses) (if the resistance is beta lactamase mediated)",
"    <strong>",
"     or",
"    </strong>",
"    &nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily given intravenously in two divided doses) for six weeks (",
"    <a class=\"graphic graphic_table graphicRef64258 \" href=\"UTD.htm?9/4/9294\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/7\">",
"     7",
"    </a>",
"    ]. The BSAC recommends the combination of gentamicin plus either vancomycin (1 g every 12 hours) or teicoplanin (10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    once daily, if MIC &le;4",
"    <span class=\"nowrap\">",
"     mcg/L)",
"    </span>",
"    for at least four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/10\">",
"     10",
"    </a>",
"    ]. The ESC recommends vancomycin plus gentamicin for six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unfortunately, most beta lactamase producing E. faecalis strains have also been highly resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     High-level aminoglycoside or vancomycin resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;E. faecium is the enterococcal strain most likely to manifest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    resistance, but this strain is an uncommon cause of endocarditis. Therefore, literature on the treatment of patients with endocarditis due to vancomycin-resistant enterococci is limited to isolated case reports and extrapolation from in vitro susceptibility studies and animal models of endocarditis. Management of endocarditis due to enterococci with high level aminoglycoside",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vancomycin resistance may require individualized consideration by the microbiology laboratory as well as infectious disease consultation.",
"   </p>",
"   <p>",
"    Results of in vitro susceptibility studies using various combinations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    have demonstrated conflicting results for both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    -resistant enterococci and methicillin-resistant S. aureus (MRSA). Some studies have shown modest additive effects [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]; other studies showed synergy with some but not all strains of MRSA [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/26\">",
"     26",
"    </a>",
"    ]. In view of these findings and the added risk of toxicity to gentamicin therapy, we do not favor using daptomycin and gentamicin in combination unless in vitro studies support addition of gentamicin and other less toxic regimens have failed.",
"   </p>",
"   <p>",
"    Some strains of enterococci that are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    -resistant lack high-level resistance (HLR) to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    , and vice versa. However, HLR to gentamicin is conferred by a bifunctional enzyme that also confers high level resistance to",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    resistance to synergism with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    , netilmicin, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    . When endocarditis is due to enterococci that are highly resistant to both streptomycin and gentamicin, the addition of an aminoglycoside is not beneficial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14314?source=see_link\">",
"     \"Treatment of enterococcal infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Success and failure of therapy for endocarditis due to resistant organisms has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. In a retrospective review of 12 cases of native valve",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    -resistant enterococcal endocarditis, all patients had significant comorbidities [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/27\">",
"     27",
"    </a>",
"    ]. Three of the 12 patients died. Four patients were successfully treated with six to nine weeks of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    (two received linezolid alone, one each received an additional antibiotic, either alatrofloxacin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Optimal therapy for such patients has not been defined, but a number of possible regimens were mentioned in the major society guidelines (",
"    <a class=\"graphic graphic_table graphicRef66444 \" href=\"UTD.htm?42/0/43021\">",
"     table 5",
"    </a>",
"    ). Subsequent to publication of the guidelines, a six week regimen of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    (2 g IV every four hours) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (2 g IV every 12 hours) was evaluated in patients with E. faecalis endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/30\">",
"     30",
"    </a>",
"    ] based upon demonstrated efficacy in experimental endocarditis due to E. faecalis strains that were highly resistant to aminoglycosides [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The study consisted of 21 patients with an isolate with high level aminoglycoside resistance and 22 without such resistance; all patients were at risk for aminoglycoside nephrotoxicity. The clinical cure rate was 67 percent at six months and, among patients with high level aminoglycoside resistance who completed the six week protocol, the clinical and microbiologic cure rate was 100 percent. We have used this regimen in several patients with HLR enterococcal endocarditis with similar good results.",
"   </p>",
"   <p>",
"    In patients who do not respond to antimicrobial therapy, surgical resection of the involved valve may be necessary for cure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22297?source=see_link\">",
"     \"Surgery for native valve endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     STAPHYLOCOCCAL ENDOCARDITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The success of therapy for staphylococcal endocarditis is dependent upon numerous factors, including involvement of right versus left-sided valvular structures, whether the staphylococcus is coagulase negative or positive, the susceptibility of the staphylococcal isolate, and whether the infection occurs on a native or prosthetic valve.",
"   </p>",
"   <p>",
"    Rare, occasional strains of S. aureus are found to be penicillin-susceptible; the strain should be tested to confirm the MIC is &le;0.1",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    <strong>",
"     and",
"    </strong>",
"    that the strain does not produce beta lactamase in vitro. If penicillin-susceptibility is documented, penicillin (24 million",
"    <span class=\"nowrap\">",
"     units/day",
"    </span>",
"    in four to six divided doses) can be substituted for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"     nafcillin",
"    </a>",
"    or another semisynthetic penicillin in the regimens discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Methicillin susceptible",
"    </span>",
"    &nbsp;&mdash;&nbsp;Native valve endocarditis due to methicillin-susceptible S. aureus is best treated with a semisynthetic penicillin, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"     nafcillin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"     oxacillin",
"    </a>",
"    (12 g per day intravenously in four to six equally divided doses) or flucloxacillin (2 g every four to six hours) (",
"    <a class=\"graphic graphic_table graphicRef81429 \" href=\"UTD.htm?26/56/27533\">",
"     table 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Low-dose aminoglycosides should NOT be combined routinely with antistaphylococcal penicillins or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    for treatment of left-sided native valve S. aureus endocarditis. Although in vitro and in experimental models of endocarditis have demonstrated that combination therapy facilitates more rapid killing of methicillin-susceptible S. aureus than monotherapy, the evidence for clinically significant benefit is minimal. This was illustrated by a randomized trial of 48 patients with methicillin-susceptible S. aureus (MSSA) native valve endocarditis; patients who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"     nafcillin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    for the first two weeks of therapy had more rapid clearing of bacteremia than those who received nafcillin alone [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/32\">",
"     32",
"    </a>",
"    ]. However, cure rates were comparable and combination nafcillin and gentamicin therapy was associated with a higher incidence of renal dysfunction.",
"   </p>",
"   <p>",
"    Subsequently a randomized trial including 236 patients with S. aureus bacteremia and endocarditis demonstrated that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    monotherapy is not inferior to low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    plus an antistaphylococcal penicillin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    , although those in the standard therapy arm experienced significantly more renal impairment than those in the daptomycin arm [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/33\">",
"     33",
"    </a>",
"    ]. An investigation of the safety data from the trial noted significantly greater reduction in creatinine clearance among those who received initial low dose gentamicin than those who did not (22 versus 8 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therefore, initial low-dose aminoglycoside should NOT be combined routinely with antistaphylococcal penicillins or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    for treatment of S. aureus endocarditis. The limited benefit must be weighed against evidence for potential harm, particularly in the elderly and in those with diabetes and mild baseline renal dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24249?source=see_link\">",
"     \"Treatment of Staphylococcus aureus bacteremia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In adults, six weeks of therapy is recommended for complicated right-sided infective endocarditis (IE) and for all left-sided IE; complicated IE is defined as metastatic infections or when the course is otherwise complicated by secondary cardiac problems (eg, heart failure). In patients with uncomplicated right-sided IE, the duration of therapy is two weeks if synergistic therapy can be given. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Uncomplicated right sided'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In children, six weeks of therapy is recommended regardless of the site of infection or absence of complications because of insufficient clinical experience to support a duration of therapy of two weeks for uncomplicated right-sided IE [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Penicillin allergy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with native valve endocarditis due to S. aureus, who have a history of penicillin allergy, can be treated with a first generation cephalosporin, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    (2 g intravenously every eight hours), if there is no prior history of penicillin reaction that is typical of an immediate-type allergy. Some experts caution against substituting cefazolin for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"     nafcillin",
"    </a>",
"    in the treatment of staphylococcal endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/36\">",
"     36",
"    </a>",
"    ]. However, to our knowledge, the only study purporting to show that cefazolin was inferior to nafcillin in staphylococcal endocarditis was based on anecdotal observations of two patients with S. aureus endocarditis who either relapsed after treatment or who failed therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/37\">",
"     37",
"    </a>",
"    ]. The American Heart Association (AHA) recommends cefazolin as an alternative in patients with penicillin allergy that is not anaphylactoid type [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/7\">",
"     7",
"    </a>",
"    ], however, the British Society for Antimicrobial Chemotherapy (BSAC) and European Society for Cardiology (ESC) recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    therapy for all patients with penicillin allergy regardless of type [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/10,22\">",
"     10,22",
"    </a>",
"    ]. In addition, the BSAC 2012 guidelines recommend adding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    (300 to 600 mg orally q 12h) to vancomycin when treating methicillin-susceptible native valve endocarditis in patients with penicillin allergy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     Vancomycin",
"    </a>",
"    is an acceptable alternative in the patient with immediate-type penicillin allergy. However, vancomycin should not be used on the basis of convenience related to pharmacokinetics in patients without a history of penicillin allergy, since clinical experience and in vitro studies have suggested that vancomycin is a less effective antistaphylococcal antibiotic than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"     nafcillin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"     oxacillin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/7,38\">",
"     7,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     Clindamycin",
"    </a>",
"    is not an acceptable alternative for staphylococcal endocarditis because relapse is common [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Uncomplicated right sided",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selected patients with native valve right-sided endocarditis due to S. aureus with no evidence of renal failure, extrapulmonary metastatic infections, or simultaneous left-sided valvular infection, may be successfully treated with two week regimens utilizing the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"     nafcillin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Regimens that substitute",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    or teicoplanin for nafcillin (eg, for penicillin allergic patients) are not considered to be reliably effective if only two weeks of therapy are given [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/36\">",
"     36",
"    </a>",
"    ]. Although one randomized study showed that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/45/31446?source=see_link\">",
"     cloxacillin",
"    </a>",
"    alone for two weeks was equivalent to the combination of cloxacillin plus gentamicin in the treatment of right-sided IE in IDUs, we do not routinely advise short-course monotherapy for such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Short course regimens utilizing combination therapy are also not suitable for patients with simultaneous infection of the left-side heart valves, isolates that demonstrate high-level",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    resistance (MIC &gt;500",
"    <span class=\"nowrap\">",
"     mcg/mL),",
"    </span>",
"    metastatic infections outside of the lungs, or in patients who fail to defervesce in a normal time period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Methicillin resistant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Native valve endocarditis due to either methicillin-resistant S. aureus (MRSA) or coagulase-negative staphylococci should be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    for six weeks (",
"    <a class=\"graphic graphic_table graphicRef81429 \" href=\"UTD.htm?26/56/27533\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/7,22,40\">",
"     7,22,40",
"    </a>",
"    ]. However, there have been a number of reports of vancomycin treatment failure in serious infections due to MRSA even when isolates are proven to be susceptible using current microbiological testing methods [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/41-43\">",
"     41-43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/10\">",
"     10",
"    </a>",
"    ] recommend the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    (300 to 600 mg orally q12 h) to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    in the treatment of native valve endocarditis due methicillin-resistant but vancomycin-susceptible S. aureus. However the evidence for this approach is not conclusive and the risk of rifampin-induced drug interactions or hepatic toxicity should be weighed before utilizing such therapy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     Gentamicin",
"    </a>",
"    should NOT be combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    for treatment of MRSA native valve IE [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Methicillin susceptible'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     Daptomycin",
"    </a>",
"    is an acceptable alternative to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/40\">",
"     40",
"    </a>",
"    ]. In a randomized trial of 246 patients with SAB with or without endocarditis, daptomycin (6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV per day) was not inferior to standard therapy for SAB or right-sided endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/33\">",
"     33",
"    </a>",
"    ]. Daptomycin resistance (MIC &ge;2",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    developed in six patients.",
"   </p>",
"   <p>",
"    Randomized controlled trials of the effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/17/34068?source=see_link\">",
"     quinupristin-dalfopristin",
"    </a>",
"    in humans with IE have not yet been published. Both treatment failures and successes with linezolid in humans with IE due to MRSA have been reported by several authors, and experimental studies in animal models have shown promising results [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/44-50\">",
"     44-50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Coagulase negative staphylococci",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment regimens for coagulase-negative staphylococci are identical to those for coagulase-positive staphylococci. Most strains of coagulase-negative staphylococci are methicillin-resistant. As a result, unless susceptibility to methicillin can be conclusively demonstrated, coagulase-negative staphylococci causing prosthetic valve endocarditis (PVE) should be assumed to be methicillin-resistant and treated accordingly [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5317?source=see_link\">",
"     \"Endocarditis due to coagulase-negative staphylococci\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     HACEK ORGANISMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of fastidious gram-negative bacilli, collectively grouped by the acronym \"HACEK,\" account for 5 to 10 percent of all cases of native valve endocarditis in individuals who do not use illicit intravenous drugs. Organisms in this category include the following:",
"    <strong>",
"     H",
"    </strong>",
"    aemophilus aphrophilus (subsequently called Aggregatibacter aphrophilus and Aggregatibacter paraphrophilus);",
"    <strong>",
"     A",
"    </strong>",
"    ctinobacillus actinomycetemcomitans (subsequently called Aggregatibacter actinomycetemcomitans);",
"    <strong>",
"     C",
"    </strong>",
"    ardiobacterium hominis;",
"    <strong>",
"     E",
"    </strong>",
"    ikenella corrodens; and",
"    <strong>",
"     K",
"    </strong>",
"    ingella kingae. If traditional (non-automated) blood culture systems are used, longer incubation periods (&gt;6 days) may be required to detect their growth. This delayed growth made these organisms synonymous with culture-negative endocarditis. Since the introduction of automated blood culture systems, the HACEK organisms are easily isolated when incubated for five days. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34646?source=see_link\">",
"     \"Culture-negative endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although most HACEK organisms were",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    -sensitive in the past, this is no longer true, as many species in this group have acquired the ability to produce beta lactamase. However, virtually all of these organisms, even strains that produce beta lactamase, are highly susceptible to third generation cephalosporins, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (2 g once daily, given IV or IM).",
"   </p>",
"   <p>",
"    The American Heart Association (AHA) recommends treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1160?source=see_link\">",
"     ampicillin-sulbactam",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    for four weeks (",
"    <a class=\"graphic graphic_table graphicRef70411 \" href=\"UTD.htm?38/47/39676\">",
"     table 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/7\">",
"     7",
"    </a>",
"    ]. The British Society for Antimicrobial Chemotherapy (BSAC), in contrast, recommends combination therapy with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    (if susceptible) or ceftriaxone for four weeks with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    added for the initial two weeks of treatment (",
"    <a class=\"graphic graphic_table graphicRef70411 \" href=\"UTD.htm?38/47/39676\">",
"     table 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/10\">",
"     10",
"    </a>",
"    ]. The European Society for Cardiology (ESC) recommends either ceftriaxone alone or ampicillin plus gentamicin; both regimens are given for three to four weeks (",
"    <a class=\"graphic graphic_table graphicRef70411 \" href=\"UTD.htm?38/47/39676\">",
"     table 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H933452042\">",
"    <span class=\"h1\">",
"     OTHER GRAM-NEGATIVE ORGANISMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Native valve endocarditis due to other gram-negative bacilli, such as E. coli, Pseudomonas, or mucoid strains of Klebsiella or Serratia, is extremely rare. The most common predisposing factor is an implanted endovascular device, and most cases occur in the setting of recent healthcare contact [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The choice of antimicrobial therapy is dependent on the antimicrobial susceptibility of the causative organism. Third-generation cephalosporins, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (2 g once daily IV), or a fluoroquinolone, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (400 mg q 12 IV), are acceptable regimens if the organism is susceptible in vitro. Combination antimicrobial therapy with an antipseudomonal penicillin and an aminoglycoside is an effective regimen for patients with infections due to Pseudomonas [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     CULTURE-NEGATIVE ENDOCARDITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood culture-negative infective endocarditis (IE) is defined as endocarditis without etiology following inoculation of three blood samples in a standard blood culture system (eg, negative cultures after seven days).",
"   </p>",
"   <p>",
"    Cultures are negative in infective endocarditis for three major reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Previous administration of antimicrobial agents",
"     </li>",
"     <li>",
"      Inadequate microbiological techniques",
"     </li>",
"     <li>",
"      Infection with highly fastidious bacteria or nonbacterial pathogens (eg, fungi)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most common causative agents of blood culture-negative IE are fastidious organisms (eg, zoonotic agents and fungi) and Streptococcal spp in patients who have received previous antibiotic treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34646?source=see_link\">",
"     \"Culture-negative endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Coxiella burnetii and Bartonella spp are relatively commonly agents of culture-negative endocarditis, although the frequency varies in different geographic locations. Treatment of these cases is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/57/15255?source=see_link\">",
"     \"Q fever endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/5/31830?source=see_link\">",
"     \"Endocarditis caused by Bartonella\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Empiric treatment of patients with culture-negative endocarditis should cover both gram-positive and gram-negative organisms. The American Heart Association (AHA) recommends treatment with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1160?source=see_link\">",
"     ampicillin-sulbactam",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    &nbsp;",
"    <strong>",
"     OR",
"    </strong>",
"    &nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    plus gentamicin plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    for four to six weeks (",
"    <a class=\"graphic graphic_table graphicRef70094 \" href=\"UTD.htm?8/37/8797\">",
"     table 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/7\">",
"     7",
"    </a>",
"    ]. The British Cardiac Society (BCS) and the European Society for Cardiology (ESC), in contrast, recommend combination therapy with vancomycin for six (BCS) or four to six (ESC) weeks with gentamicin added for the initial two weeks of treatment (",
"    <a class=\"graphic graphic_table graphicRef70094 \" href=\"UTD.htm?8/37/8797\">",
"     table 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/37/20058/abstract/22,52\">",
"     22,52",
"    </a>",
"    ]. When diagnostic tests (eg, polymerase chain reaction (PCR) or serology) identify the etiologic agent, therapy should be directed to the specific microorganism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=see_link\">",
"     \"Diagnostic approach to infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/48/26370?source=see_link\">",
"       \"Patient information: Endocarditis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H286258840\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Only bactericidal, not bacteriostatic, therapy is effective in treating endocarditis. Thus, antimicrobial therapy should be administered in a dose designed to give sustained bactericidal serum concentrations throughout much of the entire dosing interval. In vitro determination of the minimum inhibitory concentration or other susceptibility testing of the etiologic cause of the endocarditis should be performed in all patients. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapy for infective endocarditis (IE) should be targeted to the organism isolated from blood cultures; cultures are positive in over 90 percent of patients with IE. For acutely ill patients with signs and symptoms strongly suggestive of IE, empiric therapy may be necessary. Such empiric therapy should be administered ONLY after at least two (preferably three) sets of blood cultures have been obtained from separate venipunctures. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Empiric therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice of empiric therapy in such cases should take into consideration the most likely pathogens. In general, empiric therapy should cover staphylococci (methicillin-susceptible and resistant), streptococci, and enterococci.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"      (30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per 24 h IV in two divided doses) is an appropriate choice for initial therapy in most patients. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Empiric therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal antibiotic regimen depends upon the causative organism and in vitro susceptibility results. The treatment of native valve endocarditis caused by viridans streptococci, other streptococci, enterococci, staphylococci, HACEK organisms, other gram-negative organisms, and culture-negative endocarditis is discussed in the sections devoted to these organisms. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Viridans streptococci and Streptococcus bovis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Other streptococcal species'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Enterococci'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Staphylococcal endocarditis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'HACEK organisms'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H933452042\">",
"       'Other gram-negative organisms'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Culture-negative endocarditis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Duration of therapy in patients with native valve endocarditis ranges from two to six weeks, depending on the pathogen and site of valvular infection. Short (two-week) therapeutic regimens are effective in a small number of carefully selected patients with right-sided endocarditis and in some patients with endocarditis due to highly susceptible viridans streptococci. Most patients are treated parenterally with regimens given for&nbsp;either four or six weeks. In general, longer (six-week) treatment regimens are used in patients with highly virulent or more resistant pathogens, those with secondary cardiac or extracardiac complications, and in patients with infections of long duration prior to diagnosis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early consultation with a cardiac surgeon should be obtained for all cases in which complications are observed or expected (such as in infections involving prosthetic valves or in the presence of moderate to severe heart failure or heart block or systemic emboli). In addition, consultation by specialists in infectious diseases",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cardiology may be useful if the treating clinician does not have experience in managing this life-threatening illness. Patients with endocarditis require careful regular clinical follow-up that includes performing serial physical examinations and obtaining blood cultures to insure that antimicrobial therapy is effective. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Empiric therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/1\">",
"      Fowler VG Jr, Miro JM, Hoen B, et al. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 2005; 293:3012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/2\">",
"      CHRISTIE RV. Penicillin in subacute bacterial endocarditis. Br Med J 1948; 1:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/3\">",
"      HAMBURGER M, STEIN L. Streptococcus viridans subacute bacterial endocarditis; two week treatment schedule with penicillin. J Am Med Assoc 1952; 149:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/4\">",
"      Durack DT, Beeson PB. Experimental bacterial endocarditis. II. Survival of a bacteria in endocardial vegetations. Br J Exp Pathol 1972; 53:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/5\">",
"      Francioli P, Ruch W, Stamboulian D. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone and netilmicin for 14 days: a prospective multicenter study. Clin Infect Dis 1995; 21:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/6\">",
"      Chambers HF, Miller RT, Newman MD. Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy. Ann Intern Med 1988; 109:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/7\">",
"      Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005; 111:e394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/8\">",
"      Habib G, Hoen B, Tornos P, et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J 2009; 30:2369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/9\">",
"      Nishimura RA, Carabello BA, Faxon DP, et al. ACC/AHA 2008 guideline update on valvular heart disease: focused update on infective endocarditis: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/10\">",
"      Gould FK, Denning DW, Elliott TS, et al. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2012; 67:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/11\">",
"      Heldman AW, Hartert TV, Ray SC, et al. Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. Am J Med 1996; 101:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/12\">",
"      Tice AD, Rehm SJ, Dalovisio JR, et al. Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines. Clin Infect Dis 2004; 38:1651.",
"     </a>",
"    </li>",
"    <li>",
"     Clinical Laboratory Standards Institute. Performance Standards for Susceptibility Testing. Twenty-second informational supplement CLSI document M100-S22, vol 32. Wayne, PA 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/14\">",
"      Knoll B, Tleyjeh IM, Steckelberg JM, et al. Infective endocarditis due to penicillin-resistant viridans group streptococci. Clin Infect Dis 2007; 44:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/15\">",
"      Senn L, Entenza JM, Greub G, et al. Bloodstream and endovascular infections due to Abiotrophia defectiva and Granulicatella species. BMC Infect Dis 2006; 6:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/16\">",
"      Aronin SI, Mukherjee SK, West JC, Cooney EL. Review of pneumococcal endocarditis in adults in the penicillin era. Clin Infect Dis 1998; 26:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/17\">",
"      Baddour LM. Infective endocarditis caused by beta-hemolytic streptococci. The Infectious Diseases Society of America's Emerging Infections Network. Clin Infect Dis 1998; 26:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/18\">",
"      Lefort A, Mainardi JL, Selton-Suty C, et al. Streptococcus pneumoniae endocarditis in adults. A multicenter study in France in the era of penicillin resistance (1991-1998). The Pneumococcal Endocarditis Study Group. Medicine (Baltimore) 2000; 79:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/19\">",
"      Fontana R, Canepari P, Lle&ograve; MM, Satta G. Mechanisms of resistance of enterococci to beta-lactam antibiotics. Eur J Clin Microbiol Infect Dis 1990; 9:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/20\">",
"      Murray BE. Beta-lactamase-producing enterococci. Antimicrob Agents Chemother 1992; 36:2355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/21\">",
"      Anderson DJ, Murdoch DR, Sexton DJ, et al. Risk factors for infective endocarditis in patients with enterococcal bacteremia: a case-control study. Infection 2004; 32:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/22\">",
"      Horstkotte D, Follath F, Gutschik E, et al. Guidelines on prevention, diagnosis and treatment of infective endocarditis executive summary; the task force on infective endocarditis of the European society of cardiology. Eur Heart J 2004; 25:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/23\">",
"      Wilson WR, Wilkowske CJ, Wright AJ, et al. Treatment of streptomycin-susceptible and streptomycin-resistant enterococcal endocarditis. Ann Intern Med 1984; 100:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/24\">",
"      Leclercq R, Bingen E, Su QH, et al. Effects of combinations of beta-lactams, daptomycin, gentamicin, and glycopeptides against glycopeptide-resistant enterococci. Antimicrob Agents Chemother 1991; 35:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/25\">",
"      Caron F, Kitzis MD, Gutmann L, et al. Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium. Antimicrob Agents Chemother 1992; 36:2611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/26\">",
"      Credito K, Lin G, Appelbaum PC. Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology. Antimicrob Agents Chemother 2007; 51:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/27\">",
"      Stevens MP, Edmond MB. Endocarditis due to vancomycin-resistant enterococci: case report and review of the literature. Clin Infect Dis 2005; 41:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/28\">",
"      Babcock HM, Ritchie DJ, Christiansen E, et al. Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid. Clin Infect Dis 2001; 32:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/29\">",
"      Zimmer SM, Caliendo AM, Thigpen MC, Somani J. Failure of linezolid treatment for enterococcal endocarditis. Clin Infect Dis 2003; 37:e29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/30\">",
"      Gavald&agrave; J, Len O, Mir&oacute; JM, et al. Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone. Ann Intern Med 2007; 146:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/31\">",
"      Gavald&agrave; J, Torres C, Tenorio C, et al. Efficacy of ampicillin plus ceftriaxone in treatment of experimental endocarditis due to Enterococcus faecalis strains highly resistant to aminoglycosides. Antimicrob Agents Chemother 1999; 43:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/32\">",
"      Korzeniowski O, Sande MA. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: A prospective study. Ann Intern Med 1982; 97:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/33\">",
"      Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/34\">",
"      Cosgrove SE, Vigliani GA, Fowler VG Jr, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis 2009; 48:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/35\">",
"      Ferrieri P, Gewitz MH, Gerber MA, et al. Unique features of infective endocarditis in childhood. Pediatrics 2002; 109:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/36\">",
"      DiNubile MJ. Short-course antibiotic therapy for right-sided endocarditis caused by Staphylococcus aureus in injection drug users. Ann Intern Med 1994; 121:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/37\">",
"      Bryant RE, Alford RH. Unsuccessful treatment of staphylococcal endocarditis with cefazolin. JAMA 1977; 237:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/38\">",
"      Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991; 115:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/39\">",
"      Ribera E, G&oacute;mez-Jimenez J, Cortes E, et al. Effectiveness of cloxacillin with and without gentamicin in short-term therapy for right-sided Staphylococcus aureus endocarditis. A randomized, controlled trial. Ann Intern Med 1996; 125:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/40\">",
"      Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/41\">",
"      Sander A, Beiderlinden M, Schmid EN, Peters J. Clinical experience with quinupristin-dalfopristin as rescue treatment of critically ill patients infected with methicillin-resistant staphylococci. Intensive Care Med 2002; 28:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/42\">",
"      Moise PA, Schentag JJ. Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. Int J Antimicrob Agents 2000; 16 Suppl 1:S31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/43\">",
"      Moise-Broder PA, Sakoulas G, Eliopoulos GM, et al. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004; 38:1700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/44\">",
"      Batard E, Jacqueline C, Boutoille D, et al. Combination of quinupristin-dalfopristin and gentamicin against methicillin-resistant Staphylococcus aureus: experimental rabbit endocarditis study. Antimicrob Agents Chemother 2002; 46:2174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/45\">",
"      Dailey CF, Dileto-Fang CL, Buchanan LV, et al. Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2001; 45:2304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/46\">",
"      Ruiz ME, Guerrero IC, Tuazon CU. Endocarditis caused by methicillin-resistant Staphylococcus aureus: treatment failure with linezolid. Clin Infect Dis 2002; 35:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/47\">",
"      Pistella E, Campanile F, Bongiorno D, et al. Successful treatment of disseminated cerebritis complicating methicillin-resistant Staphylococcus aureus Endocarditis unresponsive to vancomycin therapy with linezolid. Scand J Infect Dis 2004; 36:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/48\">",
"      Andrade-Baiocchi S, Tognim MC, Baiocchi OC, Sader HS. Endocarditis due to glycopeptide-intermediate Staphylococcus aureus: case report and strain characterization. Diagn Microbiol Infect Dis 2003; 45:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/49\">",
"      Howden BP, Ward PB, Charles PG, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/50\">",
"      Sakoulas G, Eliopoulos GM, Alder J, Eliopoulos CT. Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47:1714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/51\">",
"      Morpeth S, Murdoch D, Cabell CH, et al. Non-HACEK gram-negative bacillus endocarditis. Ann Intern Med 2007; 147:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/37/20058/abstract/52\">",
"      Ramsdale DR, Turner-Stokes L, Advisory Group of the British Cardiac Society Clinical Practice Committee, RCP Clinical Effectiveness and Evaluation Unit. Prophylaxis and treatment of infective endocarditis in adults: a concise guide. Clin Med 2004; 4:545.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2152 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-125.39.66.146-3A500C5829-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_37_20058=[""].join("\n");
var outline_f19_37_20058=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H286258840\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Empiric therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Combination antimicrobial therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Oral antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Home antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      VIRIDANS STREPTOCOCCI AND STREPTOCOCCUS BOVIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      OTHER STREPTOCOCCAL SPECIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pneumococcus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ENTEROCOCCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Susceptible strains",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Gentamicin-resistant strains",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      High-level penicillin resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      High-level aminoglycoside or vancomycin resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      STAPHYLOCOCCAL ENDOCARDITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Methicillin susceptible",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Penicillin allergy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Uncomplicated right sided",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Methicillin resistant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Coagulase negative staphylococci",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      HACEK ORGANISMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H933452042\">",
"      OTHER GRAM-NEGATIVE ORGANISMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      CULTURE-NEGATIVE ENDOCARDITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H286258840\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2152\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2152|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/53/7006\" title=\"table 1\">",
"      Rx strep endocarditis I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/16/22797\" title=\"table 2\">",
"      Rx strep endocarditis II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/24/31117\" title=\"table 3\">",
"      Rx entero endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/4/9294\" title=\"table 4\">",
"      Rx entero endocarditisII",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/0/43021\" title=\"table 5\">",
"      Rx VRE endocarditisII",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/56/27533\" title=\"table 6\">",
"      Rx staph endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/47/39676\" title=\"table 7\">",
"      Rx HACEK endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/37/8797\" title=\"table 8\">",
"      Rx Culture neg endocarditis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=related_link\">",
"      Allergy to penicillins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34712?source=related_link\">",
"      Antimicrobial therapy of prosthetic valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/33/22041?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of Streptococcus bovis infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18249?source=related_link\">",
"      Complications and outcome of infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34646?source=related_link\">",
"      Culture-negative endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=related_link\">",
"      Diagnostic approach to infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/5/31830?source=related_link\">",
"      Endocarditis caused by Bartonella",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5317?source=related_link\">",
"      Endocarditis due to coagulase-negative staphylococci",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40215?source=related_link\">",
"      Infective endocarditis in injection drug users",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31094?source=related_link\">",
"      Infective endocarditis: Historical and Duke criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/56/26506?source=related_link\">",
"      Mechanisms of antibiotic resistance in enterococci",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29926?source=related_link\">",
"      Microbiology, pathogenesis, and epidemiology of Streptococcus bovis infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17718?source=related_link\">",
"      Pathogenesis of vegetation formation in infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/48/26370?source=related_link\">",
"      Patient information: Endocarditis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/57/15255?source=related_link\">",
"      Q fever endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/5/81?source=related_link\">",
"      Resistance of Streptococcus pneumoniae to beta-lactam antibiotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22297?source=related_link\">",
"      Surgery for native valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24249?source=related_link\">",
"      Treatment of Staphylococcus aureus bacteremia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14314?source=related_link\">",
"      Treatment of enterococcal infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_37_20059="Damage control surgery for liver injury";
var content_f19_37_20059=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55259&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55259&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Damage control surgery for liver injury",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td rowspan=\"3\">",
"        <strong>",
"         Phase I",
"        </strong>",
"       </td>",
"       <td>",
"        Exploratory laparotomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Control of bleeding and contamination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Packing and temporary abdominal closure",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        <strong>",
"         Phase II",
"        </strong>",
"       </td>",
"       <td>",
"        Aggressive ICU resuscitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rewarming",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Correction of coagulopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Optimization of blood volume and oxygen delivery",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"5\">",
"        <strong>",
"         Phase III",
"        </strong>",
"       </td>",
"       <td>",
"        Planned reoperation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Packing change",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Evacuation of blood clot",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Definitive repair of injuries",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal closure",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_37_20059=[""].join("\n");
var outline_f19_37_20059=null;
var title_f19_37_20060="Acute NSAID toxicity - Rapid overview";
var content_f19_37_20060=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F59428&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F59428&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Acute NSAID toxicity: Rapid overview",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <span style=\"color: #ff0000;\">",
"         To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (",
"        </span>",
"        <a href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">",
"         www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"        </a>",
"        <span style=\"color: #ff0000;\">",
"         ).",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        History",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ask specifically about acetaminophen and aspirin ingestion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ascertain type of NSAID, amount ingested, when ingested",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical and laboratory features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NSAIDS are usually well tolerated in overdose, with minimal toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe acute overdose may result in alterations in mental status, seizure, metabolic acidosis, or renal insufficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anaphylaxis may occur",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diagnostic evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Basic electrolytes to assess concentrations and acid-base status; baseline renal function (indicated only in moderate to severe overdose)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acetaminophen and salicylate concentrations to rule out concurrent pain medication ingestion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fingerstick glucose to rule out hypoglycemia as an etiology of any alteration in mental status",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Electrocardiogram to assess for toxin-induced prolongation of the QRS or QTc intervals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arterial blood gas in severe overdose or altered mental status",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pregnancy test for women of child-bearing age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Secure airway, breathing, and circulation (rarely an issue in pure NSAID poisoning)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Give gastrointestinal decontamination: activated charcoal, 1 g/kg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        There is no antidote for NSAID poisoning; supportive care will usually suffice",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_37_20060=[""].join("\n");
var outline_f19_37_20060=null;
var title_f19_37_20061="Risk of mortality among hemodial pts according to serum albumin";
var content_f19_37_20061=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F70749&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F70749&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Risk of mortality among hemodialysis patients according to serum albumin during maintenance dialysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 436px; height: 234px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Odds ratio for death, adjusted for age, sex, race, and underlying disease, according to the plasma albumin concentration in patients on maintenance hemodialysis. The likelihood of dying was inversely related to the plasma albumin concentration, being greatest at a plasma albumin concentration below 3.0 g/dL (30 g/L). All values are signficantly different (p&lt;0.001 to 0.03) from the odds ratio of 1.0 at a normal plasma albumin concentration of 4.0 to 4.4 g/dL (40 to 44 g/L).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Owen, WF Jr, Lew, NL, Liu, Y, et al, N Engl J Med 1993; 329:1001.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_37_20061=[""].join("\n");
var outline_f19_37_20061=null;
var title_f19_37_20062="Mitral annular time velocity";
var content_f19_37_20062=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64924&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64924&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mitral annular time-velocity plots",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 406px; height: 418px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shown are the mitral annular time-velocity plots obtained by tissue Doppler echocardiography from a normal subject (panel A) and a patient with a cardiomyopathy (panel B) In a cardiomyopathy, the peak systolic (S) and peak early diastolic (E) velocities are reduced and the peak atrial velocity (A) is increased compared to normal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_37_20062=[""].join("\n");
var outline_f19_37_20062=null;
var title_f19_37_20063="Mobilization of the ascending colon";
var content_f19_37_20063=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F78271&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F78271&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mobilization of the ascending colon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 332px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts mobilizing the ascending&nbsp;colon by incising the peritoneal reflection sharply with scissors. While the right colon is retracted medially, the peritonal attachments of the cecum and ascending colon are divided along the whilte line of Toldt.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_37_20063=[""].join("\n");
var outline_f19_37_20063=null;
